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Abstract 
To establish a productive infection pathogens must counteract the innate immune response. 
VACV is a large DNA virus that was used as the vaccine to eradicate smallpox and expresses 
many proteins that modulate the host response to the benefit of the virus. Protein C6, encoded 
by ORF 022 of VACV strain WR, is one such example.  
C6 is a small intracellular protein that is expressed early during infection and localises to both 
the nucleus and cytoplasm, and can form homo-dimers. This protein is a predicted member of 
the VACV Bcl-2 protein family and like other members of this family C6 possesses 
immunomodulatory properties. C6 is an inhibitor of IFNβ production, targeting the IRF3, but 
not the NF-κB, innate signalling pathway. C6 exerts its inhibitory effect at the level of the 
non-canonical IKK complex and TANK, SINTBAD and NAP1, important adaptor molecules 
for IFNβ activation, were identified as C6 interaction partners. C6 interacts with TANK via 
the N-terminal coiled-coil region of this adaptor, a domain that is shared amongst all three 
adaptor molecules. In addition C6 is an inhibitor of ISRE activation downstream of IFNα. 
Tandem affinity purification followed by mass spectrometry was used as a non-biased 
method to find interaction partners and identified UBR1, UBR2, Hsp70, SMARCC1, 
TROVE2 and VACV protein I1 as C6 binding partners. Of these, the interaction of C6 with 
UBR1 and SMARCC1 was confirmed by co-immunoprecipitation assays.  
Deletion of C6 from VACV strain WR had no effect on replication and spread in vitro, but 
significantly attenuated the virus in both the intranasal and intradermal models of murine 
infection. In addition, a virus lacking C6 had enhanced immunogenicity in a VACV 
challenge model, identifying this gene as a target for removal to improve VACV as a vaccine 
vector.  
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Chapter 1: Introduction 
1.1 Viruses, the poxvirus family and vaccinia virus 
1.1.1 Viruses and their classification 
Viruses are small infectious particles that are obligate parasites, requiring cells of a living 
organism in order to replicate. The virus family is large and diverse, containing 
microorganisms with the ability to infect animals, plants, bacteria and archaea. Viruses vary 
greatly in their size, shape, complexity, genetic material and replication cycle. As such, 
viruses can be classified in a number of ways. The Baltimore classification, defined in 1971 
by David Baltimore, classifies viruses into seven groups depending on the genome type of the 
virus, how the genome is coverted into mRNAs, and mode of replication (see Table 1.1) 
(Baltimore, 1971).   
Groups I and II of the Baltimore classification contain viruses with a DNA genome. Viruses 
with a double-stranded (ds) deoxyribonucleic acid (DNA) genome are classified as group I. 
These viruses replicate their genetic material using a DNA-dependent DNA polymerase. For 
members of the adenovirus and herpesvirus families this occurs within the nucleus of infected 
cells. For poxviruses, however, replication occurs in the cytoplasm, requiring viruses in this 
family to encode their own machinery for replication and transcription. Group II viruses have 
a single-stranded (ss)DNA genome, from which a dsDNA intermediate is produced before 
replication of the genome can occur.  
Viruses in groups III, IV and V have ribonucleic acid (RNA) genomes. Group III viruses 
have a dsRNA genome. In order to produce positive-sense (+)ssRNA that can be used as a 
template for host ribosomes in the production of proteins, an RNA-dependent RNA 
polymerase, an enzyme which is not encoded by the host, is packaged in the virion core. 
Viruses in group IV have a (+)ssRNA genome meaning their genetic material can be directly 
utilised for the production of proteins, akin to messenger RNA (mRNA). A virus-encoded 
RNA-dependent RNA polymerase copies the viral RNA to a dsRNA form, which can be 
replicated to form new virions. Group V viruses on the other hand have a negative-sense (-
)ssRNA genome and therefore, like group III viruses, their virions are packaged with an 
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RNA-dependent RNA polymerase which uses the (-)ssRNA as a template to produce 
(+)ssRNA. 
Groups VI and VII of the Baltimore classification contain reverse transcribing (RT) viruses. 
Group VI viruses have a ssRNA genome that is replicated via a DNA intermediate. This 
group includes the retroviruses, which encode a reverse transcriptase enzyme that converts 
the (+)ssRNA genome into DNA, which is then integrated into the host genome by a virus-
encoded integrase enzyme. Replication of the proviral genome thus occurs during cell 
division. Retroviruses also make use of the host RNA polymerase II enzyme to make new 
genomes. Group VII is a small group of viruses including the hepadnavirus hepatitis B virus. 
This virus has a partially dsDNA genome and utilises a virus-encoded reverse transcriptase to 
replicate via an RNA intermediate.  
Table 1.1 The Baltimore classification of viruses  
 
Baltimore classification Genome Examples 
I dsDNA adenoviruses (e.g. adenovirus 5), 
poxviruses (e.g. vaccinia virus), 
herpesviruses (e.g. herpes simplex virus 1) 
II ssDNA parvoviruses (e.g. parvovirus B19), 
anelloviruses (e.g. torque teno virus) 
III dsRNA reoviruses (e.g. bluetongue virus), 
birnaviruses (e.g. infectious bursal disease 
virus) 
IV (+)ssRNA picornaviruses (e.g. hepatitis A virus), 
togaviruses (e.g. Sindbis virus) 
V (-)ssRNA rhabdoviruses (e.g. rabies virus), 
orthomyxoviruses (e.g. influenza A virus) 
VI ssRNA-RT retroviruses (e.g. human 
immunodeficiency virus 1) 
VII dsDNA-RT hepadnaviruses (e.g. hepatitis B virus) 
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1.1.2 Vaccinia virus classification 
Vaccinia virus (VACV) is a large dsDNA virus that replicates in the cytoplasm of infected 
cells. It is the prototype member of the Poxviridae, a large family of cytoplasmic viruses that 
infect a wide range of eukaryotic hosts including mammals, reptiles, birds and insects. 
Poxviruses are classified into two subfamilies; the Chordopoxvirinae that infect vertebrates 
and the Entomopoxvirinae that infect insects. These subfamilies are further subdivided into 
genera. The Chordopoxvirinae consist of 8 genera; Orthopoxvirus (OPV), Parapoxvirus, 
Avipoxvirus, Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus and 
Yatapoxvirus, whilst the Entomopoxvirinae consist of 3 genera termed A, B and C. VACV, a 
member of the OPV genus, is the best studied poxvirus and is well known as the agent used 
for the vaccination against and eradication of smallpox (Fenner, 1988), a devastating human 
disease caused by Variola virus (VARV), another member of the OPV genus.  
1.1.3 Phylogenetic analysis 
The viral DNA polymerase gene is one of several conserved genes used to determine the 
phylogenetic relationship for the poxvirus family, since this gene is essential for replication 
and it is likely to have been inherited vertically from a common ancestral virus. Phylogenetic 
analysis of poxvirus genomes, of which there are over 100 complete genomic sequences, 
have indicated poxviral proteins to be more similar to eukaryotic proteins than bacterial or 
archaebacterial proteins (Lefkowitz et al, 2006). Phylogenetic analysis of chordopoxvirus 
genomes using multiple gene alignments shows that they separate into four main sub-groups 
(Gubser et al, 2004). The Molluscipox and Avipox genera group separately and are more 
divergent, with the largest number of unique genes. The largest cluster of chordopoxviruses 
includes the Yatapoxvirus, Capripoxvirus, Suipoxvirus and Leporipoxvirus genera. Finally the 
OPVs form a fourth group and cluster together. Many poxviral proteins appear to have a 
common evolutionary origin with proteins of their eukaryotic hosts indicating that gene 
acquisition by horizontal transfer may have occurred during viral evolution. There is also 
evidence of duplication of viral genes and subsequent divergence, thus creating paralogues 
(Smith et al, 1991b). This may be the case for VACV protein C16, which is diploid in the 
genome (Fahy et al, 2008) and C4, which shares 43 % amino acid identity with C16. A 
further interesting example is the VACV B cell lymphoma (Bcl)-2-like family of proteins 
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which may have arisen from a single gene acquisition from a eukaryotic host and subsequent 
duplication and diversification of genes (see 1.4.5.1). Importantly, the virion structure is able 
to accommodate variable amounts of genetic material allowing such gene acquisitions and 
duplications to occur (Ball, 1995; Smith & Moss, 1983). 
1.1.4 Poxviruses that cause disease in humans 
In addition to VARV, the poxvirus family contains several other viruses capable of causing 
disease in humans. Of these, molluscum contagiosum virus is the only human-specific 
pathogen, with no known animal reservoir, that causes benign wart-like lesions (Hanson & 
Diven, 2003). More serious cases of human disease have resulted after zoonotic transmission 
events with monkeypox virus (MPXV), which can produce a smallpox-like disease (Reynolds 
et al, 2004) and cowpoxvirus (CPXV), where fatalities in immune-compromised individuals 
have been reported (Czerny et al, 1991). In addition, other zoonotic transmissions have been 
reported with VACV, orf virus, bovine papular stomatitis, tanapox virus, pseudocowpox 
virus and parapoxvirus of seals and reindeer, which normally result in uncomplicated 
localised lesions (reviewed in (Essbauer et al, 2010)). 
1.1.5 VACV as a vaccine 
The history of vaccination began with poxviruses. In the late eighteenth century Jenner 
discovered that inoculation with CPXV protected individuals from smallpox, and this was 
later explained by the significant antigenic similarity between CPXV and VARV (Macdonald 
& Downie, 1950). High antigenic similarity was also observed with VACV, which was used 
as the live vaccine during the smallpox eradication campaign organised by the World Health 
Organisation (WHO) in the 1960s (Fenner et al, 1988). This campaign was successful, in 
part, due to the lack of an animal reservoir for the virus and the fact that VACV provides 
effective and long-lasting immunity. Despite VARV being the first human infectious disease 
to be eradicated through the use of VACV as a vaccine, arguably one of the greatest 
achievements of mankind, VACV remains an enigma because its origin and natural host are 
unknown (Baxby, 1981). 
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Other than its use as a smallpox vaccine, VACV is still studied intensely as a vaccine vector 
to protect against other human and animal pathogens. In particular, the highly attenuated 
VACV strain modified virus Ankara (MVA) is being tested as a vaccine for several diseases 
including acquired immune deficiency syndrome (AIDS), malaria and tuberculosis (Gomez et 
al, 2008). This virus has proven useful as a vaccine vector due to its safety record, efficient 
expression of foreign antigens and ability to induce a robust immune response. MVA cannot 
replicate fully in most mammalian cell lines and therefore is a safe vaccine even in immune-
compromised individuals (Moss et al, 1996). 
1.1.6 Other research on VACV 
Despite smallpox being eradicated more than 30 years ago VACV remains a very useful tool 
in many fields of biological research. As VACV is easy to manipulate and has a wide cell 
tropism it has been used as a model to study many aspects of virus replication, 
morphogenesis and interactions between the virus and the host cell. A significant topic of 
interest in poxvirus research involves understanding viral immune evasion strategies, which 
includes modulation of both the innate and adaptive immune responses (Haga & Bowie, 
2005; Smith et al, 1997b). Studying the roles of these proteins leads not only to a better 
understanding of how viruses evade elimination by the host, but also enhances our knowledge 
of the host immune system and the signalling pathways involved. Ultimately this can lead to 
the design of enhanced and/or novel therapeutics not only for viral infection, but also for 
disorders caused by inflammation and autoimmunity (Unterholzner & Bowie, 2008). 
Growing interest in VACV and poxvirus research has also arisen from the potential threat of 
an intentional release of VARV as a bio-terrorism weapon (Mahy, 2003). Further, VACV is 
being studied as an oncolytic therapy for the treatment of cancer (Breitbach et al, 2011; 
Worschech et al, 2009).  
1.1.7 Life cycle 
The life cycle of VACV is complicated by the existence of 4 virion types. There are 2 
intracellular forms; the intracellular mature virus (IMV) and the intracellular enveloped virus 
(IEV), a cell-associated form; the cell-associated enveloped virus (CEV) and an extracellular 
form; the extracellular enveloped virus (EEV). These forms differ in their structure and their 
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relative contributions to the spread of infection within the host. Importantly the IMV, IEV, 
CEV and EEV are surrounded by different numbers of membranes which are associated with 
different viral proteins making these forms of virion structurally, antigenically and 
functionally different (Boulter & Appleyard, 1973).  
1.1.7.1 Morphogenesis 
During entry into the cell the membrane(s) surrounding the virion are removed and the core is 
transported further into the cytoplasm on microtubules (Figure 1.1) (Carter et al, 2003). The 
cores accumulate in the perinuclear region and partial uncoating occurs, allowing the 
transcription of early mRNAs by the virus-associated DNA-dependent RNA polymerase to 
occur. Here, viral factories are formed and within these the viral genome is replicated, viral 
structural proteins are synthesised and new virions are produced. Viral cytoplasmic factories 
are largely devoid of cellular organelles. The first visible structure is crescent-shaped and 
composed of protein and lipid. The structure grows to form a spherical or oval structure that 
encloses the virion core, forming an immature virion. The genome is packaged in this 
structure and the proteolytic cleavage of core proteins yields the characteristic brick-shaped 
IMV (Figure 1.1) (Moss & Rosenblum, 1973).  
The majority of virions remain as IMV, however a significant minority are transported away 
from the viral factory on microtubules. The IMVs move to an area of the cytoplasm where 
they become wrapped by a double layer of membrane, forming an IEV particle (Figure 1.1) 
(Hiller & Weber, 1985). The wrapping membranes have been reported to derive from both 
endosomal (Tooze et al, 1993) and trans-Golgi cisterna (Hiller & Weber, 1985). At least 9 
proteins are associated with this membrane, including B5, F13, A33, A34, A36, A56, F12, 
K2 and E2 (Roberts & Smith, 2008). The IEVs then move to the periphery on microtubules, a 
process involving both F12 (Zhang et al, 2000), a protein containing a motor binding motif, 
and with structural similarity to kinesin light chain (Morgan et al, 2010), and protein A36 
(Ward & Moss, 2001).  
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Figure 1.1: The VACV life cycle. Upon entry the membranes of the EEV and IMV are 
removed (1) and the viral cores are transported on microtubules to a perinuclear region (2). 
Here, within virus factories the genome is replicated and viral proteins are synthesised. A 
spherical structure composed of protein and lipid is formed and encapsidates the DNA (3) 
forming an immature virion (IV). Proteolytic cleavage of core proteins and core 
condensation forms the brick-shaped IMV particle (4). A proportion of IMV are transported 
away from the factory on microtubules where they become wrapped in a double layer of 
intracellular membrane forming an IEV particle (5). The IEVs move to the cell surface on 
microtubules where the outer membrane fuses with the plasma membrane exposing a CEV 
particle on the cell surface (6). The formation of actin tails under the CEV push it away from 
the cell surface. If a CEV particle is released from the cell it is called an EEV particle (7). 
(Adapted from Roberts & Smith, 2008).   
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At the cell surface the IEV membrane and plasma membrane fuse, exposing a CEV particle 
on the cell surface. Protein A36 is then observed to localise underneath the CEV where it 
becomes phosphorylated by Src kinase, triggering a signalling cascade that leads to actin 
polymerisation (Frischknecht et al, 1999). The formation of actin filaments pushes the CEV 
outward away from the infected cell, releasing it as an EEV (Figure 1.1). Viral re-entry (or 
super-infection) is prevented by proteins A56 and K2, which form a complex on the cell 
surface and bind to the fusion machinery on the IMV surface and so block entry (Brum et al, 
2003). 
 1.1.7.2 Spread 
The IMV represent the majority of infectious progeny and are retained in the cell until their 
release during cell lysis at late stages of infection. The IMV particle is physically robust and 
resistant to freezing and thawing, allowing it to survive outside of the host for prolonged 
periods. These virions are therefore important for transmission from one host to another 
(Boulter & Appleyard, 1973). These particles, however, are poorly adapted for spread within 
the host because several IMV proteins including L1, A27 and H3 are targets of host 
neutralising antibodies (Abs) (Putz et al, 2006). The IMV are also destroyed by complement, 
even in the absence of specific Ab (Vanderplasschen et al, 1998). 
The CEV particle is important for intercellular viral spread, particularly between 
neighbouring cells. Although EEV are less abundant than IMV or CEV, they play a crucial 
role in the long-range dissemination of the virus within the host, and also in tissue culture 
(Payne, 1980; Smith et al, 2002). This is demonstrated by the small plaque phenotype 
observed with mutant viruses that are unable to make actin tails (Smith et al, 2002). Both 
CEV and EEV are suited to viral spread as they are wrapped in a host-derived membrane, so 
reducing exposure to host Ab and complement. Nevertheless, EEV protein B5 is a target of 
neutralising Abs (Chen et al, 2006b; Putz et al, 2006).  
Recently VACV was demonstrated to employ a novel mechanism to enhance viral spread, 
where the expression of 2 early proteins, A33 and A36, on the surface of an infected cell led 
to the induction of actin tail formation upon contact with an incoming EEV (Doceul et al, 
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2010). This actin tail was shown to repel the superinfecting virion away from the infected cell 
towards uninfected cells.  
1.1.7.3 Entry 
To date, the cell receptors for the IMV or EEV particle are unknown. A number of proteins 
have been reported to interact with cell surface glucosoaminoglycans (GAGs) including H3 
(Lin et al, 2000), A27 (Chung et al, 1998) and D8 (Hsiao et al, 1999), however GAGs were 
later shown to be non-essential for infection (Carter et al, 2005). A number of pathways have 
been suggested for IMV entry and are both cell type- and VACV strain-specific. One 
suggestion is that the IMV membrane fuses with the plasma membrane in a pH-independent 
manner (Carter et al, 2005). Another suggestion is that IMV are endocytosed, followed by the 
fusion of the virus and vesicular membranes, releasing the virion into the cytoplasm 
(Townsley et al, 2006). The process of membrane fusion, either at the plasma membrane or in 
endocytic vesicles is complex and requires at least 9 proteins (Senkevich et al, 2005). It has 
also been suggested that IMV can induce cell-surface blebbing and macropinocytosis to gain 
entry into cells (Mercer & Helenius, 2008). For EEV entry, it has been demonstrated that the 
EEV membrane is ruptured upon contact with the cell surface,  revealing an IMV particle that 
can presumably enter by one of the mechanisms described above (Law et al, 2006). More 
recently it has been demonstrated that EEV particles can enter via a macropinocytic 
mechanism of endocytosis, actively triggered by the particle itself. Acid exposure in 
endocytic vacuoles was then needed to disrupt the outer EEV membrane exposing the IMV 
particle which presumably fused its membrane with the vacuolar membrane thus releasing the 
core into the cytoplasm (Ichihashi, 1996; Schmidt et al, 2011). 
1.1.8 Genome structure and replication 
Poxvirus genomes are large linear dsDNA molecules, differing in size from 130 to 360 kb. 
The ends of the genome contain inverted terminal repeats (ITRs) of variable size (<0.1 – 12.4 
kb), and the two strands of DNA are covalently linked to produce hairpin termini (Baroudy et 
al, 1982). The length of the ITRs varies considerably and is influenced by recombination 
between blocks of repeated sequences within the ITRs and also by terminal transpositions 
from one end of the genome to the other. Poxviral genes tend to be arranged in blocks that are 
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transcribed in the same direction, possibly reducing collisions between transcription 
complexes and reducing the formation of dsRNA from overlapping transcripts. A common 
feature of poxvirus genomes is that they contain little non-coding DNA and the open reading 
frames (ORFs) lack introns. 
Approximately 50 core genes, found in the central region of the genome are common to all 
sequenced poxviruses. There are a further 40 genes that are also common to all 
chordopoxviruses (Gubser et al, 2004; Upton et al, 2003). These genes fulfil important 
functions such as replication, transcription and virion assembly. An array of additional genes 
that can vary greatly between species are found towards the ends of the genome. These 
variable peripheral genes are generally non-essential for virus replication but have allowed 
the poxvirus family to include viruses that infect a large range of eukaryotic hosts (reviewed 
in (Lefkowitz et al, 2006)). Many of the VACV terminal genes encode proteins that modulate 
the host‟s anti-viral response and many of these contribute to virulence.  
Replication requires the viral transcription complex within the core. DNA replication is 
initiated after 1-2 h post-infection (p.i.) and progeny virions are produced after 8 h (Salzman, 
1960). In order to replicate in the cytoplasm VACV encodes its own DNA polymerase, as 
well as other enzymes such as thymidine kinase, thymidylate kinase, ribonucleotide 
reductase, DNA topoisomerase and a DNA ligase (Moss, 2007). The mechanism by which 
poxviruses replicate their DNA is not fully understood, although the rolling hairpin strand 
displacement mechanism, as suggested for parvoviruses, is generally the accepted model 
(Tattersall & Ward, 1976). In this model a nick is introduced within the terminal 200 base 
pairs (bp) of the genome providing a 3‟ end for priming of the replication complex (Moyer & 
Graves, 1981). The resulting newly synthesised DNA strand, which includes the hairpin loop, 
folds back on itself allowing the rest of the genome to then be copied. 
1.1.9 Gene transcription 
Like other viruses, the transcription of VACV genes is regulated temporally. Three major 
classes of genes exist; early, intermediate and late, and their transcription is mediated by the 
timed synthesis of class-specific transcription initiation factors (Broyles, 2003). All classes of 
genes are transcribed by the virus-encoded RNA polymerase, a large complex consisting of 
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more than nine subunits and totalling more than 500 kilo Dalton (kDa) (Moss, 1994). Despite 
significant differences in genome composition, poxviruses use similar transcriptional 
mechanisms (Broyles, 2003). The genes involved in mRNA synthesis are among the most 
conserved genes in poxviruses, as are the promoter structures themselves (reviewed in 
(Lefkowitz et al, 2006)). Accordingly, promoters from one poxvirus species are functional in 
cells, or extracts from cells, infected with another poxvirus species (Prideaux et al, 1990; Vos 
et al, 1992). 
After entry the virion undergoes a preliminary uncoating allowing a large set of early genes 
to be transcribed. Amongst the early mRNAs are those encoding for proteins involved in 
blocking host anti-viral defences, transcription, DNA replication and transcription factors for 
intermediate class genes (reviewed in Broyles, 2003). Approximately half of VACV genes 
are transcribed early and have been suggested to be subdivided into immediate (within 30 
min p.i.) and delayed (within 2 h p.i.) early classes (Assarsson et al, 2008), although a more 
recent study found no evidence for these early subgroups (Yang et al, 2010). Viral mRNA is 
synthesised within the virus core where all the enzymes and proteins required for this are 
packaged together with the genome. Viral mRNA then leaves through pores on the virion 
surface (Kates & McAuslan, 1967).  
Intermediate transcription occurs after the viral DNA has replicated. It is thought that 
replication provides a suitable naked DNA template for intermediate and late transcription 
(Keck et al, 1990). Intermediate mRNAs include those that encode the RNA polymerase, 
capping enzyme and late transcription factors (Baldick & Moss, 1993). The late genes encode 
virion proteins, envelope proteins and factors required for early transcription to be packaged 
into the progeny virion particles (Broyles, 2003). 
1.2 The immune response to infection 
1.2.1 Detection of pathogens  
The mammalian immune system, consisting of both innate and adaptive components, 
provides the host with a defence mechanism against invading pathogens.  The innate immune 
system is the primary, early barrier to infection and leads to the initiation of an adaptive 
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response, the activation of which is crucial for long-lasting immunity and importantly, the 
induction of immune memory.  
The innate immune system (discussed in detail in 1.3) recognises conserved molecular 
structures on pathogens, also known as pathogen-associated molecular patterns (PAMPs). 
PAMPs include proteins, lipids, carbohydrates and nucleic acids, and distinguish pathogens 
from self molecules, and their detection initiates the host innate immune response to 
infection. PAMPs are recognised by germline encoded pattern recognition receptors (PRRs) 
(Janeway, 1989; Medzhitov, 2009). PRRs include the Toll-like receptors (TLRs), retinoic 
acid inducible gene (RIG-I)-like receptors (RLRs), nucleotide-binding oligomerisation 
domain-containing protein (NOD)-like receptors (NLRs) and cytoplasmic DNA sensors. The 
detection of pathogens by PRRs initiates complex signalling cascades that ultimately activate 
key transcription factors including nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), the interferon (IFN) regulatory factors (IRFs), in particular IRF3 and 
activating protein-1 (AP-1). Together these transcription factors co-ordinate the transcription 
of pro-inflammatory cytokines and type I IFNs.  
Inflammatory cytokines such as tumour necrosis factor α (TNFα) and interleukin-6 (IL-6), 
and inflammatory chemokines such as CCL-5 and CXCL-10 initiate and coordinate innate 
immune responses through the recruitment of professional immune cells including 
macrophages and dendritic cells (DCs). These cells play a critical role in pathogen clearance 
and the priming of an adaptive response. Type I IFN is particularly important for the defence 
against invading viral pathogens. IFN was discovered in 1957 by Isaacs and Lindeman as a 
secreted molecule produced by cells after treatment with heat-inactivated influenza virus. It 
was named IFN due to its ability to “interfere” with live virus replication (Isaacs & 
Lindenmann, 1957). Work over the last 50 years has indicated the existence of a whole 
family of IFNs. These molecules can bind to cells in a paracrine or autocrine manner and 
induce the transcription of IFN-stimulated genes (ISGs). These induce an antiviral state in the 
cell and enhance viral clearance by inhibiting viral replication, inducing apoptosis, increasing 
the lytic capacity of natural killer (NK) cells, upregulating major histocompatibility complex 
(MHC) class I molecules and activating various components of the adaptive immune 
response (Hoebe & Beutler, 2004). 
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1.2.2 Cells of the innate immune system 
The cells of the innate immune system provide the first defence against pathogens. They play 
an important role in detecting pathogens, promoting pathogen clearance and activating the 
adaptive immune response. 
1.2.2.1 Macrophages 
Macrophages are myeloid cells that mature from monocyte precursors. These cells play a 
major role in pathogen clearance by phagocytosing whole pathogens or pathogen-infected 
cells. Once phagocytosed, the pathogen is encapsulated in an intracellular compartment 
called the phagosome, which then fuses with the lysosome causing digestion of the 
microorganism or infected cell. Macrophages are professional antigen presenting cells 
(APCs) and play a major role in activating the adaptive immune system. These cells present 
antigen to T cells on MHC molecules. Macrophages are also contributors to inflammation 
because they secrete a range of pro-inflammatory cytokines and chemokines. A subset of 
macrophages known as alternatively activated, or M2 macrophages are thought to play a role 
in immune regulation and tissue repair following infection (Martinez et al, 2008). During 
VACV infection both DCs and macrophages have been demonstrated to present antigen to T 
cells within 2 h p.i. (Ramirez & Sigal, 2002).  
1.2.2.2 Dendritic cells 
Like macrophages, DCs are professional APCs and contribute to the presentation of antigen 
on MHC molecules to T cells. DCs sample the environment and are therefore found in tissues 
such as the skin, the respiratory tract, the lungs and the digestive system which are 
continuously in contact with the external environment. Once activated, for example by 
encountering a pathogen, DCs then migrate to the lymph nodes where they present antigen to 
cells of the adaptive immune system. Importantly these activated DCs express co-stimulatory 
molecules on their surfaces that are essential for T cell activation. Two subsets of DCs exist; 
the conventional DCs (cDCs) and the plasmacytoid DCs (pDCs). TLRs are highly expressed 
on both type of DCs, but the pDCs express particularly high levels and these cells produce 
very large amounts of type I IFN in antiviral immunity (Shortman & Naik, 2007). 
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1.2.2.3 Neutrophils 
Neutrophils are some of the first cells recruited to the site of infection, migrating towards 
sites of IL-8 and IFNγ release. Neutrophils are an important source of cytokines and 
contribute to the recruitment of other immune cells during inflammation. Neutrophils 
contribute to pathogen clearance via three main processes. Firstly, like macrophages, 
neutrophils are professional phagocytes. Secondly, they can degranulate, releasing anti-
microbial compounds, such as cathepsins, bactericidal/permeability-increasing protein and 
defensins, into the extracellular environment (Segal, 2005). More recently neutrophils have 
also been shown to release web-like structures of chromatin and serine proteases called 
neutrophil extracellular traps (NETs), which can trap and kill pathogens (Brinkmann et al, 
2004).  
1.2.2.4 NK cells 
NK cells play an important role in the immune response, particularly to viral infection. These 
cells provide an immediate method for containing viral infection whilst the antigen-specific 
adaptive immune response is being generated. NK cells are of lymphoid origin and contribute 
to antiviral immunity in two ways. Firstly, they are major producers of IFNγ, contributing to 
the antiviral state of neighbouring cells and the activation of other immune cells such as 
macrophages. Secondly, NK cells act by lysing pathogen-infected cells, often by recognising 
their lack, or low level of MHC class I molecule expression. NK cells can release 
cytoplasmic granules that contain perforin, a molecule that inserts into lipid membranes 
leading to cell lysis and granzyme which causes cells to undergo apoptosis (Vivier et al, 
2008).  
1.2.3 Adaptive immunity 
Adaptive immunity is mediated via the generation of antigen-specific B and T lymphocytes. 
The adaptive immune response provides a mechanism for clearing pathogens in a specific 
manner and allows for the formation of immunological memory.  
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 1.2.3.1 T lymphocytes 
T cells are part of the cell-mediated immune response and have a unique cell surface receptor 
known as the T cell receptor (TCR), arising from recombination of various germline encoded 
segments (V(D)J recombination). There are many subsets of T cells with unique functions 
and roles in contributing to the host defence against invading microorganisms. Cytotoxic T 
lymphocytes (CTLs) are crucial for the defence against viruses as they are able to specifically 
kill virus-infected cells, as well as tumour cells. CTLs can be identified by the expression of 
the glycoprotein cluster of differentiation 8 (CD8) on their surface. CTLs recognise antigen 
(peptide) presented by MHC class I. T helper (TH) cells on the other hand express CD4 on 
their surface and recognise antigen presented by MHC class II. These cells assist other 
leukocytes in immunological processes such as the maturation of B cells, and the activation 
of CTLs and macrophages by the secretion of cytokines. A number of TH cell subsets exist 
including TH1 cells that secrete IFNγ and TNFβ and aid the killing capacity of macrophages 
and CTLs, TH2 cells that secrete IL-4, -5, -6, -10 and -13 and stimulate B cell proliferation 
and Ab class switching and TH17 cells that secrete IL-17 and play a role in the defence against 
extracellular pathogens (McGeachy & Cua, 2008). Memory T cells, along with Ab contribute 
to immunological memory and persist long after the infection has been cleared. Upon 
encountering antigen they divide rapidly, providing immediate protection against the 
invading pathogen. Regulatory T cells are crucial for the maintenance of immune tolerance 
and the resolution of immune responses (Rudensky, 2011).  
1.2.3.2 B lymphocytes 
B lymphocytes are part of the humoral response and their principal functions include Ab 
production in response to specific antigens, acting as APCs and eventually developing into 
memory B cells. Each B lymphoctye has a unique B cell receptor (BCR) on its surface, which 
is a membrane-bound immunoglobulin (Ig) and recognises a single antigen. Once the BCR 
encounters antigen and a second signal is received from a TH cell the B cell differentiates into 
a plasma B cell, which secretes Ab, or into a memory B cell. The BCR Ig is composed of two 
light chains and two heavy chains, with a variable region that is determined in the process of 
VDJ recombination, similar to the TCR, thus producing a unique Ig. Plasma B lymphocytes 
secrete soluble Ig, also known as Ab, of which there are five isotypes; IgG, IgD, IgM, IgA 
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and IgE, each of which has a distinct function. The function of Ab is to bind to antigens 
exposed by pathogens leading to direct neutralisation of pathogen infectivity, or opsonisation 
and subsequent phagocytosis, or activation of the complement cascade leading to pathogen 
destruction (Murphy, 2008). 
1.2.4 Complement 
The complement system is composed of a cascade of zymogens that once activated contribute 
to the opsonisation and destruction of invading pathogens (Ricklin et al, 2010). Complement 
can be activated via three main pathways. The classical pathway is initiated when C1q of the 
C1 complement complex binds to Ab complexed with antigen. This leads to a cascade of 
cleavages of various complement proteins including C4, C2 and C3. The alternative pathway 
is activated by the spontaneous proteolytic activation of C3 on microbial surfaces. Finally the 
lectin pathway is initiated following the recognition of lectins on the pathogen surface by 
mannose-binding-lectin and ficolins. All three pathways ultimately lead to the formation of 
the membrane attack complex that can insert into the membranes of pathogens, or pathogen-
infected cells, and initiate lysis. In addition some complement components can act as 
opsonins and others can trigger mast cell degranulation.     
1.2.5 Apoptosis 
Apoptosis, or programmed cell death is a mechanism by which cells can undergo death 
without causing local inflammation and potential damage. During apoptosis cells undergo 
changes such as cell shrinkage, nuclear fragmentation, chromatin condensation and 
chromosomal DNA fragmentation. Unlike necrosis, apoptosis produces small cell fragments 
that can be phagocytosed by neighbouring macrophages and other phagocytic cells, without 
the release of the cytoplasmic contents of the dying cell. Apoptosis is an important part of the 
innate immune response because it provides a means for infected cells to undergo death thus 
preventing the completion of virus replication and potential spread of infection. As such, 
many pathogens have evolved ways of preventing apoptosis (see 1.4.2) (Taylor & Barry, 
2006).   
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Apoptosis can be triggered by two main pathways; the extrinsic pathway and the intrinsic (or 
mitochondrial) pathway. The extrinsic pathway can be induced by the binding of TNFα 
(Carswell et al, 1975),  Fas ligand (Trauth et al, 1989; Yonehara et al, 1989) or TNF-related 
apoptosis-inducing ligand (TRAIL) (Wiley et al, 1995) to their respective receptors. This 
induces receptor oligomerisation and the subsequent assembly of the death-inducing 
signalling complex (Kischkel et al, 1995). This activates a caspase cascade starting from 
caspase-8 and ending with the effector caspases and nucleases; caspase-3, -6, -7 and caspase-
activated DNase (Kroemer et al, 2007). The intrinsic pathway is controlled by mitochondria. 
Several intracellular signals including DNA damage, reactive oxygen species and 
endoplasmic reticulum (ER) stress can induce mitochondrial outer membrane 
permeabilisation, causing the release of pro-apoptotic factors from the intermembrane space. 
These include cytochrome c, which induces the apoptosis protease-activating factor 1 
(APAF-1) and ATP/dATP to assemble the apoptosome, a molecular platform that promotes 
the activation and proteolytic cleavage of pro-caspase-9 (Zou et al, 1999). Caspase-9 then 
cleaves and activates the effector caspases, which finally lead to the apoptotic phenotype 
(Kroemer et al, 2007). A family of proteins with a Bcl-2 fold play an important role in 
controlling the permeability of the mitochondrial membrane and includes pro-apoptotic 
members such as Bid, Bad and Bax, and anti-apoptotic members such as Bcl-2, Bcl-xl and 
Bcl-w (Youle & Strasser, 2008). 
1.3 The innate immune response 
1.3.1 PRRs in detail 
1.3.1.1 TLRs 
The TLRs are a family of type I membrane glycoproteins consisting of extracellular leucine 
rich repeats (LRRs) that recognise PAMP ligands and a cytoplasmic Toll/interleukin-1 
receptor (TIR) domain which is required for interactions with adaptor molecules and 
downstream signalling. The first TLR was discovered in flies (Lemaitre et al, 1996). In 
humans there are 10 TLRs and in mice there are 12. Of these, TLRs 1-9 are conserved in both 
species. TLRs 1, 2, 4, 5 and 6 are expressed primarily at the cell surface and recognise 
PAMPs derived from bacteria, fungi and protozoa. TLRs 3, 7, 8 and 9 are expressed 
exclusively in endocytic compartments and primarily recognise nucleic acid PAMPs derived 
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from various viruses and bacteria (Kumar et al, 2011). These receptors are delivered to 
endosomes through their association with ER membrane protein UNC93B1 (Kim et al, 2008). 
Crystal structures have been solved for the TLR3 homodimer (Bell et al, 2005; Choe et al, 
2005), the TLR1-TLR2 heterodimer (Jin et al, 2007) and the TLR4-MD2 complex (Kim et al, 
2007). From these structures it appears that ligand binding induces receptor dimerisation and 
a conformational change. The TIR domains are thus brought into close proximity and the 
formation of dimers or oligomers provides a platform for the recruitment of TIR domain-
containing adaptor proteins to bind to. These adaptor molecules then recruit kinases that via 
signalling cascades activate NF-κB, IRFs and AP-1.   
  1.3.1.1.1 Bacterial recognition  
Various bacterial PAMPs are recognised by multiple TLRs including 1, 2, 4, 5, 6, 7 and 9. 
Much research has focussed on TLR4, which along with the accessory protein MD2 
(Shimazu et al, 1999) senses lipopolysaccharide (LPS), a major bacterial cell wall component 
(Poltorak et al, 1998). Bacterial peptidoglycan on the other hand is sensed by TLR2 
(Schwandner et al, 1999), as is mycobacterial lipoarabinomannan (Underhill et al, 1999). 
TLR2 in conjunction with TLR1 or TLR6 also senses diacyl or triacyl lipopeptides. TLR5 
senses bacterial flagellin. Bacterial nucleic acids are sensed by TLRs 7 and 9 (Kumar et al, 
2011). TLR9 senses DNA rich in unmethylated CpG, whereas TLR7 recognises ssRNA and 
is important for detection of Group B streptococci in the phagosome (Mancuso et al, 2009). 
The recognition of PAMPs by TLRs 1, 2, 4, 5 and 6 induces the production of pro-
inflammatory cytokines, whereas engagement of TLRs 7 and 9 induces type I IFN.  
1.3.1.1.2 Viral recognition 
As with bacterial pathogens, nucleic acid from viruses is sensed by both TLRs 7 and 9.  DNA 
from herpes simplex virus (HSV) and murine cytomegalovirus (MCMV) is sensed by TLR9, 
whereas viral RNA is sensed by TLRs 3, 7 and 8. TLR7 is activated by ssRNA from viruses 
such as influenza virus and vesicular stomatitis virus (VSV) (Diebold et al, 2004).  TLR8 is a 
close paralogue of TLR7 and there seems to be some functional redundancy. For example, 
both TLR7 and 8 recognise human immunodeficiency virus (HIV)-1-derived uridine-rich 
RNAs (Meier et al, 2007).  TLR3 recognises dsRNA (Alexopoulou et al, 2001) and in the 
38 
 
case of influenza virus it has been shown to actually promote disease due to excessive 
downstream inflammation (Le Goffic et al, 2006). This is an example of how an 
inappropriate or uncontrolled immune response can be detrimental to the host. In addition 
MCMV and VACV are also sensed by TLR3 because convergent transcription of DNA 
viruses produces dsRNA. Beside viral nucleic acids the coat protein of respiratory syncytial 
virus (RSV) and mouse mammary tumour virus (MMTV) are recognised by TLR4 and the 
measles virus heamagglutinin protein is sensed by TLR2 (Bowie & Unterholzner, 2008).  
1.3.1.1.3 Fungal recognition 
TLRs play a role in the recognition of several fungi including Candida albicans and 
Aspergillus fumigatus, however to induce an inflammatory response additional receptors are 
required. These include dectins, CD14, mannose receptors or DC-SIGN. Beta-glucans for 
example are recognised by TLR2 in association with dectin-1 and glucuronoxylomannans are 
sensed by TLR4 and CD14 (Kumar et al, 2011).   
1.3.1.1.4 Protozoal recognition 
TLRs 2 and 4 are also important in the detection of protozoa. Unsaturated alkylacylglycerol 
from Trypanosoma species and lipophosphoglycan from Leishmania species are both 
recognised by TLR2. Glycoinositolphospholipids and glycosylphosphatidylinositol anchors 
from Trypanosoma species, Plasmodium falciparum and Toxoplasma gondii are recognised 
by both TLR2 and 4. In addition TLR9 plays a role in sensing the genomic DNA of 
Trypanosoma species and hematin crystals of Plasmodium species (Kumar et al, 2011). 
1.3.1.2 RLRs 
The RLR family of cytoplasmic RNA sensors comprises three members; RIG-I (Yoneyama et 
al, 2004), melanoma differentiation-associated protein 5 (MDA5) (Andrejeva et al, 2004) and 
laboratory of genetics and physiology 2 (LGP2) (Rothenfusser et al, 2005). All three 
members contain a DExD/H-box RNA helicase domain that is required for ligand 
recognition. In addition, RIG-I and MDA5 contain N-terminal caspase activation and 
recruitment domains (CARDs) that are essential for downstream signalling. Engagement of 
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RIG-I and MDA5 with their ligands leads to a conformational change within the sensor 
exposing the CARD domains which can then interact with the CARD-containing adaptor 
protein mitochondrial antiviral signalling adaptor (MAVS) (Seth et al, 2005) (also known as 
IPS-1 (Kumar et al, 2006), Cardif (Meylan et al, 2005) and VISA (Xu et al, 2005). MAVS 
localises to the mitochondrion and peroxisomes and both localisations are required for robust 
antiviral responses. A recent study indicated that peroxisomal MAVS signals via IRF1, 
contributing to the early response to infection, whereas mitochondrial MAVS induces a 
delayed response via IRF3 (Dixit et al, 2010). MAVS is regulated negatively by NLRX1, a 
NLR family member that also localises to the mitochondrion (Moore et al, 2008). It is also 
regulated negatively by autophagosome components Atg5 and Atg12 (Jounai et al, 2007).  
Endogenous host RNAs do not activate the RLRs because they are generally ssRNA and have 
5‟ ends that are protected with a methylguanosine cap or are monophosphates, or are 
modified with unusual bases such as pseudouridine, preventing recognition by RIG-I and 
MDA-5. 
1.3.1.2.1 RIG-I 
RIG-I recognises members of the Paramyxoviridae family including Newcastle disease virus 
(NDV) and VSV and also members of the Flaviviridae family including Japanese 
encephalitis virus and hepatitis C virus. In addition, RIG-I recognises enzymatically 
synthesised RNA in vitro. Originally it was believed that ssRNAs bearing a 5‟ triphosphate 
were the only essential component for this recognition (Hornung et al, 2006; Pichlmair et al, 
2006), however recent studies have indicated that during enzymatic synthesis a secondary 
structure of dsRNA is generated and this „pan handle‟ acts as the ligand (Schlee et al, 2009; 
Schmidt et al, 2009).  As with other innate immune signalling pathways, Ub plays a key role 
in RIG-I-mediated cascades. For signalling to occur the CARDs within RIG-I require K63-
linked ubiquitination in the presence of RNA and ATP, and recently it was shown that free 
K63-linked Ub chains activate RIG-I-dependent signalling (Zeng et al, 2010). Further, the 
initial recognition of ligands by RIG-I is regulated positively by the two E3 Ub ligases 
tripartite motif (TRIM) 25 (Gack et al, 2007) and RNF135 via K63-linked ubiquitination 
(Oshiumi et al, 2009), whereas K48-linked ubiquitination by RNF125 leads to down-
regulation of RIG-I-mediated signalling (Arimoto et al, 2007). 
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1.3.1.2.2 MDA5 
Viruses that produce large amounts of dsRNA during their life cycle, such as picornaviruses 
are sensed my MDA5 (Gitlin et al, 2006). Some DNA viruses can produce considerable 
amounts of dsRNA owing to convergent transcription from opposite DNA strands, where two 
adjacent reading frames are transcribed in opposite directions and the transcripts can overlap. 
Positive-sense RNA viruses that use a dsRNA intermediate during their replication cycle are 
also subject to recognition by MDA5 (Weber et al, 2006). In addition MDA5 recognises the 
synthetic dsRNA analogue poly I:C, whereas only enzymatically shortened poly I:C was 
recognised by RIG-I. These data suggested that these two RLRs recognise RNAs of different 
lengths, with MDA5 showing a preference for longer molecules (Kato et al, 2008). Studies 
with RIG-I- and/or MDA5-deficient cells have indicated that some viruses, such as dengue 
virus and West Nile Virus, are recognised by both RIG-I and MDA5 and this dual recognition 
is required to generate a robust innate response (Takeuchi & Akira, 2008).  
1.3.1.2.3 LGP2 
Unlike RIG-I and MDA5, LGP2 lacks a CARD and therefore does not interact with the 
CARD-containing protein MAVS and does not initiate downstream signalling. Instead this 
molecule was described as a negative regulator of RIG-I- and MDA5-mediated signalling 
(Rothenfusser et al, 2005). However, more recent studies have suggested LGP2 to have a 
positive regulatory role on these pathways (Satoh et al, 2010).  
1.3.1.3 NLRs 
The NLRs are a group of cytoplasmic molecules that sense a wide range of ligands including 
PAMPs and host-derived damage-associated molecular patterns (DAMPs). In humans there 
are 23 members, comprising three domains; the C-terminal domain consisting of several 
LRRs thought to be involved in ligand recognition, the N-terminal domain consisting of a 
death effector domain, a pyrin domain (PYD), a CARD, baculovirus inhibitor repeats (BIRs) 
and an acidic domain, and the intermediate domain consisting of nucleotide-binding and 
oligomerisation (NACHT) domains. The NACHT domains are required for ligand-induced, 
ATP-dependent oligomerisation of the sensors and subsequent formation of active receptor 
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complexes. These sensors either activate NF-κB or mitogen-activated protein kinases 
(MAPKs) leading to the production of inflammatory cytokines, or they activate multiprotein 
complexes called inflammasomes. The inflammasomes then facilitate the maturation of 
inflammatory cytokines such as IL-1β and IL-18 from their zymogen forms, or they induce 
cell death (Kanneganti, 2010).  
1.3.1.3.1 NOD1 and NOD2 
The NOD1 and NOD2 receptors recognise peptidoglycans, a major component of bacterial 
cell walls (McDonald et al, 2005). NOD2 is also important for the immune defence against 
pathogenic protozoal parasites such as Toxoplasma gondii (Shaw et al, 2009). Ligand 
recognition by NOD1 and NOD2 induces the oligomerisation of these sensors and the 
subsequent recruitment of the adaptor molecule receptor interacting protein (RIP)2 via 
CARD-CARD interactions (Park et al, 2007). This leads to the activation of NF-κB and 
MAPKs. Evidence for the direct recognition of these PAMPs by NOD1 and NOD2 is lacking, 
a common theme in the field of NLRs. 
1.3.1.3.2 NLRP3 
The NLRP3 inflammasome is the best studied inflammasome complex and plays an 
important role in macrophages and DCs. It is composed of NLRP3, apoptosis-associated 
speck-like protein containing a CARD (ASC) and pro-caspase 1 (Martinon et al, 2002). Upon 
stimulation NLRP3 oligomerises and clusters ASC via PYD-PYD interactions. The CARD of 
ASC then interacts with the CARD of procaspase-1, inducing its proteolysis. Active caspase-
1 further promotes the proteolysis of the zymogen form of the IL-1 cytokine family members 
IL-1β and IL-18. This inflammasome responds to all classes of pathogens including viruses, 
for example adenovirus (Barlan et al, 2011), bacteria (Muruve et al, 2008), fungi, for example 
via β-glucans (Hise et al, 2009) and DAMPs such as β-amyloid (Halle et al, 2008), uric acid 
crystals (Martinon et al, 2002), silica crystals and aluminium salts, an adjuvant used 
frequently in vaccines (Hornung et al, 2008). The mechanism by which this inflammasome 
senses so many ligands is not well understood and again the question is raised as to whether 
NLRP3 senses ligands directly or indirectly. 
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1.3.1.3.3 NLRC4 
 NLRC4 (also known as IPAF) is also part of an inflammasome containing procaspase-1 
(Poyet et al, 2001). The requirement for the adaptor protein ASC in this complex is unclear. 
NLRC4 senses bacteria such as Legionella pneumophilia, Salmonella typhimurium, 
Pseudomonas aeruginosa and Shigella flexneri indicating a type III or IV secretion system 
might be involved in NLRC4 inflammasome activation. 
1.3.1.3.4 NLRP1 
The NLRP1 infammasome comprises NLRP1, ASC and procaspase-1 and it senses the 
bacterial cell wall constituent muramyldipeptide (MDP) (Faustin et al, 2007). ASC does not 
seem to be essential but facilitates the activation of caspase-1. In mice the NLRP1 paralogue 
NLRP1b senses lethal toxins from Bacillus anthracis and plays a role in pathogenesis 
(Boyden & Dietrich, 2006). 
1.3.1.3.5 NLRC5 
NLRC5 is the most recently characterised NLR and conflicting data exists as to the role it 
plays in innate immunity. NLRC5 mRNA and protein expression are induced by stimulation 
of myeloid and lymphoid cells with IFNγ, LPS, poly I:C and viral infection (Benko et al, 
2010). Several studies have demonstrated that NLRC5 over-expression dampens 
inflammatory cytokine and type I IFN production (Benko et al, 2010; Cui et al, 2010). 
Mechanistically, Cui et al found NLRC5 to interact with the inhibitor of κB (IκB) kinase 
(IKK) complex and inhibit its activation, as well as interacting with RIG-I and MDA-5 and 
suppressing downstream signalling (Cui et al, 2010). However, other studies have suggested 
that NLRC5 over-expression induces IFNβ promoter activation and enhances RIG-I and 
MDA5-mediated antiviral responses (Kuenzel et al, 2010; Neerincx et al, 2010) as well as 
inducing caspase-1-dependent maturation of IL-1 family cytokines (Kumar et al, 2010). A 
further study demonstrated that this molecule enhances the transcription of MHC class I 
molecules (Meissner et al, 2010). However, work performed in vivo with NLRC5-deficient 
mice found comparable levels of inflammatory cytokines and type I IFNs in response to a 
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challenge with poly I:C compared to wild-type mice and thus the role of this molecule is still 
unclear (Kumar et al, 2010).   
1.3.1.4 Cytoplasmic DNA sensors 
The existence of cytoplasmic DNA sensors was first questioned when work by Ishii et al and 
Stetson and Medzhitov demonstrated that type I IFN could be induced in cells by delivery of 
B-form dsDNA to the cytoplasm (Ishii et al, 2006) or by infection with invasive Listeria 
monocytogenes (Stetson & Medzhitov, 2006). Both groups described this induction to be 
dependent on IRF3, but independent of TLR9, the only characterised sensor of foreign DNA 
at the time. Much work was then focussed on identifying the sensor(s) for DNA delivered to 
the cytoplasm.  
1.3.1.4.1 DAI 
The first identified putative sensor of foreign DNA was DNA-dependent activator of IFN 
(DAI, also known as DLM1 and ZBP1) (Takaoka et al, 2007). These initial in vitro studies 
indicated DAI to be essential for type I IFN induction, and this was via the non-canonical 
IKK kinases TRAF family member-associated NF-κB activator (TANK)-binding kinase 
(TBK)1 and IKKε. However further in vitro and in vivo studies questioned this finding and 
demonstrated DAI to be dispensable for DNA-mediated innate immune responses (Ishii et al, 
2008; Wang et al, 2008). 
1.3.1.4.2 AIM2 
A second putative DNA sensor to be identified was absent in melanoma 2 (AIM2). This 
cytoplasmic molecule and member of the HIN-200 family has a PYD domain, allowing it to 
interact with ASC to form an AIM2 inflammasome along with procaspase-1. Infection with 
DNA viruses or introduction of DNA into the cytoplasm was demonstrated to induce the 
production of IL-1β through this AIM2 inflammasome (Burckstummer et al, 2009; 
Fernandes-Alnemri et al, 2009; Hornung et al, 2009; Roberts et al, 2009). The use of AIM2-
deficient mice has demonstrated that this molecule is critical for caspase-1 activation and 
subsequent production of IL-1β and IL-18 after infection with Francisella tularensis 
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(Fernandes-Alnemri et al, 2010), VACV and MCMV (Rathinam et al, 2010). Nonetheless 
AIM2 was shown not to act via IRF3 and thus other DNA sensors were believed to exist. 
1.3.1.4.3 RNA polymerase III 
RNA polymerase III has also been identified as a DNA sensor. This molecule transcribes 
DNA into RNA with a 5‟ tri-phosphate, which is then sensed by RIG-I (Ablasser et al, 2009; 
Chiu et al, 2009). RNA polymerase III recognises AT-rich DNA, such as the synthetic ligand 
poly dA:dT, and interruption of the AT rich sequence leads to abrogation of type I IFN 
induction (Chiu et al., 2009).  This sensor has only been shown to be important in HEK293 
cells and studies in vivo are currently lacking.  
1.3.1.4.4 Ku 70 
Recently Ku70 was described as a novel cytosolic DNA sensor that induces type III rather 
than type I IFN in HEK293 cells (Zhang et al, 2011). Also our group has described the DNA-
protein kinase (DNA-PK) complex, comprising Ku 70, Ku 80 and DNA-PK catalytic subunit 
(DNA-PKcs) as a DNA sensor important in murine embryonic fibroblasts (MEFs) and adult 
skin fibroblasts that induces type I IFN, CXCL-10 and IL-6 expression via a pathway 
dependent on stimulator of IFN genes (STING), TBK1 and IRF3 (Brian Ferguson et al, 
submitted). 
1.3.1.4.5 IFI16 
Recently, a molecule with similarity to AIM2, IFI16, was shown to activate IRF-3 in 
response to DNA in macrophages (Unterholzner et al, 2010). A subsequent study further 
highlighted the role for this molecule in the activation of the inflammasome in response to 
Kaposi‟s sarcoma herpesvirus (KSHV) (Kerur et al., 2011), although this virus, like other 
herpes viruses, replicates in the nucleus and is not thought to expose genomic DNA in the 
cytoplasm.  
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1.3.1.4.6 LRRFIP1 
Further, the leucine rich repeat flightless interacting protein 1 (LRRFIP1) has been 
characterised as a DNA sensor functioning within macrophages to upregulate type I IFN 
(Yang et al., 2010). This pathway involved β-catenin and IRF3. Interestingly DNA from 
Listeria monocytogenes and RNA from VSV both appeared to stimulate LRRFIP1 indicating 
it to be a nucleic acid sensor rather than a DNA-specific receptor.  
1.3.1.4.7 STING 
STING was identified by functional screening for IFNβ promoter activators and appears to be 
essential for the induction of cytokines and IFNs in response to cytoplasmic DNA. This 
molecule is localised in the ER, interacts with TBK1 and signals via IRF3. As this molecule 
does not interact directly with DNA it has been suggested as an adaptor molecule rather than 
a DNA sensor (Ishikawa & Barber, 2008; Zhong et al, 2008). Furthermore STING-deficient 
mice are more susceptible to infection with both a DNA virus (HSV) and an RNA virus 
(VSV) suggesting a wider role for this adaptor protein than initially thought (Ishikawa et al, 
2009).  
1.3.2. The NF-κB signalling pathway 
NF-κB is a key mediator of the immune inflammatory response and is activated downstream 
of the TLRs, RLRs, some NLRs and DNA sensors, as well as the TNFα receptor (TNFR) and 
IL-1 receptor (IL-1R). NF-κB refers to a family of transcription factors consisting of p65 
(also known as RelA), c-Rel, RelB, p50 and p52. These molecules all have a C-terminal Rel-
homology domain in common, which mediates their homo- and hetero-dimerisation. p65 and 
c-Rel typically hetero-dimerise with p50, whereas RelB hetero-dimerises with p52 
(Vallabhapurapu & Karin, 2009).  
All TLRs activate NF-κB and all TLRs, except TLR3, recruit myeloid differentiation factor 
99 (MyD88) to do this (Medzhitov et al, 1998). On the other hand, TLR3 recuits TIR 
domain-containing adaptor-inducing IFNβ (TRIF) to activate downstream signalling events 
(see Figure 1.2). NF-κB-activating signalling converges on the IKK complex, consisting of  
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Figure 1.2: Overview of immune signalling pathways leading to NF-κB activation. 
Signalling pathways leading to the activation of NF-κB converge on the canonical IKK 
complex (IKKα, IKKβ, NEMO). This complex phosphorylates IκBα, targeting it for 
degradation by the proteasome, and thus allowing NF-κB components p50 and p65 to 
translocate to the nucleus and bind to the promoter of NF-κB-responsive genes. Signalling 
downstream of thr TLRs, the IL-1R and the TNFR at the cell surface, and downstream of 
TLR3 and TLR4 in endosomes occurs via the TAK1 complex. Signalling downstream of the 
RLRs activates the canonical IKKs via a complex consisting of caspase-8 and -10, whereas 
signalling downstream of NOD1 and NOD2 requires RIP2.  
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the canonical IKKs; IKKα and IKKβ (Zandi et al, 1997) and NF-κB essential modulator 
(NEMO) or IKKγ, a non-enzymatic regulatory component (Rothwarf et al, 1998). Recently 
the crystal structure of xenopus IKKβ was solved and comprises of a kinase domain, a Ub-
like domain (ULD) and an elongated, α-helical scaffold/dimerisation domain (SDD) (Xu et 
al, 2011). The IKKs phosphorylate members of the inhibitor of κB (IκB) family directly, 
which normally sequester NF-κB in an inactive form in the cytosol. The phosphorylation of 
the IκB proteins induces their polyubiquitination, followed by their degradation by the 26 S 
proteasome (Scherer et al, 1995). NF-κB is then free to translocate to the nucleus to induce 
transcription of pro-inflammatory cytokines and IFNβ.  
For TLRs 1, 2, 4 and 6 TIR domain-containing adaptor protein (TIRAP) is required to link 
ligand recognition to MyD88 (Horng et al, 2001). On the other hand, TLR4 is able to activate 
NF-κB via both MyD88-dependent and –independent pathways.  At the cell surface TLR4 
first recruits TIRAP and signals in a MyD88-dependent manner for the first round of 
activation. Following dynamin-dependent endocytosis TLR4 then engages the TIR domain-
containing TRIF-related adaptor molecule (TRAM), which can recruit TRIF for a second 
wave of NF-κB, and also IRF3 signalling (Oshiumi et al, 2003b).  
1.3.2.1 MyD88-dependent signalling 
MyD88-dependent signalling occurs via the recruitment of IL-1R-associated kinase (IRAK) 
family of signalling proteins. IRAK4 is first recruited to MyD88, followed by the activation 
and recruitment of IRAK1 and IRAK2. Recently the crystal structure of the MyD88-IRAK4-
IRAK2 complex was solved and was shown to consist of six molecules of MyD88 and four 
molecules of both IRAK4 and the IRAK2 death domain (Lin et al, 2010). This active 
signalling complex then interacts with TNF receptor-associated factor 6 (TRAF6), an E3 
ubiquitin (Ub) ligase. TRAF6, along with the E2 Ub-conjugating enzymes Ubc13 and 
Uev1A, ubiquitinates itself and IRAK1, forming K63-linked polyUb chains (Deng et al, 
2000). This leads to the recruitment and activation of the transforming growth factor-β (TGF-
β)-activating kinase 1 (TAK1) complex, consisting of the kinase TAK1 and adaptor proteins 
TAB2 and TAB3. The adaptor proteins are essential for this recruitment as they bind Ub 
chains (Kanayama et al, 2004). Active TAK1 then promotes the downstream activation of the 
IKK complex. 
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1.3.2.2 TRIF-dependent signalling 
In the case of TLR3-induced signalling, TRIF interacts directly with the TIR domain of this 
receptor (Oshiumi et al, 2003a). However, downstream of other PRRs an adaptor molecule is 
required to link to TRIF, such as TRAM in the case of TLR4 (Oshiumi et al, 2003b). 
Downstream of TRIF, TRAF6, RIP1 and TNF receptor type 1-associated death domain 
protein (TRADD) are recruited (Meylan et al, 2004). TRIF undergoes K63-linked 
polyubiquitination, activating the TAK1 complex, and further activating NF-κB via the IKK 
complex (see Figure 1.2).  
1.3.2.3 RLR activation of NF-κB 
Signalling downstream of the RLRs is achieved via MAVS, which has a TRAF-interaction 
motif allowing it to interact with TRAF6. A complex containing MAVS, TRADD, Fas-
associated protein with death domain (FADD), caspase-8 and caspase-10 is recruited and this 
activates the IKK complex (Kumar et al, 2006; Takahashi et al, 2006) (see Figure 1.2).  
 1.3.2.4 Other pathways activating NF-κB 
Other than recognition of pathogens by the TLRs and RLRs, engagement of the TNFR and 
IL-1R by their respective ligands initiates a signalling cascade leading to the activation of 
NF-κB. Signalling downstream of the TNFR involves the adaptor proteins TRADD and 
TRAF2. This leads to the activation of RIP, a kinase that can activate the TAK complex, 
subsequently activating the canonical IKK complex. Downstream of the IL-1R a different 
pathway is stimulated. This involves the adaptor MyD88, IRAK1 and IRAK4 and TRAF6, 
which ultimately activates the TAK complex as with TNF signalling (Verstrepen et al, 2008) 
(see Figure 1.2). 
Other stimuli such as lymphotoxin-β (Dejardin et al, 2002), B cell-activating factor belonging 
to the TNF family (BAFF) (Claudio et al, 2002) and CD40L (Coope et al, 2002) trigger NF-
κB activation through an alternative pathway which is dependent on IKKα, but independent 
of IKKβ and NEMO. This signalling cascade uses NF-κB-inducing kinase (NIK) rather than 
TAK1 (Xiao et al, 2004). NF-κB can also be activated downstream of NOD1 and NOD2 via 
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RIP2 and the subsequent activation of the canonical IKK complex (Park et al, 2007) (see 
Figure 1.2).  
1.3.3 The IRF3 signalling pathway 
In response to viral infection IRF3 and IRF7 are the most important transcription factors 
regulating type I IFN expression. IRF3 is expressed at high constitutive levels in most cells 
and is believed to be responsible for the early wave of IFNβ production (reviewed in 
(Taniguchi et al, 2001)). IRF3 shuttles to the nucleus via its nuclear localisation sequence 
(NLS), but due to the existence of a nuclear export signal (NES) it remains mainly 
cytoplasmic at steady state. IRF3 can be activated and induced to translocate to the nucleus 
downstream of a number of PRRs including TLRs 3 and 4, RLRs and cytoplasmic DNA 
sensors. 
IRF3 is activated following phosphorylation by the non-canonical IKKs; TBK1, also known 
as NF-κB-activating kinase and TRAF2-interacting kinase, and IKKε, also known as 
inducible IKK (Fitzgerald et al, 2003; Sharma et al, 2003). Phosphorylation of a 
serine/threonine cluster in the C-terminal region of IRF3 induces a conformational change, 
revealing an IRF-association domain and DNA-binding domain, and allowing IRF3 to 
dimerise and bind to the promoters of IRF3-dependent genes. Phosphorylation also facilitates 
the association of IRF3 with cAMP response element-binding protein (CREB)-binding 
protein (CBP) and p300, further preventing the export of IRF3 to the cytoplasm (Lin et al, 
1999b). A consensus motif in both IRF3 and IRF7 has been identified as a target for 
phosphorylation; SxSxxxS that is targeted by the non-canonical IKKs (Paz et al, 2006). 
Residues in IRF3 whose phosphorylation is critical for activation are Ser386 (Mori et al, 
2004) and also Ser396 in response to stimulation by dsRNA (Servant et al, 2003).  
Downstream of TLRs 3 and 4 the adaptor molecule TRIF recruits the non-canonical IKKs via 
another adaptor molecule TRAF3 (Oganesyan et al, 2006). In addition, TRAF3 links 
signalling downstream of the RLRs to the non-canonical IKKs by interacting with MAVS 
(Saha et al, 2006). The detection of cytosolic DNA downstream of DNA sensors leads to the 
activation of IRF3 in a pathway dependent on STING (Ishikawa et al, 2009) and TBK1 
activation (Ishii et al, 2008). Finally, IRF3 can further be phosphorylated by the kinase Akt, 
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which is activated downstream of phosphatidylinositol-3 kinase (PI3K). TLR3 can be 
phosphorylated on two key tyrosine residues in response to its engagement with dsRNA and 
this recruits PI3K (Sarkar et al, 2004) (see Figure 1.3). 
 1.3.3.1 The non-canonical IKKs 
The structure of the non-canonical IKKs, TBK1 and IKKε, are predicted to be highly similar 
to the canonical IKKs, IKKα and IKKβ. Despite a predicted structural similarity the 
enzymatic properties of these kinases are distinct and these proteins have different substrate 
preferences. In addition, the non-canonical IKKs require phosphorylation at serine 172 in the 
kinase activation loop for the induction of enzymatic activity (Kishore et al, 2002).  
The involvement of the non-canonical IKKs in the phosphorylation of IRF3 took a number of 
years to uncover. Initially TBK1 was described as an NF-κB-activating kinase, based on the 
construction of TBK1-null mice, which died from massive liver apoptosis in utero (Bonnard 
et al, 2000), similar to mice with abrogated NF-κB signalling such as those deficient in p65 
(Beg et al, 1995), IKKβ (Li et al, 1999a; Li et al, 1999b) or NEMO (Rudolph et al, 2000). 
TBK1 was also shown to target IKKβ in vitro (Tojima et al, 2000). Despite this earlier work, 
both non-canonical IKKs were later shown to target IRF3 in vitro (McWhirter et al, 2004).  
IRF3-dependent gene expression and type I IFN production in response to infection with 
Sendai virus (SeV) or NDV, or treatment of cells with dsRNA or LPS was reduced severely 
in TBK1-null MEFs, indicating a crucial role for this protein in IRF3 activation (Hemmi et al, 
2004; McWhirter et al, 2004). On the other hand, MEFs deficient for IKKε showed no defect 
in IRF3 gene induction in these cells, but double knockout MEFs were completely devoid of 
IFN production (Hemmi et al, 2004). The authors concluded that IKKε might account for the 
residual gene expression remaining in TBK1-null MEFs. Supporting this proposal was the 
fact that IKKε partially compensates for the lack of TBK1, suggesting some functional 
redundancy between these two molecules (Hemmi et al, 2004).  
The differential requirement for the non-canonical IKKs in deficient MEFs may be explained 
by the existence of cell-specific roles for these two proteins. Indeed the expression of the 
non-canonical IKKs differs, with TBK1 being constitutively expressed and IKKε expression 
being restricted to immune cells (Perry et al, 2004; Shimada et al, 1999). IKKε expression  
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Figure 1.3: Overview of immune signalling pathways leading to IRF3 activation. 
Signalling downstream of TLRs, RLRs and cytoplasmic DNA sensors converges on the non-
canonical IKKs; TBK1 and IKKε. These PRRs utilise various adaptors but generally require 
TRAF3 to co-ordinate upstream signalling events and the activation of TBK1 and IKKε, 
which in turn phosphorylate IRF3 causing it to dimerise and translocate to the nucleus. The 
adaptors TANK, SINTBAD, NAP1 and DDX3 have all been shown to play a role in 
activating IRF3 and are able to interact with the non-canonical kinases. TLR3 can activate 
IRF3 via an alternative pathway involving the kinases PI3K and Akt.  
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can also be induced in non-haematopoietic cells after pro-inflammatory stimulation and this 
was shown to be NF-κB dependent (Kravchenko et al, 2003). More recently, it has been 
demonstrated that IKKε is required for the transcription of a subset of ISGs because the IFN-
stimulated gene factor 3 (ISGF3) complex, activated downstream of type I IFNs, failed to 
bind to the promoters of the affected genes including Adar1, Ifit3 and Ifi203 in IKKε-
deficient cells. IKKε was found to phophorylate the signal transducer and activator of 
transcription 1 (STAT1) component of ISGF3 and this was required to induce binding to the 
promoters of these ISGs (Tenoever et al, 2007).  
Whilst the composition of the heterodimeric canonical IKK complex has been well described 
and documented, it is currently unclear whether the non-canonical IKKs function in a similar 
manner or whether they function as separate homodimeric complexes. Given their different 
expression patterns and the differential requirement for these kinases in IRF3 activation the 
formation of homodimeric complexes seems more probable. Like the canonical IKKs, the 
non-canonical IKKs also seem to make use of non-enzymatic adaptor proteins. Rather than a 
single regulatory subunit, as is the case for the canonical IKKs, a number of potential adaptor 
proteins have been described to bind TBK1 and IKKε and contribute to IRF3 activation, 
including NF-κB-activating kinase-associated protein 1 (NAP1) (Fujita et al, 2003), similar to 
NAP1 TBK1 adaptor (SINTBAD) (Ryzhakov & Randow, 2007), TANK (Pomerantz & 
Baltimore, 1999) and DEAD box protein 3 (DDX3) (Soulat et al, 2008). This field is still in 
its infancy and although data would suggest that there is a differential requirement for the 
adaptor proteins downstream of distinct ligands, it remains unclear what these exact 
requirements are, which other signalling molecules are involved and whether functional 
redundancy exists. In addition, mechanistic data of how these adaptors might contribute to 
the activation of the kinases and subsequent downstream signalling is lacking. Recently, two 
splice variants of IKKε have been identified that are unable to activate IRF3. Both of these 
splice variants are able to form dimers with full-length IKKε and act in a dominant-negative 
manner (Koop et al, 2011). The lack of IRF3 activation by these molecules is likely due to 
their failure to interact with the adapter proteins TANK, NAP1, and/or SINTBAD, 
highlighting an important role for IKKε adaptor proteins in IRF3 activation.  
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1.3.3.2 TANK 
Like the non-canonical IKKs, TANK, also known as I-TRAF, was thought originally to have 
a role in the NF-κB pathway as a TNFα-induced NF-κB activator (Rothe et al, 1996). TANK 
associated with TRAF2, but when phosphorylated by either of the non-canonical IKKs this 
interaction was lost allowing TRAF2 to activate NF-κB via the canonical IKK complex 
(Nomura et al, 2000; Pomerantz & Baltimore, 1999). Further support for a role for this 
molecule in the NF-κB pathway came from the demonstration that TANK also interacts with 
NEMO (Chariot et al, 2002), an interaction that is regulated negatively by the 
phosphorylation of TANK by IKKβ following TNFα stimulation (Bonif et al, 2006). 
Furthermore the knockdown of TANK by RNA interference (RNAi) reduced the induction of 
a subset of NF-κB target genes in response to TNFα treatment (Bonif et al, 2006; Gatot et al, 
2007). This reduction was only observed for a subset of genes and this may be explained by 
later work from a number of groups indicating that the non-canonical IKKs, in addition to the 
canonical IKKs, contribute to NF-κB activation by directly phosphorylating numerous NF-κB 
family members (Adli & Baldwin, 2006; Harris et al, 2006; Mattioli et al, 2006; Wietek et al, 
2006). TANK may therefore act to connect upstream signals, for example via TRAF2 and/or 
NEMO to the activation of the non-canonical kinases, thus promoting canonical IKK-
independent phosphorylation of NF-κB inhibitory proteins. 
TANK also has an important role in IRF3 activation and interacts constitutively with both 
TBK1 (Pomerantz & Baltimore, 1999) and IKKε (Nomura et al, 2000). TANK knockdown in 
cells infected with SeV exhibited defective IFNβ production (Guo & Cheng, 2007) and 
TANK was important for IRF3 phosphorylation through the TLR4 pathway in LPS-
responsive cells such as macrophages (Gatot et al, 2007). TANK is subject to 
phosphorylation and non-degradative polyubiquitination in a stimulus-dependent manner 
(Gatot et al, 2007). The phosphorylation of TANK is mediated by the non-canonical IKKs 
and these molecules are also required for LPS-mediated TANK polyubiquitination, although 
their kinase activity is dispensable. The E3 ligase involved in this polyubiquitination is yet to 
be identified. Both the non-canonical IKKs have a ULD that is crucial for substrate 
recognition and kinase activity, but this has not been shown to bind to known Ub-binding 
domains so far (Ikeda et al, 2007). 
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In addition to the non-canonical IKKs, TRAF2 and NEMO, TANK interacts with a number 
of other signalling proteins. TANK is known to be part of a trimeric complex including 
TRAF3 and TBK1, which is predicted to link upstream signalling via TRAF3 to the 
activation of the non-canonical IKKs (Gatot et al, 2007). Following viral infection, TANK is 
part of complexes containing MAVS or TRIF, and TRAF3 and TBK1  (Guo & Cheng, 2007). 
Furthermore TANK interacts with the IRFs themselves. Gatot and colleagues found an 
interaction of TANK with IRF3 and also identified IRF7 as a TANK-interacting protein 
through yeast two-hybrid analyses (Gatot et al, 2007). Furthermore they showed that IRF7 
was phosphorylated by a TANK-containing immune complex in macrophages treated with a 
TLR9 ligand. Finally TANK has also been shown to homo-dimerise (Chin et al, 1999; 
Ryzhakov & Randow, 2007). 
Although the structure of TANK is yet to be solved it is predicted to consist of a single 
coiled-coil domain at the N terminus, which may be involved in TANK oligomerisation 
(Chin et al, 1999). A domain in the centre of the molecule is critical for binding to TBK1, 
termed the TBK1-binding domain (TBD). This region is predicted to be α-helical and is 
shared amongst TANK, SINTBAD and NAP1 (Ryzhakov & Randow, 2007). The binding of 
TANK to TRAF2 and TRAF3 involves residues 170 to 191 of TANK (Gatot et al, 2007). At 
the C terminus of TANK there is a Zinc finger domain, which in addition to the N terminus 
of the molecule (residues 31 to 70), is important for binding to NEMO (Gatot et al, 2007) 
(see Figure 1.4).  
1.3.3.3 NAP1 
NAP1 was identified as a TBK1-interacting protein with structural similarity to TANK 
(Fujita et al, 2003). In this study NAP1 over-expression enhanced induction of an NF-κB-
dependent reporter gene, and in vivo depletion reduced this expression. With regards to the 
IRF3 pathway, the knockdown of NAP1 by RNAi revealed a role for this protein in IFNβ 
promoter activation downstream of poly I:C or infection with RSV or VSV (Sasai et al, 2005; 
Sasai et al, 2006). These studies revealed NAP1 to be important downstream of RIG-I, and in 
the TLR3 and TLR4 pathways it acted downstream of TRIF. Furthermore an interaction 
between NAP1 and TRIF has been suggested (Funami et al, 2007; Tatematsu et al, 2010). 
Supporting these findings, RNAi knockdown of NAP1 also caused defects in SeV-induced  
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activation of an interferon-stimulated response element (ISRE) reporter plasmid (Ryzhakov 
& Randow, 2007). NAP1 also binds to nuclear dot protein 52 kDa (NDP52), an autophagy 
receptor that binds to Ub-coated Salmonella typhirium (Thurston et al, 2009). The binding of 
NAP1 to NDP52 links the detection of S. typhirium to TBK1. NAP1 consists of three N-
terminal coiled-coil regions and a TDB, but lacks a C-terminal Zinc finger domain (see 
Figure 1.4). Like TANK it is able to oligomerise, and also showed some weak interaction 
with SINTBAD, but not TANK (Ryzhakov & Randow, 2007). 
1.3.3.4 SINTBAD 
SINTBAD is the most recently identified of the three related adaptors. Like NAP1 and 
TANK, SINTBAD binds constitutively to both IKKε and TBK1 via its TBD and is believed 
to have a role in IRF3 activation because RNAi knockdown of this protein led to a reduction 
in ISRE reporter activity following infection of cells with SeV (Ryzhakov & Randow, 2007). 
Like NAP1, SINTBAD binds to NDP52, thus contributing to the immune response to 
infection by Salmonella spp. (Thurston et al, 2009). SINTBAD consists of three N-terminal 
coiled-coil regions, a TBD, a proline-rich region and two C-terminal Zinc finger domains 
(see Figure 1.4). Like the other related adaptors it is able to oligomerise, and also showed 
some weak interaction with NAP1, but not TANK (Ryzhakov & Randow, 2007). 
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Figure 1.4: Domain composition of TANK, SINTBAD and NAP1. Schematic 
representation of the domain composition of the three related non-canonical IKK complex 
adaptor proteins. CC: coiled-coil, TBD: TBK1-binding domain, TRAF: region where the 
interaction with TRAF2 and TRAF3 has been mapped, ZnF: Zinc finger domain.  
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1.3.3.5 DDX3 
DDX3 is a member of the DEAD-box helicase family whose members have roles in a wide 
variety of RNA-related cellular processes, including RNA splicing, mRNA export, 
transcriptional and translational regulation, RNA decay and ribosome biogenesis (Rocak & 
Linder, 2004). This protein was also implicated in innate immune signalling by its 
identification as a host binding partner for VACV protein K7, an inhibitor of IFNβ induction 
downstream of multiple PRRs (see 1.4.5.1.5) (Schroder et al, 2008). DDX3 was shown to 
associate transiently with IKKε after virus stimulation and knockdown of this protein by 
RNAi led to a decreased induction of the IFNβ promoter and IRF3/7-mediated 
transactivation. Furthermore, DDX3 was identified as a TBK1 phosphorylation target and 
associated with the IFNβ promoter after PRR stimulation, suggesting an additional role for 
this protein as a transcriptional cofactor. (Soulat et al, 2008). Recently, DDX3 was identified 
in a yeast two-hybrid screen as a protein that interacts with the CARD domain of MAVS, 
implicating it in the signalling pathway downstream of the RLRs (Oshiumi et al, 2010). Like 
all DEAD-box helicases, DDX3 binds to RNA and potentially also to DNA (Franca et al, 
2007). Oshiumi et al thus suggest that DDX3 acts as a sensor of viral RNAs and interacts 
with the RLRs, RIG-I and MDA5 (Oshiumi et al, 2010). Unlike RIG-I, the constitutive levels 
of DDX3 are relatively high and therefore the authors suggest that DDX3 senses viral RNA 
and facilitates signalling through MAVS at the very early stages of infection when RIG-I 
levels are low. Data implicating the role of this protein to the activation of type I IFN in vivo 
is currently lacking. 
1.3.4 Crosstalk of the IKKs and immune regulation 
It has become apparent over recent years that although the canonical IKKs and the non-
canonical IKKs have unique physiological substrates, such as IκBα, p105 and RelA for the 
canonical IKKs, and IRF3 for the non-canonical IKKs, they also share some common 
substrates such as NEMO and TANK (Clark et al, 2011). In addition, a number of molecules 
now known to have an important role in IRF3 activation were first identified as having roles 
in NF-κB signalling. For example, TBK-1 was characterised as an IKK homologue involved 
in TNFα-mediated NF-κB activation (Bonnard et al, 2000; Pomerantz & Baltimore, 1999), 
acting upstream of IKKβ (Tojima et al, 2000). Both TANK (Rothe et al, 1996) and NAP1 
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(Fujita et al, 2003) were also shown to play a role in NF-κB dependent gene transcription. 
Indeed, the canonical IKKs can directly phosphorylate and activate the non-canonical IKKs 
(Clark et al, 2011; Tenoever et al, 2007), whereas the non-canonical IKKs phosphorylate both 
the canonical IKKs and the regulatory subunit NEMO, which is associated with reduced IKK 
activity and NF-κB-dependent gene transcription (Clark et al, 2011). This is an example of 
how the activation of one pathway can impact negatively on the activation of another 
pathway, which is an important mechanism contributing to immune regulation. A direct link 
between the two pathways was also provided when the interaction between TANK and 
NEMO was discovered (Chariot et al, 2002; Zhao et al, 2007).  
In addition to crosstalk between the IKK complexes, the NF-κB and IRF3 signalling 
pathways also share some common molecules. A20 regulates negatively both signalling 
pathways by promoting the K48-linked degradative polyubiquitination of RIP1 (Wertz et al, 
2004) and preventing IRF3 dimerisation through direct binding to the non-canonical IKKs 
(Saitoh et al, 2005). TRAF3 on the other hand positively regulates TLR- and RLR-dependent 
IRF3 activation, but negatively regulates the alternative NF-κB pathway involving NIK and 
IKKα (Hauer et al, 2005). 
1.3.5 Other IRFs in innate immunity 
Another transcription factor important for the induction of the type I IFNs is IRF7. Unlike 
IRF3, IRF7 is present at much lower levels in uninfected or unstimulated cells, but its 
expression can be induced following infection or stimulation with poly I:C. Several pathways 
contribute to the activation of IRF7. TBK1 and IKKε are able to phosphorylate and activate 
IRF7 in a manner very similar to IRF3 and therefore ligands that activate these non-canonical 
IKKs activate IRF7 subsequently (Sharma et al, 2003). In pDCs an alternative pathway of 
IRF7 activation exists and IRF3 is dispensable for the induction of type I IFNs (Honda et al, 
2005). These cells express much higher levels of IRF7 than monocyte-derived DCs (Izaguirre 
et al, 2003) and when stimulated with TLR7 and TLR9 PAMPs, IKKα is induced to 
phosphorylate and activate IRF7. This pathway involves the signalling proteins MyD88, 
IRAK1, IRAK4 and TRAF6 (Kawai et al, 2004). Other proteins such as osteopontin (a 
protein induced after stimulation with TLR9), PI3K, mTOR and p70S6K also play critical 
roles in IRF7 activation. 
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IRF5 may also play an important role in the production of pro-inflammatory cytokines. 
Induction of TNF, IL-6 and IL-12 by various TLR ligands was impaired severely in a number 
of cell types from IRF5-deficient mice (Takaoka et al, 2005).  
1.3.6 MAPK signalling pathways 
A further pathway that can be activated downstream of PRRs is the MAPK pathway, which 
leads to the activation of key transcription factors such as activating transcription factor 2 
(ATF-2) and c-JUN, which together form AP-1 and contribute to the transcription of IFNβ. 
MAPKs are a family of serine/threonine kinases that require phosphorylation on both 
threonine and tyrosine residues to be activated. Phosphorylation of MAPKs occurs via an 
ordered signalling cascade where MAPK kinases (MAP2Ks) phosphorylate and activate 
MAPKs, and MAPK kinase kinases (MAP3Ks) phosphorylate MAP2Ks (Kyriakis & Avruch, 
2001).  
MAPKs are activated by signalling downstream of TLRs via TAK1. In addition to activating 
the canonical IKK complex, TAK1 (a MAP3K) can phosphorylate and activate the MAP2Ks, 
MKK3 and MKK6. These kinases act upstream of p38 MAPKs and c-Jun NH2-terminal 
kinase (JNK), which then activate AP-1 (Holtmann et al, 2001). MAPKs are also activated 
downstream of the RLRs, a pathway that requires MAVS, TRAF6 and the MAP3K MEKK1 
(Yoshida et al, 2008). Other transcription factors activated by the MAPK signalling pathway 
are c-Fos, Elk-1 and c-Myc (Kyriakis & Avruch, 2001). 
1.3.7 IFNs 
IFNs are cytokines that induce an antiviral state and can inhibit viral growth. IFN genes have 
been cloned from mammals, birds and fish, and some IFN-like activity has also been detected 
in amphibians (Schultz et al, 2004). In mammals the IFNs are divided into three types. 
 1.3.7.1 Type I IFNs 
Type I IFNs include numerous IFNα proteins and a single IFNβ protein. The expression of 
these IFNs can be induced in most cell types. In addition IFNω, IFNε, IFNκ, IFNτ and IFNξ 
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are also type I IFNs but are expressed in a cell-type and species-specific manner. pDCs are 
the major producers of IFNα, and expression requires the activation of IRF7 (Honda et al, 
2005). Transcription of IFNβ requires the formation of a large multi-protein complex called 
the enhanceosome, comprising several transcription factors, structural components such as 
the architectural protein HMG I(Y), which binds to the nucleosome-free positive regulatory 
domains of the promoter (Merika & Thanos, 2001), and basal transcription machinery 
(Agalioti et al, 2000; Thanos & Maniatis, 1995). The transcription factors required for IFNβ 
transcription are NF-κB, IRFs, in particular IRF3 and AP-1.  
All type I IFNs bind the heterodimeric IFNα/β receptor (IFNAR) consisting of IFNAR1 and 
IFNAR2c. Upon engagement of the IFNAR a Janus tyrosine kinase (JAK)-STAT signalling 
pathway is initiated. The JAKs TYK2 and JAK1 are first recruited, phosphorylating each 
other and then the transcription factors STAT1 and STAT2.  The STATs forms a heterodimer 
and associate with IRF9, forming the ISGF3 complex. This then translocates to the nucleus 
and binds to the promoter of ISGs with an ISRE (see Figure 1.5). Importantly, type I IFNs 
contribute to DC and macrophage activation and the up-regulation of MHC class I molecules 
(Fensterl & Sen, 2009). 
1.3.7.2 Type II IFN 
IFNγ is the only type II IFN and is mainly produced by activated T cells and NK cells. It is 
unrelated to the type I IFNs and is not produced in direct response to PAMPs. Instead IFNγ 
production is stimulated by IL-12 and IL-18 (which was called IFN-inducing factor 
originally), two cytokines produced by activated macrophages. IFNγ induction requires the 
transcription factors NF-κB, AP-1 and nuclear factor of activated T cells (NFAT). This IFN 
uses the heterodimeric IFNγ receptor (IFNGR) to initiate a signalling cascade. Dimeric IFNγ 
binds to IFNGR1, resulting in a complex that is stabilised by IFNGR2. In this instance the 
JAK-STAT pathway involves JAK1 and JAK2, which phosphorylate STAT1 inducing it to 
homodimerise and form the gamma-activated factor (GAF). This complex then translocates 
to the nucleus and binds to ISGs with a gamma-activated site (GAS) (Fensterl & Sen, 2009) 
(see Figure 1.5). The expression of type II IFN contributes to the transition from innate to 
adaptive responses by inducing the transcription factors IRF1 and CIITA, which govern 
MHC class II expression. In addition IFNγ regulates NK and B cell functions and  
60 
 
  
cytoplasm
nucleus
P
IF
N
A
R
2
IL
-1
0
R
IL
-2
8
R
IF
N
A
R
1
JAK2
IF
N
G
R
1
STAT1 STAT2
IRF9
ISRE
GAS
IF
N
G
R
2
JAK1
STAT1 STAT1
P P
P
JAK1JAK1 TYK2TYK2
P
STAT1 STAT2
P
IFNγIFNλIFNα/β
Figure 1.5: Overview of the intracellular signalling cascades induced by the IFNs. The 
binding of IFNα or IFNβ to the IRNAR (consisting of IFNAR1 and IFNAR2), and the 
binding of IFNλ to the heterodimeric IL-10R/IL28R initiates JAK-STAT signalling cascades 
involving JAK1 and TYK2. Once activated, these kinases phosphorylate STAT1 and 
STAT2, which can then interact with IRF9 to form the ISGF3 complex. This translocates to 
the nucleus to induce the expression of ISRE-dependent genes. The binding of IFNγ to the 
IFNGR (consisting of IFNGR1 and IFNGR2) on the other hand initiates a cascade involving 
JAK1 and JAK2, which phosphorylate STAT1, causing it to homo-dimerise and form the 
GAF complex. This then translocates to the nucleus, inducing the expression of GAS-
dependent genes.  
 
61 
 
macrophage activation (reviewed in (Schroder et al, 2004)). IFN is an important cytokine 
promoting the TH1 cell-mediated adaptive immune response.  
 1.3.7.3 Type III IFNs 
The type III IFNs comprise IFNλ1, 2 and 3, also known as IL-29, IL-28A and IL-28B 
respectively. These IFNs, like the type I IFNs are produced by most cell types in response to 
infection, and particularly by epithelial cells. Upon binding of a type III IFN to the 
heterodimeric IFNλ receptor, also known as IL10R2, a JAK-STAT signalling cascade is 
initiated, identical to that induced by the type I IFNs, leading to the activation of ISGF3 and 
its subsequent binding to the ISRE of ISGs (Fensterl & Sen, 2009) (see Figure 1.5). 
1.3.8 Actions of ISGs 
ISGs encode proteins that can directly impact on viral clearance, bring about an antiviral state 
in the cell and regulate the induction of an adaptive immune response. In addition ISGs 
include innate immune molecules such as RIG-I, TLR3, DAI, IRF7 and STAT1, whose up-
regulation leads to an increased sensitivity of cells to PAMPs.  Numerous ISRE-driven genes 
can be induced by virus-activated IRF3 directly due to sequence similarity in IRF elements 
and ISREs, providing an immediate ISG induction in infected cells (Andersen et al, 2008; 
Elco et al, 2005). 
 1.3.8.1 PKR 
dsRNA-activated protein kinase (PKR) is constitutively expressed at low levels in many cell 
types and its expression is up-regulated rapidly by IFN. PKR becomes activated upon binding 
to dsRNA, causing dimerisation and autophosphorylation. Active PKR then phosphorylates 
translation initiation factor 2α (eIF2α), thus inhibiting all protein synthesis (Balachandran et 
al, 2000). PKR also inhibits the replication of RNA viruses such as VSV, 
encephalomyocarditis virus (EMCV) and hepatitis C virus, as well as the DNA virus HSV-1. 
Further PKR has been identified as a regulator of cytokine expression following viral 
infection or treatment of cells with poly I:C (Gilfoy & Mason, 2007; Silva et al, 2004). 
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 1.3.8.2 2‟-5‟-OAS 
2‟-5‟-Oligoadenylate synthetases (2‟-5‟-OAS) also require binding to dsRNA for activation. 
These enzymes synthesise 2‟-5‟-linked adenosine monophosphate (AMP)-oligomers from 
adenosine triphosphate (ATP), and these activate the latent ribonuclease, RNAseL. Upon 
activation, this enzyme dimerises and cleaves both cellular and viral ssRNA, thus inhibiting 
protein expression (Silverman, 2007). This has been demonstrated to be particularly effective 
against EMCV and influenza A virus infections. The cleavage products of RNAse L also act 
as ligands for RIG-I, further activating the innate immune response (Malathi et al, 2007). 
 1.3.8.3 MxA 
Human MxA accumulates at cellular membranes around the nucleus, binds to viral 
nucleocapsids and inhibits viral intracellular trafficking. It is a particularly important defence 
mechanism against infection with influenza virus, measles virus, VSV and Semliki Forest 
virus. MxA forms a ring-like structure that surrounds the influenza virus nucleocapsid and 
inhibits viral trafficking, transcription and genome replication (Haller & Kochs, 2011). 
 1.3.8.4 APOBEC3 proteins 
APOBEC3F and APOBEC3G are deoxycytidine deaminases and thus nucleic acid-editing 
enzymes. These proteins play an important role in inhibiting retroviruses by introducing C to 
U mutations in viral reverse transcribed DNA, or by directly interfering with reverse 
transcription (Aguiar & Peterlin, 2008; Bishop et al, 2004). 
1.3.8.5 ISG15  
ISG15 is a Ub-like protein that can be attached to a number of molecules involved in the 
innate immune response including JAK1, STAT1, RIG-I, PKR and RNase L (Zhao et al, 
2005). ISG15 plays an important role in modulating signalling cascades much like K63-
linked ubiquitination. The addition of ISG15 to IRF3 prevents its degradation and therefore 
enhances the IFN response (Lu et al, 2006).  VACV Western Reserve (WR) infection is 
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enhanced in ISG15-null MEFs suggesting an important role for this protein in controlling 
poxviral infection (Guerra et al, 2008).  
1.4 VACV and modulation of the immune response 
1.4.1 VACV-specific immunity and detection 
An extensive study in both human and mouse macrophages demonstrated that MDA-5, 
TLR2-TLR6 and the NALP3 inflammasome play an important role in the response to 
infection by VACV strain MVA. Deletion or knockdown of any of these components by 
RNAi led to a large defect in the production of IFNβ and pro-inflammatory cytokines and 
chemokines. MAVS was also demonstrated to contribute to MVA detection in these cells, but 
RIG-I was found to be dispensable (Delaloye et al, 2009). In addition, the cytoplasmic DNA 
sensors IFI16 (Unterholzner et al, 2010) and DNA-PK (B. Ferguson et al, submitted) 
contribute to IFNβ induction in response to infection with VACV strain MVA.  
Both type I (Rodriguez et al, 1991) and type II (Huang et al, 1993) IFNs are crucial for the 
restriction of poxviral infections and mice deficient in IFN receptors are highly susceptible to 
VACV infection (van den Broek et al, 1995).  In addition, type III IFN plays an important 
role against VACV in vivo because recombinant VACVs strain WR expressing either IFN-λ2 
or IFN-λ3 were attenuated in a mouse intranasal (i.n.) infection model (Bartlett et al, 2005). 
In addition, cells of the innate immune system play a critical role in poxvirus infection. Mice 
depleted of macrophages are unable to control ectromelia virus (ECTV) infection due to 
impaired virus clearance and antigen presentation (Karupiah et al, 1996). Furthermore, NK 
cells have a direct cytotoxic activity against VACV-infected cells in vitro (Brutkiewicz et al, 
1992) and depletion of these cells in vivo increased disease caused by VACV (Bukowski et 
al, 1983). During VACV infection, complement is activated via the alternative pathway 
(Leddy et al, 1977) and IMV is sensitive to complement in the absence of Ab. 
To establish a productive infection VACV must therefore counteract the innate immune 
response. The activation of NF-κB, IRFs and MAPKs leading to the induction of IFNs and 
inflammation clearly contributes to controlling infection because VACV has evolved a 
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multitude of mechanisms to counteract this. Not only does VACV inhibit the induction of 
these inflammatory mediators, their actions and the recruitment of immune cells, it also has 
measures to inhibit apoptosis and complement. 
1.4.2 Inhibition of apoptosis 
Several poxviral proteins have anti-apoptotic functions. The serine protease inhibitor 
(serpins) are a group of enzymes that regulate the function of several proteolytic enzymes 
involved in a range of cellular processes such as complement activation, inflammation and 
apoptosis. VACV encodes three serpins; SPI-1 (protein B22) and SPI-2 (protein B13) and 
SPI-3 (protein K2). SPI-2 has been described to inhibit apoptosis triggered by TNFα or Fas 
ligand, and inhibits caspase-1 function (Kettle et al, 1997). The CPXV orthologue of SPI-2, 
cytokine response modifier (Crm)A, in addition to inhibiting caspase-1 (Ray et al, 1992) is 
also a potent inhibitor of caspase-8 (Zhou et al, 1997). Furthermore, CrmA binds granzyme 
B, thus inhibiting apoptosis induced by lytic granules released by CTLs (Quan et al, 1995). 
Deletion of the rabbitpox virus (RPXV) counterpart of SPI-1 caused A459 cells to undergo 
apoptosis, suggesting that this viral serpin may also contribute to apoptosis inhibition (Brooks 
et al, 1995).   
Deletion of the CPXV gene encoding the protein CP77 caused Chinese hamster ovary (CHO) 
cells infected by the CPXV deletion mutant to undergo apoptosis whereas CHO cell infected 
by WT CPXV did not, indicating a role for this protein in the inhibition of apoptosis 
(Ramsey-Ewing & Moss, 1998). Furthermore the deletion of E3, a host range factor, led to 
accelerated apoptosis in restricted cells (Kibler et al, 1997). Protein F1, which adopts a Bcl-2 
fold, exerts its anti-apoptotic function by binding to a subset of BH3-containing death ligands 
and subsequently interfering with cytochrome c release (Kvansakul et al, 2008; Stewart et al, 
2005). This protein also inhibits caspase-9 (Zhai et al, 2010). A second VACV protein that 
adopts a Bcl-2 fold and inhibits apoptosis is N1, which binds a subset of cellular pro-
apoptotic Bcl-2 proteins (Cooray et al, 2007). In addition, myxoma virus expresses a protein 
with a Bcl-2 fold, M11 (Douglas et al, 2007), which also has a role in apoptosis inhibition 
(Everett et al, 2000). Viral Golgi anti-apoptotic protein (vGAAP) is able to protect cells from 
apoptosis induced by both intrinsic and extrinsic pathways (Gubser et al, 2007). 
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1.4.3 Inhibition of soluble immune factors 
1.4.3.1 Inhibition of cytokine activity 
The first viral cytokine receptor or binding protein to be identified was from a poxvirus. The 
Shope fibroma counterpart of VACV protein A53 is a soluble TNF receptor that binds TNFα 
and inhibits its actions (Smith et al, 1991a). In the same year, two proteins from VACV strain 
WR were shown to be related to the IL-1 receptor (Smith & Chan, 1991) and, subsequently, 
one of these (B15) was shown to be a secreted protein that bound IL-1β (Alcami & Smith, 
1992; Spriggs et al, 1992). This protein is specific for IL-1β, and did not bind IL-1 or the 
IL-1 receptor antagonist protein, a selectively which later led to the characterisation of IL-1β 
as the major endogenous pyrogen activated during a poxvirus infection (Alcami & Smith, 
1996). Further, the myxoma virus counterpart of VACV protein B8 is a soluble IFNγ receptor 
(Upton et al, 1992) (see Figure 1.6). All of these proteins have sequence similarity to the 
extracellular binding domains of the host cytokine receptors, but lack the transmembrane and 
signalling domains. VACV B18, which can be secreted or surface bound encodes a type I 
IFN binding protein (Colamonici et al, 1995; Symons et al, 1995) (see Figure 1.6), whereas 
as protein C12 binds to IL-18 and blocks its activity (Smith et al, 2000). C12 is related to 
both the human and mouse IL-18 binding proteins, which regulate IL-18 activity negatively 
by preventing IL-18 from binding to its receptor and inducing IFNγ induction (Novick et al, 
1999). VACV protein A39 is a viral semaphorin that is secreted and binds to a virus encoded 
semaphorin receptor in macrophages, inducing the expression of cytokines (Comeau et al, 
1998). This protein therefore has a pro-inflammatory effect in these cells. A39 binds to the 
semaphorin receptor plexin C1 found on DCs and inhibits integrin-mediated adhesion and 
spread, including phagocytosis (Walzer et al, 2005). 
1.4.3.2 Chemokine inhibition 
A number of poxviruses express a viral CC chemokine inhibitor (vCCI), which is unrelated to 
any known cellular proteins but binds CC chemokines with a high affinity (Lalani & 
McFadden, 1997; Smith et al, 1997a). vCCI is secreted from infected cells, binds to multiple 
CC chemokines including CCL2, CCL3, CCL5 and CCL11 and inhibits their functions 
(Alcami et al, 1998). The expression of vCCI inhibits eosinophil recruitment (Alcami et al, 
1998) and leukocyte recruitment in vivo leading to decreased morbidity of mice and reduced  
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binding protein, which binds IFNα and IFNβ, thus preventing them from engaging the 
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weight loss from VACV infection (Reading et al, 2003). VACV protein A41 shares some 
sequence similarity with vCCI and also binds to CC chemokines including CCL21, CCL25, 
CCL26 and CCL28 (Bahar et al, 2008). This glycoprotein is non-essential for replication but 
is a virulence factor in vivo (Ng et al, 2001).  
1.4.3.3 Inhibition of complement 
Protein C21, or VACV complement control protein (VCP) provides an effective 
countermeasure against the effects of complement during a VACV infection. C21 binds to 
both C3b and C4b, accelerating their decay and thus inhibiting both the classical and 
alternative complement pathways (Kotwal et al, 1990; Sahu et al, 1998). This protein shows 
amino acid similarity to human complement regulators such as factor H and C4b-binding 
protein. Functional studies demonstrated that VCP protects virions from Ab-dependent 
complement-mediated neutralization, and mutant viruses lacking this gene are attenuated in 
vivo (Isaacs et al, 1992). VACV incorporates the host complement proteins CD46, CD55 and 
CD59 into the EEV outer membrane, thus rendering it resistant to complement attack 
(Vanderplasschen et al, 1998). 
1.4.4 Inhibition of inflammasomes 
VACV WR protein B13/SPI-2 blocks caspase-1 activity and therefore inhibits 
inflammasome-mediated cleavage of proIL-1β or pro-IL18 (Dobbelstein & Shenk, 1996; 
Kettle et al, 1997). Myxoma protein M13, a PYD-containing protein, is also able to inhibit 
inflammasome activity by binding to ASC via a PYD-PYD interaction. This then inhibits 
caspase-1 activation with a similar downstream effect to SPI-2 (Johnston et al, 2005). A 
homologue of this protein is found in Shope fibroma virus (S013), but not in other poxviruses 
(Dorfleutner et al, 2007).  
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1.4.5 Evasion of intracellular innate immune signalling cascades 
 1.4.5.1 The VACV Bcl-2 family 
Originally, VACV strain WR protein N1 was described as a secreted protein that contributes 
to virulence (Kotwal et al, 1989) but was shown subsequently to be an intracellular homo-
dimer (Bartlett et al, 2002). Later N1 was described as an inhibitor of intracellular signalling 
pathways leading to the activation of IRF3 and NF-κB (DiPerna et al, 2004). In 2007 the 
crystal structure of N1 was determined and revealed a Bcl-2 fold (Aoyagi et al, 2007; Cooray 
et al, 2007). Cooray et al also demonstrated that the N1 protein had anti-apoptotic activity 
(Cooray et al, 2007). The following year structural studies revealed VACV proteins B14, A52 
(Graham et al, 2008), K7 (Kalverda et al, 2008) and F1 (Kvansakul et al, 2008) also had Bcl-
2 structures. Although F1 was found to have anti-apoptotic properties (Kvansakul et al, 
2008), B14 and A52 lacked this function (Graham et al, 2008). Structural analyses identified 
a surface groove in cellular anti-apoptotic Bcl-2 proteins that binds BH3 peptides (Youle & 
Strasser, 2008) and a similar groove is conserved in proteins N1 and F1 (Cooray et al, 2007, 
Kvansakul et al., 2008). This groove is lacking in B14 and A52 and hence they are not anti-
apoptotic (Graham et al., 2008). Instead these proteins (Bowie et al, 2000; Chen et al, 2008), 
in addition to K7 (Schroder et al, 2008) interfere with intracellular immune signalling 
cascades (see Figures 1.7 and 1.8).  
Phylogenetic analysis indicates that these genes may have arisen from the acquisition of an 
ancestral mammalian gene encoding an anti-apoptotic Bcl-2 protein, followed by gene 
duplication and diversification, allowing these Bcl-2 proteins to inhibit innate immune 
signalling cascades rather than apoptosis (Graham et al, 2008). Interestingly phylogenetic 
analysis places N1, which is both anti-signalling and anti-apoptotic, as an evolutionary 
intermediate between F1, which is anti-apoptotic and does not have anti-signalling capacity, 
and B14 and A52 which are only anti-signalling. Subsequently, structural-based predictions 
indicated that VACV encodes additional Bcl-2-like proteins including A46, C6, C1, C16/B22 
and N2 (Gonzalez & Esteban, 2010; Graham et al, 2008), of which A46 had also already 
been described to inhibit NF-κB activation (Bowie et al, 2000).  
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Figure 1.7: VACV inhibition of NF-κB activation. NF-κB activation is inhibited by 
VACV at multiple steps. E3 can bind RNA and sequester it from detection by the RLRs. 
A46 interacts with the TIR-containing adaptors TRAM, TRIF, TIRAP and MyD88 
inhibiting downstream signalling cascades. A52 on the other hand interacts with IRAK2 and 
TRAF6. N1 is thought to inhibit NF-κB activation by targeting the TAK1 complex (C. 
Maluquer de Motes, unpublished results). B14 binds IKKβ, preventing the subsequent 
phosphorylation of IκBα, whereas K1 acts to inhibit IκBα degradation by the proteasome. 
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1.4.5.1.1 N1 
N1L is an early gene (Assarsson et al, 2008; Bartlett et al, 2002). It is expressed as an 
intracellular homo-dimer that is non-essential for replication in vitro, but is a virulence factor 
as a virus lacking this gene is attenuated in both the i.n. and intradermal (i.d.) models of 
murine infection (Bartlett et al, 2002). Subsequently N1 was described to bind to both the 
canonical and non-canonical IKK complexes, thus inhibiting IRF3 and NF-κB activation 
(DiPerna et al, 2004). Although binding to these kinase complexes and inhibition of IRF3 has 
not been reproduced in our laboratory, N1 inhibits NF-κB activation downstream of both 
TNFα and IL-1β, although this action is upstream of the IKK complex (C. Maluquer de 
Motes, unpublished results, see Figure 1.7). N1 clearly has immunomodulatory functions in 
vivo because a stronger NK cell response was observed following infection with a virus 
lacking N1 expression (Jacobs et al, 2008) and the ECTV counterpart of N1 has been 
described to contribute to spread in vivo and may modulate T cell function (Gratz et al, 2011).  
1.4.5.1.2 B14 
Like N1, B14 is also expressed early during infection (Assarsson et al, 2008; Chen et al, 
2006a) and is a potent inhibitor of NF-kB activation downstream of multiple pathways (Chen 
et al, 2008). This is achieved by the binding of B14 to IKKβ, which inhibits the 
phosphorylation of IKKβ in its activation loop (Chen et al, 2008) (see Figure 1.7). Like N1, 
B14 is also a virulence factor because a virus lacking this gene was attenuated in the i.d. 
model of murine infection, characterised with an increased infiltration of cells into the 
infected lesion (Chen et al, 2006a). This protein forms homo-dimers in the crystal (Graham et 
al, 2008), but this dimerisation was not required for functionality or binding to IKKβ and in 
fact the dimerisation and IKKβ-binding interfaces were found to overlap (Benfield et al, 
2011). The MVA version of VACV WR B14, called 183, lacks an internal 6 amino acids that 
cause the protein to be unstable and to be unable to inhibit NF-B activation (McCoy et al, 
2010). 
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 1.4.5.1.3 A52 
A52 blocks both IL-1- and TLR4-mediated NF-κB activation (Bowie et al, 2000) and also 
contributes to virulence (Harte et al, 2003). Later work showed A52 inhibited NF-κB 
activation by TLR2, -3, -4, -5, -7, and -9 ligands via its interaction with IRAK2, but it did not 
inhibit IRF activation (Keating et al, 2007). In addition to IRAK2, A52 also interacts with 
TRAF6 (Harte et al, 2003) (see Figure 1.7), which leads to the activation of MAPK p38 and 
subsequently the IL-10 promoter (Maloney et al, 2005). IL-10 is an important cytokine for 
determining viral persistence in vivo (Brooks et al, 2006). Like B14, A52 is expressed very 
early after infection (Assarsson et al, 2008; Harte et al, 2003) and is a dimer in the crystal 
(Graham et al, 2008). 
 1.4.5.1.4 A46 
A46 is expressed early during VACV infection (Assarsson et al, 2008; Stack et al, 2005) and 
inhibits NF-κB activation (Bowie et al, 2000). It interacts with several TIR domain-
containing cellular proteins including MyD88, TIRAP, TRIF and TRAM allowing it to 
inhibit NF-κB downstream of multiple TLRs (Stack et al, 2005) (see Figure 1.7). Because it 
interacts with TRIF, A46 was also described to inhibit IRF3 activation downstream of TLR3 
and TLR4 (see Figure 1.8). Further, A46 contributes to virulence in the i.n. model of murine 
infection (Stack et al, 2005). A small peptide from A46, termed viral inhibitor peptide of 
TLR4 (VIPER) inhibits TLR4 activation and thus has potential therapeutic use (Lysakova-
Devine et al, 2010). 
1.4.5.1.5 K7 
K7 was identified as an inhibitor of TLR- and RLR-mediated IRF3 and IRF7 activation, and 
hence IFNβ induction. This function is presumed to be exerted by the binding of K7 to the 
cellular protein DDX3 (Schroder et al, 2008) (see Figure 1.8). This is a direct interaction and 
the binding site for K7 on DDX3 was narrowed down to the N-terminal region (Schroder et 
al, 2008). A crystal structure of K7 in complex with this DDX3 was solved and gave insight 
into the role of DDX3 in TBK1-mediated activation of IRF3 and IRF7 (Oda et al, 2009). Like 
the other Bcl-2 family members described above, K7 is expressed early after infection 
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(Assarsson et al, 2008), but nuclear magnetic resonance (NMR) (Kalverda et al, 2008) and 
crystallographic (Oda et al, 2009) structural analysis found it to be a monomer rather than a 
dimer.  
 1.4.5.2 Inhibitors of PKR 
Two VACV proteins have been described that affect PKR activation. K3 prevents eIF2α 
phosphorylation and autophosphorlyation of PKR (Davies et al, 1992). E3 on the other hand 
binds and sequesters dsRNA, thus preventing it from activating PKR and any other RNA 
sensors that bind dsRNA such as MDA5 (Chang et al, 1992) (see Figures 1.7 and 1.8). In 
addition E3 inhibits the expression of cytokines, including IFNβ and TNFα in both a PKR-
dependent and -independent manner, involving the inhibition of both NF-κB and IRF3 
pathways (Myskiw et al, 2009). 
1.4.5.3 Other inhibitors of NF-κB 
A number of other proteins in addition to Bcl-2 family members N1, B14, A52 and A46 have 
also been characterised to have roles in NF-κB inhibition. K1 is a host range factor that 
inhibits the activation of NF-κB by preventing IκBα degradation (Shisler & Jin, 2004) (See 
Figure 1.7). On the other hand, M2 inhibits the phosphorylation of ERK2, thus preventing the 
activation of NF-κB via the MAPK pathway (Gedey et al, 2006). M2 was found to localise 
with cellular ER proteins, and this localisation was essential for its ability to inhibit NF-κB 
(Hinthong et al, 2008).  E3 has also been shown to inhibit NF-κB activation in a PKR-
dependent and –independent manner (Myskiw et al, 2009), as well as by inhibiting the RNA 
polymerase III-mediated dsDNA-sensing pathway (Myskiw et al, 2009; Valentine & Smith, 
2010). 
1.4.5.3 Inhibitors of IFN signalling 
VACV protein VH1 is a phosphatase with the ability to dephosphorylate STAT proteins. This 
protein dephosphorylates both STAT1 and STAT2, but not other STATs, following the 
stimulation of cells with type I and type II IFNs (Mann et al, 2008; Najarro et al, 2001) (see 
Figure 1.6). VH1 is packaged within virions (Liu et al, 1995) suggesting that the immediate 
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inhibition of IFN signalling prior to gene expression may be beneficial to the virus. Some 
ISGs are transcribed in a STAT1-independent manner, although the factors that are required 
for this are currently not well understood. Nevertheless, VACV also has the ability to block 
the transcription of some STAT1-independent genes and the viral protein(s) responsible for 
this inhibition remain to be characterised (Mann et al., 2008). 
1.4.5.4 Inhibitors of DNA sensing 
VACV protein E3 can be split into distinct N- and C-terminal halves. The C terminus of E3 
contains a dsRNA-binding domain that serves to sequester dsRNA produced during viral 
replication and prevent the activation of PKR and other RNA sensors (see 1.4.5.2). The N 
terminus, on the other hand, contains a region with amino acid similarity to the Z-DNA-
binding domain of DAI. Subsequently E3 can inhibit IFNβ induction in response to DNA by 
preventing the activation of DAI (Wang et al, 2008) (see Figure 1.8). In this study the 
presence of E3 was found to reduce the binding of DAI to DNA. E3 has also been described 
to inhibit the RNA polymerase III-mediated dsDNA-sensing pathway, although this appears 
to be by sequestering the RNA polymerase III-transcribed RNA from RIG-I, as E3 was not 
found to interact with dsDNA (Marq et al, 2009; Valentine & Smith, 2010). Furthermore E3 
acts as an immunomodulatory protein by directly targeting and disabling the function of 
ISG15 (Guerra et al, 2008). A second VACV protein that has been characterised to interfere 
with DNA sensing is C16, an early-expressed protein with immunomodulatory functions and 
a role as a virulence factor in vivo (Fahy et al, 2008). C16 was found to bind the recently 
identified DNA sensor Ku70/80 and inhibit the activation of IFNβ in response to dsDNA (N. 
Peters, manuscript in preparation, see Figure 1.8). 
1.5 Project aims 
Given the role of the characterised members of the VACV Bcl-2 family in innate immune 
evasion, the other members of this family are predicted to have similar roles. In addition to 
being a member of this family, C6L was identified from a screen of VACV ORFs whose 
expression in HEK cells was able to inhibit IFNβ induction (Unterholzner et al, 2011). The 
C6L gene is located near the left end of the VACV strain WR genome (ORF 022), a region 
rich in immunomodulatory proteins, and has been described to be expressed early during 
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infection, like many other proteins with roles in immune evasion (Assarsson et al, 2008). 
Taken together protein C6 was a strong candidate for further investigation and was the focus 
of this study. The aims of this project were to: 
 Characterise C6 expression during viral infection 
 Confirm the ability of C6 to inhibit IFNβ induction and characterise the mechanism 
 Identify cellular interaction partners for C6 
 Characterise the contribution of C6 to VACV virulence in vivo 
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Chapter 2: Materials and Methods  
2.1 DNA preparation and manipulation 
2.1.1 Polymerase chain reaction 
Plasmids were constructed by amplifying the ORF of interest from a suitable template by 
polymerase chain reaction (PCR). Each PCR contained 100 ng template, 10 x HiFi buffer 
(Invitrogen), 2 mM MgSO4, dNTPs (0.2 mM each), 0.2 μM of each oligonucleotide primer 
(see Table 2.1) and 1 U Taq HiFi polymerase (Invitrogen), made up to a total volume of 50 μl 
with water. PCRs were carried out in a thermo cycler using the following programme: 
5 min  95 
o
C  
30 s  95 
o
C  
30 s  50 
o
C 5 cycles  
90 s  68 
o
C  
30 s  95 
o
C  
30 s  55 
o
C 25 cycles  
90 s  68 
o
C  
10 min 68 
o
C 
 
2.1.2 Agarose gel electrophoresis 
PCR products were separated by agarose gel electrophoresis on a 1 % (w/v) agarose gel at 
100 V in TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA). DNA was 
visualised by staining with Syber Safe (Invitrogen) and illumination with long wave 
ultraviolet light. 
2.1.3 Purification of DNA from agarose gel slices 
DNA bands of interest were excised from agarose gels with a scalpel and the DNA was 
purified using the QIAgen gel extraction kit according to the manufacturer‟s protocol.
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Table 2.1 Oligonucleotide primer sequences used for the plasmids constructed in this study  
 
Plasmid Primers 
Z11ΔC6 5’ CTGAGGATCCGGTATTACGATGGCTAGAAAATAAAAG 3’ 
5’ CTAGGCGGCCGCTCTAGACGTGCTGTATACCCATCATGAATGGATG 3’ 
Z11C6Rev 5’ CTGAGGATCCGGTATTACGATGGCTAGAAAATAAAAG 3’ 
5’ CTAGGCGGCCGCTCTAGACGTGCTGTATACCCATCATGAATGGATG 3’ 
Z11C6FS 5’ TATTATACGCATTCTATGATAAACTTAATGAAAAATGTT 3’  
5’ TTCATTAAGTTTATCATAGAATGCGTATAATAAAGCCGA 3’ 
Z11C6HA 5’ TACCCATACGATGTTCCAGATTACGCTTGATTTTTTTCTTCCTAAACT 3’    
5’ TCAAGCGTAATCTGGAACATCGTATGGGTATCTATCTACATCATCACGTCTCTG 3’ 
pcDNA4/TO C6-TAP 5’ CTGAGGTACCATGAATGCGTATAATAAAGCCG 3’ 
5’ CAGTGCGGCCGCTCTATCTACATCATCACGTC 3’ 
pcDNA4/TO C6FS-TAP 5’ CAGTGCGGCCGCTCTATCTACATCATCACGTC 3’ 
5’ CTGAGGTACCATAGAATGCGTATAATAAAGCCG 3’ 
pcDNA4/TO FLAG-C6 5’ CGCGAATTCGCCACCATGGACTACAAGGATGACGATGACAAGAATGCGTATAATAAAGCCGATTCG 3’ 
5’ GCCTCTAGATTATCTATCTACATCATCACGTCTC 3’  
pcDNA4/TO C6-FLAG 5’ CGCGAATTCGCCACCATGAATGCGTATAATAAA GCCGAT TCG 3’  
5’ GCCTCTAGACTTGTCATCGTCATCCTTGTAGTCTCT ATCTACATCATCACGTCTC 3’ 
pcDNA4/TO TAP-C6 5’ GCCTCTAGATTATCTATCTACATCATCACGTCTC 3’ 
5’ GAATGCGGCCGCGAATGCGTATAATAAAGCCGATTCG 3’ 
M5P LUC-C6 5’ CATGTCATGAATGCGTATAATAAAGCCGAT TCG 3’ 
5’ ATTTGCGGCCGCTTATCTATCTACATCATCACGTCTC 3’ 
M5P FLAG-hTANK 5’ CATGCCATGGATAAAAACATTGGCGAGCAACTCA 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCTCCATTGAAGTGTG 3’ 
M5P LUC- hTANK 5’ CATGCCATGGATAAAAACATTGGCGAGCAACTCA 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCTCCATTGAAGTGTG 3’ 
M5P LUC- hTANK 1-69 5’ CATGCCATGGATAAAAACATTGGCGAGCAACTCA 3’ 
5’ ATTTGCGGCCGCTTATTGAGTGGAATTCACAAG 3 
M5P LUC- hTANK 1-135 5’ CATGCCATGGATAAAAACATTGGCGAGCAACTCA 3’ 
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5’ ATTTGCGGCCGCTTACCTTTCATGGAGCAAAG 3’ 
M5P LUC- hTANK 1-173 5’ CATGCCATGGATAAAAACATTGGCGAGCAACTCA 3’ 
5’ ATTTGCGGCCGCTTAAGTTGCAGTGTCTGGTATATT 3’ 
M5P LUC- hTANK 1-391 5’ CATGCCATGGATAAAAACATTGGCGAGCAACTCA 3’ 
5’ ATTTGCGGCCGCTTAATGCAGTTCTGAGTCTGTGC 3’ 
M5P LUC- hTANK 174-425 5’ CATGCCATGGAAACACAGTGCTCTGTGCCTATAC 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCTCCATTGAAGTGTG 3’ 
M5P LUC- hTANK 135-425 5’ ATGTCATGAGGGGTAATATAGAGAAGACTTTCTGGG 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCTCCATTGAAGTGTG 3’ 
M5P LUC- hTANK 70-425 5’ CATGCCATGGATAACAATTATGGCTGTGTTCCTC 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCTCCATTGAAGTGTG 3’ 
M5P LUC- mTANK 1-120 5’ CATGACATGTCTTTAAAGAGACATAGTCTGCGAAG 3’ 
5’ ATTTGCGGCCGCTTACCTTCTGTCACTGTCTTC 3’ 
M5P LUC- mTANK 1-165 5’ CATGACATGTCTTTAAAGAGACATAGTCTGCGAAG 3’ 
5’ ATTTGCGGCCGCTTAATGCAGAGGGATGTTGAG 3’ 
M5P LUC- mTANK 120-448 5’ CATGTCATGAGGAAGAATAATTTGACCCTTGATG 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCCCCATTAAAGTG 3’ 
M5P LUC- mTANK 162-448 5’ CATGTCATGATCCCTCTGCATCACGAAAGGG 3’ 
5’ ATTTGCGGCCGCTTAAGTCTCCCCATTAAAGTG 3’ 
M5P C6-LUC 5’ CCCAAGCTTGCCGCCACCATGAATGCGTATAATAAAGCCG 3’ 
5’ CCCAAGCTTTCTATCTACATCATCACGTCTC 3' 
pcDNA4/TO TAP-019 5’ GAATGCGGCCGCGAATGCGTATAATAAAGCCGATTCG 3’ 
5’ GCCTCTAGATCAGTTTAGGAAAAAAAAATATC 3’ 
pcDNA3.1 HA 5’ AATTCGCCACCATGTACCCATACGATGTTCCAGATTACGCTGC 3’ 
5’ GGCCGCAGCGTAATCTGGAACATCGTATGGGTACATGGTGGCG 3’ 
pcDNA3.1 V5 5’ AATTCGCCACCATGGGAAAGCCGATCCCAAACCCTCTATTAGGTCTGGACTCCACCGC 3’ 
5’ GGCCGCGGTGGAGTCCAGACCTAATAGAGGGTTTGGGATCGGCTTTCCCATGGTGGCG 3’  
pcDNA3.1 HA-NAP1 5’ GAATGCGGCCGCGGACACGCTAGTAGAAGATGAC 3’ 
5’ GCCTCTAGATTAACTTTTGTAAAGGCAG 3’ 
pcDNA3.1 HA-SINTBAD 5’ GAATGCGGCCGCGGAGTCCATGTTTGAAGATGAC 3’  
5’ GCCTCTAGACTAGATCTTGCTGTTCTCAAG 3’ 
pcDNA3.1 HA-TANK 5’ GAATGCGGCCGCGTCTTTAAAGAGACATAGTCTG 3’  
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5’ GCCTCTAGATTAAGTCTCCCCATTAAAGTGTG 3’  
pcDNA3.1 HA-C6 5’ GAATGCGGCCGCGAATGCGTATAATAAAGCCGATTCG 3’ 
5’ GCCTCTAGATTATCTATCTACATCATCACGTCTC 3’ 
pcDNA3.1 V5-TBK1 5’ GAATGCGGCCGCGCAGAGCACCTCCAACCATCTG 3’ 
5’ GCCGGGCCCCTAAAGACAGTCCACATTGCG 3’  
pcDNA3.1 V5-TANK 5’ GAATGCGGCCGCGTCTTTAAAGAGACATAGTCTG 3’  
5’ GCCTCTAGATTAAGTCTCCCCATTAAAGTGTG 3’ 
pcDNA3.1 FLAG-TRAF3 5’ CGCGAATTCGCCACCATGGACTACAAGGATGACGATGACAAGGAGTCAAGCAAAAAGATGGATG 3’ 
5’ ATTTGCGGCCGCTCAGGGGTCAGGCAGATCCGAG 3’ 
pcDNA3.1 HA-IRF3 5’ GAATGCGGCCGCGGAAACCCCGAAACCGCGGATTTTG 3’ 
5’ GCCTCTAGATCAGATATTTCCAGTGGCCTG 3’ 
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2.1.4 Restriction enzyme digestion 
Each digestion contained 1.5 μg DNA, 1 μl appropriate 10 x restriction enzyme buffer 
(Roche), 0.5 μl of each restriction enzyme (Roche) and made up to 10 μl with water. 
Restriction digests were incubated at 37 
o
C for 2 h. Digestion products were analysed by 
agarose gel electrophoresis (see 2.1.2) and the DNA was purified from the gel (see 2.1.3). 
2.1.5 DNA ligation 
Each ligation reaction contained 100 ng digested plasmid vector, an appropriate quantity of 
digested insert to achieve a 2:1 molar ratio of insert:vector, 10 x T4 DNA ligase buffer 
(Promega) and 1 U T4 DNA ligase (Promega), made up to 10 μl with water. Ligation 
reactions were incubated at 16 
o
C for at least 2 h. 
2.1.6 Transformation of E. coli 
Ten μl of ligation reaction was used to transform 50 μl of transformation competent XL-10 E. 
coli. The ligation reaction and bacteria were mixed and incubated on ice for 30 min. The 
bacteria were then incubated at 42 
o
C for 1 min and returned to ice for a further 5 min. The 
bacteria were spread on Luria Broth (LB) agar plates containing the appropriate antibiotic; 
carbenicillin for ampicillin resistance (100 μg/ml) or kanamycin (50 μg/ml). When using 
plasmids with the kanamycin resistance gene, 200 μl super optimal broth with catabolite 
repression (SOC) medium (Invitrogen) was added and the bacteria were incubated with 
shaking at 37 
o
C for 1 h before plating. 
2.1.7 Screening of colonies by PCR 
To confirm the presence of the correct plasmid, bacterial colonies were subjected to screening 
by colony PCR. Colonies were picked in 2 ml LB containing the appropriate antibiotic (see 
2.1.6) and incubated shaking at 37 
o
C for 1 h. Each PCR contained 1 μl bacterial culture, 10x 
GoTaq buffer (Promega), 2 mM MgCl2, dNTPs (0.2 mM each), 0.2 μM of the primers that 
had been used to amplify the ORF of interest (see 2.1.1) and 1 U GoTaq polymerase 
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(Promega), made up to a total volume of 20 μl with water. PCRs were carried out in a thermo 
cycler using the following programme: 
5 min  95 
o
C  
30 s  95 
o
C  
30 s  50 
o
C 5 cycles  
90 s  68 
o
C 
30 s  95 
o
C  
30 s  55 
o
C 25 cycles  
90 s  72 
o
C 
10 min 72 
o
C 
PCR products were analysed by agarose gel electrophoresis (see 2.1.2).  
2.1.8 TA cloning of DNA fragments 
Where direct restriction enzyme digestion of the PCR product for insertion into a digested 
vector was not successful, the PCR product was first inserted into the pCR2.1 TA cloning 
vector (Invitrogen) according to the manufacturer‟s instructions. The ORF of interest was 
then excised from this vector using restriction enzyme digestion as described in 2.1.4. 
2.1.9 Small scale preparation of plasmid DNA 
Bacterial clones containing the plasmid of interest were grown in 2-5 ml LB containing the 
appropriate antibiotic and incubated with shaking at 37 
o
C for 8 h during the day, or 
overnight. Plasmid DNA was purified using a rapid alkaline extraction method. The bacterial 
pellets were resuspended in resuspension buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 
100 μg/ml RNase A), the cells were lysed in lysis buffer (10% (w/v) SDS, 0.2 M NaOH) and 
the proteins were precipitated by addition of a neutralisation buffer (1.32 M potassium acetate 
pH 4.8). The precipitate was collected by centrifugation at 14,000 x g for 5 min and the 
supernatant was transferred to a clean eppendorf tube. The DNA in the cleared lysate was 
precipitated with isopropanol, the DNA was then collected by centrifugation at 14,000 x g for 
5 min and was washed in 70 % (v/v) ethanol followed by centrifugation at 14,000 x g for a 
further 5 min. The purified DNA was finally dissolved in 30 μl water. 
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2.1.10 Large scale preparation of plasmid DNA 
For the large scale preparation of plasmid DNA, transformed bacteria were grown overnight 
shaking at 37 
o
C, in 200 ml LB containing the appropriate antibiotic. The DNA was then 
purified using the QIAgen midi or maxi preparation of plasmid DNA kit, depending on how 
much plasmid DNA was required, according to the manufacturer‟s protocol. 
2.1.11 DNA sequencing 
Plasmid DNA was sequenced using the service at Hammersmith Hospital, Imperial College 
London. Each reaction was prepared with 150 - 300 ng DNA per 3 kilo base pairs (kb) and 
0.2 μM of sequencing primer (see below), made up to 10 μl with water. 
Plasmid Primer Sequence 
pcDNA3.1 CMV FWD 
BGH REV 
5’ TAATACGACTCACTATAGGG 3’ 
5’ CTAGAAGGCACAGTCGAGGC 3’ 
pcDNA4/TO CMV FWD 
BGH REV 
5’ TAATACGACTCACTATAGGG 3’ 
5’ CTAGAAGGCACAGTCGAGGC 3’ 
Z11 P17 
P64 
5’ TTTTACGGTTCCTGGC 3’ 
5’ TTAATGCGCCGCTAC 3’ 
pUC13 M13 FWD 
M13 REV 
5’ GTAAAACGACGGCCAG 3’ 
5’ CAGGAAACAGCTATGAC 3’ 
M5P FLAG RS-56 
CM-02 
5’ CCACGTGAAGGCTGCCGACC 3’ 
5’ TGACTCAACAATATCACCAG 3’ 
M5P LUC CM-01 
CM-02 
5’ TCGCAAGAAGATGCACCTG 3’ 
5’ TGACTCAACAATATCACCAG 3’ 
2.2 Cell culture  
2.2.1 Maintenance of cells 
BSC-1 (African green monkey epithelial cell line of kidney origin), HEK293 and HEK293ET 
(human embryonic kidney cell lines), CV-1 (African green monkey kidney fibroblast cell 
line) and HCT116 (human colon carcinoma cell line) cells were maintained in Dulbecco‟s 
modified Eagle‟s medium (DMEM) supplemented with 10 % (v/v) foetal bovine serum 
(FBS) that had been treated for 1 h at 56 °C to inactivate complement and 
penicillin/streptomycin (P/S) (50 μg/ml). NIH3T3 (murine fibroblast cell line) cells were 
maintained in DMEM supplemented with 10 % (v/v) newborn calf serum (NCS) and P/S. 
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HeLa (human cervical cancer cell line) cells were maintained in minimum essential medium 
(MEM) supplemented with 10 % (v/v) FBS, 1:100 non-essential amino acids (NEAA) 
(Sigma) and P/S (50 μg/ml). RK-13 (rabbit kidney cell line) and TK143 (human thymidine 
kinase-null osteosarcoma) cells were maintained in MEM supplemented with 10 % (v/v) FBS 
and P/S (50 μg/ml). HEK293 T-REx cells (Invitrogen) were maintained in DMEM 
supplemented with 10 % (v/v) FBS, P/S (50 μg/ml) and blasticidin (50 μg/ml). HEK293 T-
REx C6 TAP cell lines were maintained in DMEM supplemented with 10 % (v/v) FBS, P/S 
(50 μg/ml), blasticidin (50 μg/ml) and zeocin (100 μg/ml). 
2.2.2 Calcium phosphate transfection 
Cells were seeded the day before transfection to achieve 50 % confluency at the time of 
transfection. Prior to preparing the transfection mixes the cell medium was aspirated and 
replaced with fresh medium (containing 10 % (v/v) FBS). For a 10-cm dish, 5 μg DNA, 445 
μl H20 and 50 μl 2.5 M CaCl2 were mixed and incubated at room temperature for 20 min. For 
a well of a 6-well plate 1.5 μg DNA, 66 μl H20 and 7.5 μl 2.5 M CaCl2 were mixed and 
incubated as above. An equal volume of HBS pH 7.05 (280 mM NaCl, 10 mM KCl, 1.5 mM 
Na2HPO4, 12 mM glucose, 50 mM HEPES) was then added and incubated for a further 12-15 
min. This solution was added dropwise directly into the cell medium. The following day the 
cells were either processed directly or washed twice with pre-warmed (37 
o
C) phosphate- 
buffered saline (PBS), fresh medium was added and the cells were allowed to grow for a 
further 24 h. See table 2.2 for a list of plasmids used in this study. 
2.2.3 Fugene-6 and PEI transfection 
Cells were seeded the day before transfection to achieve 70 % confluency at the time of 
transfection. Transfection mixes were prepared by mixing the appropriate quantity of DNA 
with OPTIMEM (50 μl per 1 μg of DNA). The appropriate volume of Fugene-6 reagent 
(Roche) or PEI (1 mg/ml) was then added (2 μl transfection reagent per 1 μg DNA) and 
mixed by vortexing briefly. After incubation at room temperature for 30 min, an appropriate 
volume of medium (containing 2 % (v/v) FBS) was added, the growth medium was aspirated 
from the cells and the medium containing the transfection mix was added. The cells were 
harvested after 24-48 h. See table 2.2 for a list of plasmids used in this study.
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Table 2.2 Plasmids used in this study 
Plasmid Description 
Z11ΔC6 pCI-based, 300-350 bp flanks of C6 ORF, Ecogpt.EGFP selection marker, AmpR, constructed by R. Sumner 
Z11C6Rev pCI-based, 300-350 bp flanks + C6 ORF, Ecogpt.EGFP selection marker, AmpR, constructed by R. Sumner 
Z11C6FS pCI-based, 300-350 bp flanks + C6FS ORF, Ecogpt.EGFP selection marker, AmpR, constructed by R. Sumner 
Z11C6HA pCI-based, 300-350 bp flanks + C6HA ORF, Ecogpt.EGFP selection marker, AmpR, constructed by R. Sumner 
pcDNA3.1 HA empty vector encoding HA epitope tag, AmpR, constructed by R. Sumner 
pcDNA3.1 HA-C6 C6 with N-terminal HA tag, AmpR, constructed by R. Sumner 
pcDNA3.1 HA-NAP1 NAP1 with N-terminal HA tag, AmpR, constructed by R. Sumner 
pcDNA3.1 HA-SINTBAD SINTBAD with N-terminal HA tag, AmpR, constructed by R. Sumner 
pcDNA3.1 HA-TANK TANK (murine sequence) with N-terminal HA tag, AmpR, constructed by R. Sumner 
pcDNA3.1 HA-IRF3 IRF3 with N-terminal HA tag, AmpR, constructed by R. Sumner 
pcDNA3.1 V5 empty vector encoding V5 epitope tag, AmpR, constructed by R. Sumner 
pcDNA3.1 V5-TBK1 TBK1 with N-terminal V5 tag, AmpR, constructed by R. Sumner 
pcDNA3.1 V5-TANK TANK (murine sequence) with N-terminal V5 tag, AmpR, constructed by R. Sumner 
pcDNA3.1 FLAG-TRAF3 TRAF-3 with N-terminal FLAG tag, AmpR, constructed by R. Sumner 
pcDNA4/TO empty vector control, doxy-inducible, zeocin selection marker, AmpR 
pcDNA4/TO TAP empty vector with TAP tag, doxy-inducible, zeocin selection marker, AmpR, constructed by B. Ferguson 
pcDNA4/TO C6-TAP C6 with C-terminal TAP tag, doxy-inducible, zeocin selection marker, AmpR, constructed by R. Sumner 
pcDNA4/TO C6FS-TAP C6FS with C-terminal TAP tag, doxy-inducible, zeocin selection marker, AmpR, constructed by R. Sumner 
pcDNA4/TO FLAG-C6 C6 with N-terminal FLAG tag, doxy-inducible, zeocin selection marker, AmpR, constructed by R. Sumner 
pcDNA4/TO C6-FLAG C6 with C-terminal FLAG tag, doxy-inducible, zeocin selection marker, AmpR, constructed by R. Sumner 
pcDNA4/TO TAP-C6 C6 with N-terminal TAP tag, doxy-inducible, zeocin selection marker, AmpR, constructed by R. Sumner 
pcDNA4/TO TAP-019 MVA 019 with N-terminal TAP tag, doxy-inducible, zeocin selection marker, AmpR, constructed by R. Sumner 
M5P FLAG-hTANK human TANK with N-terminal FLAG tag, AmpR, constructed by R. Sumner 
M5P FLAG-GFP GFP with N-terminal FLAG tag, AmpR, obtained from F. Randow (MRC laboratory of Molecular Biology, 
Cambridge) 
M5P FLAG-TRIFΔRIP TRIFΔRIP with N-terminal FLAG tag, AmpR, obtained from F. Randow  
M5P FLAG-TBK1 TBK1 with N-terminal FLAG tag, AmpR, obtained from F. Randow  
M5P FLAG-IKKε IKKε with N-terminal FLAG tag, AmpR, obtained from F. Randow  
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M5P FLAG-mTANK murine TANK with N-terminal FLAG tag, AmpR, obtained from F. Randow 
M5P LUC-hTANK hTANK with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 1-69 hTANK residues 1-69 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 1-135 hTANK  residues 1-135 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 1-173 hTANK residues 1-173 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 1-391 hTANK residues 1-391 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 174-425 hTANK residues 174-425 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 135-425 hTANK residues 135-425 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-hTANK 70-425 hTANK residues 70-425 with N-terminal renilla luciferase tag, AmpR, constructed by D. Muhl 
M5P LUC-mTANK 1-120 mTANK residues 1-120 with N-terminal renilla luciferase tag, AmpR, constructed by R. Sumner 
M5P LUC-mTANK 1-165 mTANK residues 1-165 with N-terminal renilla luciferase tag, AmpR, constructed by R. Sumner 
M5P LUC-mTANK 120-448 mTANK residues 120-448 with N-terminal renilla luciferase tag, AmpR, constructed by R. Sumner 
M5P LUC-mTANK 162-448 mTANK residues 162-448 with N-terminal renilla luciferase tag, AmpR, constructed by R. Sumner 
M5P LUC-NAP1 NAP1 with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow  
M5P LUC-SINTBAD SINTBAD with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow  
M5P LUC-IKKε IKKε with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow  
M5P LUC-TBK1 TBK1 with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow  
M5P LUC-NEMO NEMO with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow 
M5P LUC-IKKα IKKα with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow  
M5P LUC-IKKβ IKKβ with N-terminal renilla luciferase tag, AmpR, obtained from F. Randow  
M5P LUC-C6 C6 with N-terminal renilla luciferase tag, AmpR, constructed by R. Sumner 
M5P C6-LUC C6 with C-terminal renilla luciferase tag, AmpR, constructed by R. Sumner 
pEF.puro pEF-based, empty vector control, puromycin selection marker, AmpR 
pEF IRF3 Un-tagged IRF3, AmpR, obtained from A. Bowie (Trinity College Dublin) 
pEF FLAG-MAVS MAVS with N-terminal FLAG tag, AmpR, obtained from K. Shimotohno (Kyoto University, Japan) 
pOPINE C6 C6 with C-terminal His tag, KanR, obtained from D. Stuart (Oxford University) 
pOPINF C6 C6 with N-terminal His tag, KanR, obtained from D. Stuart  
pCI B14-FLAG B14 with N-terminal FLAG tag, AmpR, (Chen et al, 2008) 
pCI C6 Un-tagged C6, AmpR, constructed by A. Postigo 
pCS2 FLAG-Ub Ubiquitin with N-terminal FLAG tag, AmpR, obtained from C. Brou (Pasteur Institute, France) 
IFNβ-LUC IFNβ promoter fused with firefly luciferase, AmpR, obtained from A. Bowie  
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ISG56.1-LUC ISG56.1 promoter fused with firefly luciferase, AmpR, obtained from G. Sen (Lerner Research Institute, Ohio) 
NF-κB-LUC NF-κB promoter fused with firefly luciferase, AmpR, obtained from A. Bowie  
ISRE-LUC ISRE promoter fused with firefly luciferase, AmpR, obtained from A. Bowie  
GAS-LUC GAS promoter fused with firefly luciferase, AmpR, obtained from A. Bowie  
TK-Ren LUC TK promoter fused with renilla luciferase, AmpR, obtained from A. Bowie  
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2.2.4 JetPrime transfection 
Cells were seeded the day before transfection to achieve 70 % confluency at the time of 
transfection. Prior to preparing the transfection mixes the cell medium was aspirated and 
replaced with fresh medium (containing 2 % (v/v) FBS). Transfection mixes were prepared 
by mixing the appropriate quantity of DNA with JetPrime buffer (100 μl per 1 μg of DNA). 
The appropriate volume of JetPrime transfection reagent (Polyplus) was then added (2 μl 
transfection reagent per 1 μg DNA) and mixed by vortexing briefly. After incubation at room 
temperature for 20-30 min the transfection mix was added drop-wise to the cells. The cells 
were harvested after 24-48 h. See table 2.2 for a list of plasmids used in this study. 
2.3 Protein analysis 
2.3.1 Preparation of cell lysates 
Cell lysates were prepared by washing cells twice on ice with ice-cold PBS followed by 
scraping in an appropriate volume of cell lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 1 
mM EDTA, 10% (v/v) glycerol, 1 % (v/v) Triton X100, 0.05 % (v/v) NP40 supplemented 
with protease inhibitors (Roche), and phosphatase inhibitors (Roche) for immunoblotting 
with phospho-specific antibodies). The cells were collected in eppendorf tubes and the cell 
debris was collected by centrifugation at 14,000 x g for 20 min, 4 
o
C. The cleared lysate was 
transferred to a clean eppendorf and stored at -20 
o
C. 
2.3.2 Protein quantification 
To quantify the protein content of cell lysates a BCA protein assay kit (Pierce) was used 
according to the manufacturer‟s protocol. 
2.3.3 SDS-PAGE  
For sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis cell lysates were heated at 100 
o
C for 5 min in 6x protein loading buffer, containing 
β-mercaptoethanol (BME) (50 mM Tris-HCl (pH 6.8), 2 % (w/v) SDS, 10% (v/v) glycerol, 
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0.1% (w/v) bromophenol blue, 100 mM BME) prior to loading on a 10 % or 12 % 
polyacrylamide gel. The proteins were separated by electrophoresis at 120 V in SDS running 
buffer (25 mM Tris-HCl, 250 mM glycine, 0.1 % (w/v) SDS).  
2.3.4 Nu-PAGE 
For the analysis of proteins using the Invitrogen Nu-PAGE system, proteins were heated at 
100 
o
C for 5 min in 4x Nu-PAGE protein loading buffer (Invitrogen). The proteins were then 
separated on a 4-12 % Bis-Tris polyacrylamide gradient gel (Invitrogen) at 120 V in MES 
buffer (Invitrogen). 
2.3.5 Immunoblotting 
After PAGE, proteins were transferred to a Hybond ECL membrane (Amersham biosciences) 
in transfer buffer (25 mM Tris-HCl, 250 mM glycine, 20 % (v/v) methanol) using a semi-dry 
transfer system (Biorad) and blocked by incubation for 1 h at room temperature in 5 % (w/v) 
milk proteins + 0.01 % (v/v) Tween-20 in PBS (PBST). The membranes were then incubated 
overnight at 4 
o
C with primary antibody (Ab, see below) diluted in 5 % (w/v) milk proteins in 
PBST. Membranes were washed three times for 5 min in PBST and then were incubated with 
secondary Ab (see below) diluted in 5% (w/v) milk proteins in PBST for 1 h at room 
temperature. The membranes were again washed three times for 5 min in PBST, once in PBS 
and were developed with a chemiluminescent horse radish peroxidase (HRP) substrate (1.25 
mM luminol, 0.4 mM p-coumaric acid, 0.1 M Tris pH 8.8, 0.0075 % (v/v) hydrogen 
peroxide) for approximately 10-20 s and exposed to X-ray film. 
Antibody Source Dilution 
Rabbit-anti-actin Sigma (A2066) 1:1000 
Rabbit-anti-C6 purified Ab Polyclonal serum (eurogentec) 1:500-1:1000 
Mouse-anti-D8 MAb 1.1 (Parkinson & Smith, 1994) 1:1000 
Mouse-anti-DNA-PKcs Thermo Fisher (LVMS423P1) 1:1000 
Mouse-anti-FLAG Sigma (F1804) 1:1000 
Rabbit-anti-HA Sigma (H6908) 1:1000 
Rabbit-anti-IκBα Cell signalling (9242L) 1:1000 
Mouse-anti-phospho IκBα Cell signalling (9246S) 1:500 
Mouse-anti-Ku70 Abcam (ab3114) 1:1000 
Mouse-anti-Lamins A+C Abcam (ab8984) 1:1000 
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Mouse-anti-renilla luciferase Millipore (MAB4400) 1:2000 
Rabbit-anti-SMARCC1 Abcam (ab72503) 1:1000 
Goat-anti-TANK Santa Cruz (sc1997) 1:500 
Mouse-anti-tubulin Millipore (05-829) 1:5000 
Rabbit-anti-UBR1 Abcam (ab42420) 1:500 
Mouse-anti-V5 AbD Serotec Ltd. (MCA1360GA) 1:5000 
Goat-anti-mouse HRP conjugated Stratech Scientific (715-005-151) 1:20,000 
Goat-anti-rabbit HRP conjugated Stratech Scientific (111-035-003) 1:20,000 
Rabbit-anti-goat HRP conjugated DakoCytomation (P 0449) 1:20,000 
 
2.3.6 Purification of immunoglobulins from anti-C6 serum 
A C6 polyclonal antiserum was raised against C6 protein purified from E. coli (prepared by 
A. Postigo) and injected into rabbits (Eurogentec). For the purification of Igs from the serum, 
the particulate matter was first removed from 2 ml of serum by centrifugation at 3,000 x g for 
30 min at 4 
o
C. The supernatant was incubated overnight with 1 ml saturated (NH4)2SO4 (4.1 
M at 25 
o
C), rotating at 4 
o
C. The serum was then centrifuged as above and the Igs in the 
serum were purified by high performance liquid chromatography using a 1 ml HiTrap protein 
A column (GE healthcare). The column was first equilibrated with 10 column volumes (CV) 
of binding buffer (12 mM  Na2HPO4, 8.5 mM NaH2PO4) and the serum was then loaded onto 
the column diluted in binding buffer. The column was washed with 20 CV binding buffer and 
the Igs were eluted with 10 CV of elution buffer (100 mM citric acid monohydrate pH 3) into 
a 96-well collection plate containing 1.5 M Tris pH 8.8 to achieve a final pH of 7. The 
fractions containing Igs were pooled and dialysed overnight at 4 
o
C in dialysis buffer (20 mM 
NaHEPES pH 7.5, 300 mM NaCl) using a Slide-A-Lyzer 10,000 MWCO cassette (Thermo 
Fisher). 
2.3.7 Silver staining of proteins 
Proteins separated by PAGE were silver stained using the Invitrogen SilverQuest silver 
staining kit according to the manufacturer‟s protocol. 
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2.3.8 Immunofluorescence  
For immunofluorescence assays cells were seeded in wells of a six-well plate containing 
glass coverslips and transfected (see 2.2.3) or infected (see 2.7.1) where appropriate. The 
cells were washed three times with cold PBS and fixed in 4 % (v/v) paraformaldehyde in PBS 
containing 250 mM HEPES (pH 7.4) by incubation on ice for 5 min and then at room 
temperature for 15 min. The cells were washed three times with PBS and then incubated in 
50 mM ammonium chloride in PBS for 5 min to quench free aldehydes. The cells were 
washed three times in PBS and permeabilised with 0.1 % (v/v) Triton X-100 in PBS for 5 
min. The cells were again washed three times in PBS and then blocked in 5 % (v/v) FBS in 
PBS (hereafter referred to as blocking buffer) for 30 min at room temperature. The coverslips 
were then inverted and incubated on a 70 μl drop of primary Ab (see below) diluted in 
blocking buffer for 90 min in a moist chamber. The coverslips were washed three times in 
blocking buffer followed by incubation on a 70 μl drop of secondary Ab (see below) diluted 
in blocking buffer for 90 min in a moist chamber. The coverslips were then washed twice 
with blocking buffer and once with PBS. Finally the coverslips were dipped in distilled water 
to prevent the formation of PBS crystals, placed on to a slide prepared with a 30 μl drop of 
mounting medium (Mowiol 4-88, containing 4',6-diamidino-2-phenylindole (DAPI)) and 
allowed to set before storing at 4 
o
C. The cells were visualised using a Zeiss Pascal Confocal 
Microscope at 63X magnification and images were collected using Zeiss LSM Image 
Browser. 
Antibody Source Dilution 
Rabbit-anti-FLAG Sigma (F7425) 1:300 
Mouse-anti-HA Cambridge Bioscience (MMS-101P) 1:200 
Mouse-anti-p65 Santa Cruz (sc-8008) 1:50 
Alexa Fluor 488 goat anti-
rabbit IgG (H+L) 
Invitrogen (A-11008) 1:500 
Alexa Fluor 488 goat anti-
mouse IgG (H+L) 
Invitrogen (A-21202) 1:500 
Alexa Fluor 546 goat anti-
rabbit IgG (H+L) 
Invitrogen (A-11010) 1:500 
Alexa Fluor 546 goat anti-
mouse IgG (H+L) 
Invitrogen (A10036) 1:500 
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2.3.9 Conventional immunoprecipitation assays 
Prior to harvesting, the cells were washed twice on ice with ice-cold PBS followed by 
scraping in an appropriate volume of immunoprecipitation (IP) buffer (150 mM NaCl, 20 
mM Tris-HCl pH 7.4, 10 mM CaCl2, 0.1 % (v/v) Triton-X, 10 % (v/v) glycerol, 
supplemented with protease inhibitors (Roche). The cells were collected in eppendorf tubes 
and the cell debris was collected by centrifugation at 14,000 x g for 20 min, 4 
o
C. Fifty μl of 
the cleared lysate was transferred to a tube (input) and the remainder transferred to another 
tube for the IP assay. Thirty μl of protein G sepharose beads (GE healthcare), anti-FLAG M2 
agarose beads (Sigma) or strep-tactin beads (IBA) were prepared per IP by washing once 
with 1 ml water and twice with 1 ml IP buffer (centrifuging at 600 x g for 1 min per wash). 
The beads were resuspended in an appropriate volume of IP buffer and added directly to the 
cell lysates. For IP assays using the protein G sepharose beads the appropriate Ab (see below) 
was added to the lysate at the same time as the beads. The tubes were then incubated with 
rotating at 4 
o
C for 2 h. The beads were washed three times in pre-chilled IP buffer 
(centrifuging at 600 x g for 1 min per wash) and finally were resuspended in 20 μl 6x protein 
sample buffer for analysis by SDS-PAGE (see 2.3.3) and immunoblotting (see 2.3.5). 
Antibody Source Dilution 
Mouse-anti-HA Cambridge Bioscience (MMS-101P) 1:200 
Goat-anti-TANK Santa Cruz (sc1997) 1:50 
Mouse-anti-V5 AbD Serotec Ltd. (MCA1360GA) 1:300 
Mouse-anti-DNA-PKcs Thermo Fisher (LVMS423P1) 1:100 
Rabbit-anti-SMARCC1 Abcam (ab72503) 1:100 
Rabbit-anti-UBR1 Abcam (ab42420) 1:100 
 
2.3.10 LUMIER assay 
For luminescence-based mammalian interactome (LUMIER) assays HEK293 cells were 
prepared in 6-well plates and transfected with 1.5 μg of a plasmid expressing a renilla 
luciferase (LUC)-tagged protein and 1.5 μg of a plasmid expressing a FLAG-tagged protein 
using the calcium phosphate method (see 2.2.2). Prior to harvesting the cells were washed 
once on ice with ice-cold PBS followed by scraping in 250 μl IP buffer. The cells were 
collected in eppendorf tubes and the cell debris was removed by centrifugation at 14,000 x g 
for 20 min, 4 
o
C. Forty μl of the cleared lysate was transferred to a tube for immunoblotting 
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analysis, 20 μl was retained to measure total luminescence of the sample and the remainder 
was transferred to another tube for the IP assay. Thirty μl anti-FLAG M2 agarose beads 
(Sigma) were prepared per IP by washing three times in Tris-buffered saline (TBS) (2.5 mM 
Tris-HCl, 15 mM NaCl, 0.2 mM KCl) and once in IP buffer (centrifuging at 600 x g for 1 
min per wash). The beads were resuspended in an appropriate volume of IP buffer and were 
added directly to the cell lysates. The tubes were then incubated with rotating at 4 
o
C for 2 h. 
The beads were washed three times in pre-chilled TBS (centrifuging at 600 x g for 1 min per 
wash) and the associated proteins were eluted by incubation with 50 μl 150 μg/ml FLAG 
peptide (Sigma) in 5x passive lysis buffer (Promega), incubated with rotating at 4 
o
C for 1 h. 
The beads were then collected by centrifugation at 14,000 x g for 1 min and 10 μl of the 
supernatant was analysed for luminescence by addition of 50 μl coelenterazine renilla 
luciferase substrate (1 mg/ml, Prolume Ltd.) using a FLUOstar luminometer (BMG). The 
luminescence after IP was normalised to the total luminescence of the sample. A fold binding 
was calculated by normalising to a FLAG-green fluorescent protein (GFP) control. 
2.3.11 ELISA 
For enzyme-linked immunosorbent assay (ELISA), PRO-BIND flat bottom 96-well assay 
plates (BD) were coated overnight at room temperature with 100 μl capture Ab (Murine 
CXCL-10 and IL-6 ELISA Duosets, R&D Systems) per well diluted in PBS. The plates were 
washed 3 times in PBST (PBS + 0.1% Tween) and then were blocked for 1 h at room 
temperature with 300 μl 1 % (w/v) BSA in PBS (hereafter termed diluent) per well. The 
plates were washed 3 times in PBST. The standards were prepared in duplicate (CXCL-10: 
2000 pg/ml-31.3 pg/ml, IL-6: 500 pg/ml-7.8 pg/ml) by preparing a two-fold dilution in 
diluent. One-hundred μl un-diluted BAL supernatant, or cell culture supernatant was added 
per well and the mixture was incubated for 2 h at room temperature. The plates were washed 
again 3 times in PBST. The detection Ab (Murine CXCL-10 and IL-6 ELISA Duosets, R&D 
Systems) was prepared in diluent, 100 μl was added per well and the plate was incubated at 
room temperature for 2 h. The plates were washed 3 times in PBST. Streptavidin HRP (R&D 
systems) was diluted 1:200 in diluent, 100 μl was added per well and the plate was incubated 
at room temperature for 20 min. The plates were again washed 3 times in PBST and the 
ELISA substrate reagent (R&D systems) was prepared by mixing solutions A and B in a 1:1 
ratio. One-hundred μl was added per well and the plate was incubated in the dark for 20 min. 
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The reaction was stopped by the addition of 100 μl 2N H2SO4 per well. The absorbance at 
450 nm was measured, with 540 nm as a reference.  
2.4 Functional assays 
2.4.1. Reporter gene assay 
For a reporter gene assay cells were seeded in 96-well plates and transfected at 70 % 
confluency (see 2.2.3). Transfection reactions contained 60 ng of a firefly luciferase reporter 
plasmid, 10 ng of renilla luciferase transfection control plasmid and varying quantities of a 
C6 expression plasmid or an empty vector (EV) plasmid (either pcDNA4/TO or pEF.puro) 
per well. The transfections were performed in triplicate and were added to cells in DMEM + 
2 % (v/v) FBS + P/S. In each case the total amount of DNA transfected per well was made 
equal with empty vector plasmid. Twenty four h post-transfection the cells were stimulated 
with poly I:C (Autogen Bioclear), poly dA:dT (Sigma), IFNα (Peprotech) or IFNγ (R&D 
Systems) as described in the figure legends and the cells were then harvested in passive lysis 
buffer (Promega). For the stimulation of cells by ectopic expression of signalling molecules, 
plasmids expressing these molecules were included in the initial transfection mix and the 
cells were harvested approximately 30 h post-transfection. Non-stimulated cells were 
transfected with the empty vector control plasmid. Ten μl of lysate was used for 
luminescence measurements after the addition of 50 μl of firefly luciferase substrate (20 mM 
Tricine, 2.67 mM MgSO4.7H20, 0.1 mM EDTA, 33.3 mM DTT, 530 μM ATP, 270 μM 
acetyl coenzyme A, 132 μg/ml Luciferin (Prolume Ltd.), 5 mM NaOH, 0.26 mM 
(MgCO3)4Mg(OH)2.5H20) or coelenterazine renilla luciferase substrate (1 mg/ml, Prolume 
Ltd.) using a FLUOstar luminometer (BMG). The firefly luciferase activity in each sample 
was normalised to the renilla luciferase activity, and these data were further normalised to the 
un-stimulated EV control, or the un-stimulated control of each test plasmid, as indicated in 
the figure legends, to yield a fold induction. 
2.4.2 RNA extraction and cDNA synthesis 
RNA was extracted from cells using the QIAgen RNeasy RNA extraction kit according to the 
manufacturer‟s protocols. For 24- and 6-well plates the cells were harvested in 350 μl buffer 
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RNeasy lysis buffer (RLT). For reverse transcription to synthesize complementary DNA 
(cDNA), each reaction contained 1 μg RNA, 2.5 μM oligo dT, 500 μM dNTP, made up to 13 
μl with nuclease-free water. These reactions were incubated at 65 oC for 5 min and then 
transferred directly to ice for 1 min. To each reaction was then added 4 μl 5x First-strand 
buffer (Invitrogen), 5 mM DTT, 40 U RNase OUT (Invitrogen), 50 U Superscript III reverse 
transcriptase (Invitrogen), made up to a total of 20 μl with nuclease-free water. The reactions 
were incubated at 50 
o
C for 1 h, followed by 70 
o
C for 15 min. cDNA was diluted 1:2 in 
nuclease-free water before quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) analysis (see 2.4.3). 
2.4.3 qRT-PCR 
Each qRT-PCR, performed in 96-well plates, in duplicate, contained 2 μl cDNA, 10 μl 2x 
SYBR® Green PCR master mix (Applied Biosystems), 0.5 μM of each primer, made up to 
20 μl with water per well. A ΔΔCt relative quantity assay was then performed where the 
amplification of genes of interest was normalised to an endogenous control (GAPDH) on a 
7900HT Real-Time PCR machine (Applied Biosystems) using the following programme: 
2 min  50 
o
C  
10 min 95 
o
C  
15 s  95 
o
C  
1 min  60 
o
C 40 cycles  
Data were analysed using the RQ Manager 1.2 software (Applied Biosystems). 
Primer Sequence 
Human GAPDH FWD 5’ ACCCAGAAGACTGTGGATGG 3’ 
Human GAPDH REV 5’ TTCTAGACGGCAGGTCAGGT 3’ 
Human CCL-5 FWD 5’ CCCAGCAGTCGTCTTTGTCA 3’ 
Human CCL-5 REV 5’ TCCCGAACCCATTTCTTCTCT 3’ 
 
2.4.4. Statistical analysis 
Statistical analysis of data was performed using GraphPad Prism 5 software. For reporter 
gene assays, qRT-PCR, ELISA, weight loss, signs of illness, lesion measurements and flow 
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cytometry, data were analysed using an unpaired Student‟s T-test, applying Welch‟s 
correction. For IMV plaque reduction neutralisation assays the data were analysed using a 
Mann-Whitney non-parametric test. * P<0.05, ** P<0.01, *** P<0.001 
2.5 Tandem affinity purification 
2.5.1. Plasmid construction 
C6 amplified from WR genomic DNA by PCR (see 2.1.1) was cloned into the pcDNA4/TO 
tandem affinity purification (TAP) vectors (containing a zeocin resistance cassette, 
constructed by B. Ferguson) using the restriction enzymes XbaI and NotI for N-terminal TAP 
and KpnI and NotI for C-terminal TAP (see Table 2.1 for oligonucleotide primers). The TAP 
tag consisted of two Streptavidin (Strep) epitopes fused to a FLAG epitope.  
2.5.2 Construction of stable inducible cell lines 
HEK293 T-REx cells grown in 10-cm dishes were transfected with 5 μg pcDNA4/TO C6-
TAP or pcDNA4/TO TAP-C6 plasmids using Fugene-6 (see 2.2.3). Once confluent the cells 
were transferred into new dishes at varying dilutions in the presence of zeocin (100 μg/ml) to 
allow colony formation of zeocin-resistant cells. Colonies were then picked for amplification. 
Clonal cell lines were tested for inducible expression of TAP-tagged C6 by growth in the 
presence or absence of 2 μg/ml doxycycline for 24 h, followed by analysis of cell extracts by 
immunoblotting.  
2.5.3. TAP assay 
Prior to lysis, the cells were washed once with PBS and were removed from the flask by 
incubation for 3 min with 3 ml 0.05 % trypsin EDTA (Gibco) per 175 cm
2
 flask. The cells 
were resuspended in 10 ml medium per flask, pooled and collected by centrifugation at 250 x 
g for 5 min. The pellet was washed in PBS and the cells were again collected as above. The 
cells were then lysed by resuspension in 1 ml TAP IP buffer (0.5 % NP-40 (v/v) in PBS 
supplemented with protease and phosphatase inhibitors (Roche)) per flask and incubated for 
20 min, rotating at 4 
o
C. The cellular debris was collected by centrifugation at 1,000 x g, 10 
min, 4 
oC. The supernatant was removed and a sample was taken to analyse as „input‟. The 
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remaining cleared lysate was incubated with 100 μl strep-tactin beads (IBA) per condition 
(prepared by washing once in water and three times in wash buffer (0.1 % NP-40 (v/v) in 
PBS supplemented with protease and phosphatase inhibitors (Roche), centrifuging at 600 x g 
for 30 s per wash), with rotation at 4 
o
C for 1-2 h. The beads were collected by centrifugation 
at 600 x g for 5 min and washed three times in wash buffer by centrifugation at 600 x g for 30 
s. The proteins were eluted from the strep-tactin beads by incubation with a des-thiobiotin 
solution (IBA, strep-tag elution buffer), with rotation for 30-60 min. The beads were then 
collected by centrifugation, the supernatants were transferred to clean eppendorfs and were 
incubated with 100 μl anti-FLAG M2 agarose beads (Sigma) per condition (prepared by 
washing once in water and three times in wash buffer) with rotation for 1-2 h at 4 
o
C. The 
beads were collected by centrifugation and washed three times in wash buffer. The proteins 
were eluted from the anti-FLAG beads by incubation with a 250 μg/ml FLAG-peptide 
solution (Sigma), rotating for 30-60 min. The beads were then collected by centrifugation and 
the supernatants were transferred to an Amicon Ultra centrifugal filter (3K membrane, 
Millipore) and were centrifuged at 14,000 x g, 4 
oC until approximately 50 μl remained.  
2.5.4. Mass spectrometry analysis 
For the TAP assay using the HEK293 T-REx C6-TAP cell line the proteins in the final 
elution, or still associated with the beads, were separated by Nu-PAGE (see 2.3.4) and silver 
stained (see 2.3.7). The protein bands of interest were then excised carefully from the gel and 
sent for liquid chromatography-mass spectrometry (LC-MS/MS) analysis (Systems Biology 
Centre, Imperial College South Kensington Campus). For the TAP assay from HCT116 cells 
infected with vC6TAP (see 2.6.2) the final elution was sent to the Cambridge Centre for 
Proteomics (University of Cambridge) to be separated by PAGE. The lane of the gel was then 
cut into 16 equal slices and each one analysed by LC-MS/MS. 
2.6 Construction of recombinant VACV 
2.6.1 Plasmid construction 
To construct the C6L deletion virus 300-350 bp of the left and right flanking regions of the 
C6 ORF were amplified by overlapping PCR from WR genomic DNA. Each PCR contained 
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100 ng WR genomic DNA, or 10 ng of PCR product and was performed according to 2.1.1 
(see table 2.1 for oligonucleotide primers). To construct the revertant virus, the haemaglutinin 
(HA)-tagged revertant virus and the frame-shift revertant virus the C6 ORF, an HA-tagged 
version of the C6 ORF or the C6 ORF with an additional adenine nucleotide in the start 
codon, respectively, in addition to the 300-350 bp left and right flanking regions were 
amplified by overlapping PCR as described above (for schematics of the inserts see Figure 
3.6A). PCR products were cloned into the Z11 plasmid (Escherichia coli 
guanylphosphoribosyl transferase (Ecogpt) (Boyle & Coupar, 1988) fused to enhanced green
 
fluorescent protein (EGFP)) by digesting the PCR product and Z11 plasmid DNA with the 
restriction enzymes BamHI and NotI (see 2.1.4) and then ligating the digestion products 
together (see 2.1.5). To construct the TAP-tagged revertant virus the left flanking region of 
C6 plus the C6 ORF was inserted upstream of the TAP tag in the pcDNA4/TO TAP vector 
using the restriction enzymes BamHI and NotI. The right flanking region of C6 was then 
inserted downstream of the TAP tag in the resulting vector using the restriction enzymes 
SacII and XbaI. The left flanking region of C6, the C6 ORF, the TAP tag and the right 
flanking region of C6 were then excised together and inserted into the pUC13 vector 
containing the Ecogpt fused with EGFP cassette (constructed by B. Bahsoun) using the 
restriction enzymes BamHI and XbaI.  
2.6.2 Infection/transfection protocol 
C6 recombinant viruses were constructed using the transient dominant selection method 
(Falkner & Moss, 1988). For construction of vΔC6, a 25 cm2 flask of CV-1 cells was infected 
with WR at 0.01 plaque forming units (p.f.u.) per cell for 90 min in infection medium 
(DMEM + 2.5 % (v/v) FBS + P/S). The cells were then transfected with 5 μg Z11ΔC6 
plasmid using Fugene-6 (see 2.2.3) and were harvested after 48 h. The resulting virus was 
diluted in ten-fold steps and used to infect RK-13 cells in the presence of mycophenolic acid 
(MPA, 25 μg/ml), hypoxanthine (HX, 15 μg/ml) and xanthine (X, 250 μg/ml). Green plaques 
were picked and purified by three rounds of infection using RK-13 cells. The intermediate 
virus was resolved in BSC-1 cells by three rounds of infection in the absence of MPA, HX 
and X. The phenotype of resolved viruses was analysed by PCR (see 2.6.3). An intermediate 
virus that had resolved back to the wild-type phenotype was purified as the wild-type virus 
for in vivo work (vC6WR). For the construction of vC6Rev, vC6HA, vC6FS and vC6TAP, 
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CV-1 cells were infected with vΔC6, followed by transfection with Z11C6Rev, Z11C6HA, 
Z11C6FS or pUC13 C6TAP, respectively, as described above. 
2.6.3 Screening plaques by PCR 
To confirm the phenotype of plaques by PCR, plaques were picked directly into a well of a 
24 well-plate of RK-13 cells. The cells were scraped 48 h later and the medium was 
transferred to a 2 ml tube and was sonicated well at 100 W. Ten μl of lysate was treated with 
proteinase K according to the manufacturer‟s instructions (Sigma) in a total of 50 μl. Each 
PCR contained 0.5 μl proteinase K-treated lysate, 10x GoTaq buffer (Promega), 2 mM 
MgCl2, dNTPs (0.2 mM each), 0.2 μM of the primers used to construct Z11ΔC6 (see Table 
2.1) and 1 U GoTaq polymerase (Promega), made up to a total volume of 30 μl with water. 
PCR was carried out in a thermo cycler using the following programme: 
5 min 95 
o
C  
30 s 95 
o
C  
30 s 50 
o
C 5 cycles  
90 s 68 
o
C 
30 s 95 
o
C  
30 s 55 
o
C 25 cycles  
90 s 72 
o
C 
10 min 72 
o
C 
PCR products were separated by agarose gel electrophoresis (see 2.1.2). 
2.6.4 Amplification of crude virus stocks 
For the preparation of a master stock of crude virus, one 25 cm
2
 flask of RK-13 cells per 
virus was infected at 0.1 p.f.u. per cell for 48 h. The cells were scraped in their medium, 
collected by centrifugation at 500 x g for 10 min and resuspended in 1 ml infection medium. 
For preparation of working stock crude virus, five 175 cm
2
 flasks of RK-13 cells per virus 
were infected at 0.1 p.f.u. per cell for 48 h. The cells were collected as described above and 
resuspended in 5 ml infection medium. Recombinant viruses were stored at –80 oC.  
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2.6.5 Virus titration 
Viruses were titrated by plaque assay, in duplicate, on monolayers of BSC-1 grown in six-
well plates. The viruses were diluted in infection medium (10
-5
 to 10
-9
 dilutions, total volume 
500 μl) and were incubated with the cells for 90 min at 37 oC, rocking the plate every 15 min. 
After this time the virus was removed and 2 ml 50% 2x MEM (supplemented with 5 % (v/v) 
FBS and 100 μg/ml P/S): 50% 3% (w/v) carboxy methyl cellulose (CMC) was added to each 
well. The cells were incubated for 48-72 h to allow for plaque formation. The MEM/CMC 
mix was then removed, the cells were washed once with PBS and were stained for 30 min 
with crystal violet (5 % (v/v) crystal violet solution (Sigma), 25 % (v/v) ethanol). The wells 
were then washed with water and the number of plaques was counted. 
2.6.6 Virus purification by sedimentation through sucrose  
Recombinant viruses were partially purified for in vivo use by sedimentation through two 
sucrose cushions. Ten 175 cm
2
 flasks of RK-13 cells per virus were infected at 0.1 p.f.u. per 
cell for 48 h. The cells were then scraped, pooled (where appropriate) and collected by 
centrifugation at 500 x g for 5 min at 4 
o
C. The cell pellets were resuspended in 10 ml 10 mM 
Tris pH 9 for 10 min to allow the cells to swell and the cells were then disrupted by Dounce 
homogenisation on ice. The homogenised cells were transferred to a fresh tube and the nuclei 
and unbroken cells were collected by centrifugation at 250 x g for 5 min. The supernatant 
was transferred carefully to a fresh tube on ice and the pellet was resuspended in 5 ml 10 mM 
Tris pH 9 and homogenised again. The homogenates were combined and centrifuged at 500 x 
g for 30 min. Ultracentrifuge tubes (Beckman Coulter) were prepared with 18 ml 36 % (w/v) 
sucrose solution. The cytoplasmic extracts were sonicated at 100 W for 10 s and then layered 
carefully on the sucrose cushion. The supernatants were centrifuged at 32,900 x g for 80 min 
at 4 
o
C. The supernatants were discarded and the pellet containing the virus was resuspended 
in 1 ml 10 mM Tris pH 9 by sonicating briefly for 10 s as above, followed by incubation on 
ice for 30 s, repeated three times. Fresh ultracentrifuge tubes were prepared with 18 ml 36 % 
(w/v) sucrose solution and the resuspended virus pellet was layered on top. The samples were 
centrifuged a second time at 32,900 x g for 80 min at 4 
o
C. The supernatant was again 
discarded and the pellet was washed by resuspension in 36 ml 10 mM Tris pH 9. The tubes 
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were finally centrifuged at 26,000 x g for 50 min at 4 
o
C. The supernatant was discarded and 
the pellet was resuspended in 1 ml 10 mM Tris pH 9, aliquotted and stored at -80 
o
C. 
2.7 Analysis of recombinant VACV 
2.7.1 Infection of cells 
For infection with VACV, the viruses were thawed in a 37 
o
C water bath and sonicated for 
10-15 s at 100 W. The viruses were diluted in infection medium and added to cells in the 
minimal volume required to cover them. The cells were incubated with virus for 90 min at 37 
o
C, with rocking of the plate or dish every 15 min. After this time the unbound virus was 
removed and replaced with an appropriate volume of fresh infection medium. For infection of 
cells with NDV (provided by the laboratory of W. Barclay, Imperial College London), the 
virus was thawed and incubated with the cells as described above, without sonication.    
2.7.2 Timing of C6 expression 
To analyse the time p.i. at which C6 protein could be detected, BSC-1 cells that had been 
grown in 3.5-cm dishes were infected in the presence or absence of 40 μg/ml cytosine 
arabinoside (AraC) at 10 p.f.u. per cell of WR in 500 μl infection medium for 90 min, 
rocking on ice. After this time one dish of cells was harvested (0 h) and for the remaining 
dishes the unbound virus was removed by washing with infection medium, the cells were 
incubated in 2 ml infection medium (-/+ AraC where appropriate) and the dishes returned to 
37 
o
C. The cells were harvested at various time points p.i. as described in 2.3.1. 
2.7.3 Localisation by cellular fractionation 
For cellular fractionation HeLa cells were prepared in 14.5-cm dishes and infected with 
recombinant viruses overnight at 5 p.f.u. per cell. The cells were washed twice in ice cold LS 
buffer (20 mM Hepes pH 7.8, 0.5 mM DTT, 0.5 mM MgCl2) and allowed to swell in 20 ml 
LS buffer on ice for 20 min. The buffer was then removed and the cells were scraped gently. 
The cells were then disrupted by Dounce homogenisation on ice with 20 strokes with a loose 
homogeniser. The lysates were transferred to eppendorf tubes and were centrifuged at 600 x g 
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for 2 min at 4 
o
C to sediment the nuclei. The supernatant (cytoplasmic fraction) was 
transferred to a clean eppendorf tube. The nuclei were washed five times in PBS by gentle 
resuspension and re-collected by centrifugation at 600 x g for 2 min at 4 
o
C. Finally the nuclei 
were resuspended in 100 μl nuclei resuspension buffer (50 mM Tris/HCl pH 8, 0.5 mM 
MgCl2, 20 mM iodoactetamide supplemented with protease inhibitor (Roche)) and sonicated 
until well disrupted. 
2.7.4 Purification and digestion of viral genomic DNA 
Viral genomic DNA was purified from IMV cores that had been purified by sucrose density 
ultracentrifugation. The sucrose gradients were prepared in 36 ml ultracentrifuge tubes 
(Beckman Coulter) the day before use and stored at 4 
o
C. The gradient was prepared by 
adding 5.8 ml 24 % (w/v) sucrose to the ultracentrifuge tube, followed by the drop-wise 
addition of 5.8 ml 28 % (w/v) sucrose, 5.8 ml 32 % (w/v) sucrose, 5.8 ml 36 % (w/v) sucrose 
and finally 5.8 ml 40 % (w/v) sucrose. Five-hundred μl of recombinant virus that had been 
sedimented through a 36 % (w/v) sucrose cushion (see 2.6.6) was carefully added to the top 
of the sucrose gradient and then centrifuged at 26,000 x g for 50 min, 4
o
C. The sucrose above 
the white virus band was aspirated, the virus was removed carefully using a 5 ml pipette and 
was transferred to a clean ultracentrifuge tube. The virus was diluted 1:3 in 10 mM Tris pH 9 
and was centrifuged at 32,900 x g for 80 min, 4 
o
C. Finally the viral pellet was finally 
resuspended in 600 μl 50 mM Tris pH 7.8. To extract viral DNA, proteinase K reactions were 
incubated at 37 
o
C for 4-6 h and consisted of 600 μl sucrose gradient-purified virus, 0.05 M 
Tris pH 7.8, 0.5 % (w/v) SDS, 6 % (w/v) sucrose and 4000 U proteinase K. Viral genomic 
DNA was then purified by phenol-chloroform extraction. One volume of 
phenol:chloroform:isoamyl alcohol was added to the proteinase K-treated virus, the sample 
was mixed and then centrifuged at 2,500 x g for 2 min. The aqueous phase was transferred to 
a clean eppendorf and one volume of phenol:chloroform:isolamyl alcohol was added and 
centrifuged as above. The aqueous phase was again transferred to a clean eppendorf and one 
volume of phenol:chloroform:isolamyl alcohol was added and the mixture was centrifuged as 
above. The aqueous phase was transferred to a clean eppendorf and one volume of 
chloroform:isoamyl alcohol was added and the mixture was centrifuged as above. The 
aqueous phase was transferred to a clean eppendorf tube and the DNA was precipitated by 
the addition of sodium acetate pH 7.0 (final concentration 0.1 M) and one volume of ice-cold 
102 
 
100 % ethanol and incubation at -20 
o
C for 30-60 min. The DNA was collected by 
centrifugation at 14,000 x g for 30 min at 4 
o
C. The pellet was washed with 1 ml 70 % 
ethanol and then centrifuged again at 14,000 x g for 10 min. The ethanol was removed 
completely and the pellet was allowed to air-dry for 15 min. Finally the pellet was dissolved 
in 100 μl water. 
2.7.5 In vitro growth curves 
For the single-step growth curves six 25 cm
2 
flasks of BSC-1 cells per virus were infected at 
10 p.f.u. per cell in 1.5 ml infection medium for 90 min. After this time the virus was 
removed and the cells were washed twice with fresh medium to remove any unbound virus. 
The cells were then incubated in 5 ml infection medium. At 0 h, 12 h and 24 h time points the 
medium was removed carefully and the cells were collected by centrifugation at 500 x g for 
10 min. The supernatant (extracellular virus) was carefully removed and titrated immediately 
(see 2.6.5). The cells were then scraped in 3 ml fresh medium and added to the pellet from 
the first centrifugation step. The cells were collected as described above, resuspended in 500 
μl infection medium and stored at -20 oC (intracellular virus). For the multi-step growth curve 
eight 25 cm
2
 flasks of BSC-1 cells per virus were infected at 0.01 p.f.u. per cell as described 
above. Virus was harvested at 0 h, 12 h, 48 h and 72 h p.i. as described above. Harvested 
viruses were titrated on BSC-1 cells as described in 2.6.5. 
2.7.6 Plaque size analysis 
RK-13, BSC-1 and TK143 cells were prepared in six-well plates and infected in duplicate 
with virus at 50 p.f.u. per well. Plaques were allowed to form over a period of 72 h. The cells 
were washed once with PBS and stained for 60 min with crystal violet (5 % (v/v) crystal 
violet solution (Sigma), 25 % (v/v) ethanol). The wells were then washed with water and the 
size of six plaques per well measured using Axiovision 4.6 software and a Zeiss Axiovert 
200M microscope. 
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2.8 Murine in vivo experiments 
2.8.1 Intranasal infection 
Groups of female BALB/c mice, aged 6-8 weeks old, were inoculated i.n. with 20 μl sucrose-
purified recombinant VACV (see 2.6.6) diluted in PBS whilst under anaesthetic (Williamson 
et al, 1990). The titre of each inoculum was confirmed by plaque assay (see 2.6.5). The 
animals were weighed daily and scored for signs of illness as follows: 
1 – hair ruffling 
2 – back arching 
3 – reduced mobility 
4 – severe pneumonia 
 
2.8.2 Preparation of cells from BAL 
The bronchoalveolar lavage (BAL) was harvested in 1 ml PBS containing 10 U/ml heparin 
per animal. The cells were collected by centrifugation at 1,000 x g for 5 min and the 
supernatant was transferred to a clean tube for cytokine analysis by ELISA (see 2.3.11). The 
cells were resuspended in 500 μl ACK buffer (150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM 
Na2EDTA, pH 7.4) and incubated at room temperature for 3 min to lyse the red blood cells. 
Ten ml RPMI + 10 % (v/v) FBS + P/S (hereafter termed „RPMI-10‟) was added and the cells 
were collected as above. The cells were then resuspended in 300 μl fluorescence-activated 
cell sorting (FACS) buffer (0.1 % (w/v) BSA, 0.1 % (w/v) sodium azide in PBS) and were 
enumerated by trypan blue exclusion. 
2.8.3. Extraction of cells from lung 
The lung tissue was cut into small pieces and incubated in 3 ml digestion medium (1 mg/ml 
collagenase, 30 μg/ml DNaseI in RPMI-10) for 30 min at 37 oC with periodic agitation. The 
lung homogenate was passed through a cell strainer into a 50 ml Falcon tube and 250 μl was 
retained for virus titration (see 2.8.6). The strainer was washed with 2 ml RPMI-10 and the 
cells were collected by centrifugation at 1000 x g for 5 min. The pellet was vortexed briefly, 
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the cells were resuspended in 1 ml ACK buffer and then incubated at room temperature for 3 
min. Nineteen ml of RPMI-10 was added and the cells were collected as above. The pellet 
was resuspended in 5 ml 20 % Percoll (Sigma) in RPMI-10 and centrifuged at 1000 x g for 
20 min. The cells were then resuspended in 2 ml FACS buffer and enumerated by trypan blue 
exclusion (using a 1:10 dilution). 
2.8.4. Extraction of cells from spleen 
A 10-cm dish was prepared with 5 ml RPMI-10 and a fine metal mesh was placed over the 
top. The spleen was cut into small pieces and then mashed on top of the mesh using the end 
of the plunger of a 10 ml syringe by the addition of 1 ml RPMI-10 at a time (5 ml in total). 
The cell suspension was passed through a cell strainer into a 50 ml Falcon tube and 500 μl 
was retained for virus titration (see 2.8.6). Ten ml of RPMI-10 was added to wash the cell 
homogenate and the cells were collected by centrifugation at 1,000 x g for 5 min. The pellet 
was resuspended in 4 ml ACK buffer and was incubated at room temperature for 3 min. 
Sixteen ml RPMI-10 was then added and the cells were collected as above. Finally the cells 
were resuspended in 10 ml FACS buffer and enumerated by trypan blue exclusion (using a 
1:10 dilution). 
2.8.5. Staining of cells and flow cytometry 
Cells in FACS buffer were collected by centrifugation at 1,000 x g for 5 min, resuspended in 
an appropriate volume of FACS block (10 % (v/v) normal rat serum (AbD Serotec Ltd.), 
1:500 anti-CD16/CD32 Fc gamma receptor (BD Biosciences) in FACS buffer) for the 
number of staining conditions required (100 μl per condition) and transferred into wells of a 
round-bottom 96-well plate. The plate was incubated at 4 
o
C for 30 min. The FACS Abs were 
prepared by diluting in FACS block (100 μl per well). Ab panel 1 included anti-CD3, anti-
CD4, anti-CD8 and anti-CD69 or anti-CD44 Abs for T lymphocytes and anti-CD19 to stain 
for B lymphocytes (see below). Ab panel 2 included anti-F4/80 and anti-CD11b Abs to stain 
for macrophages, anti-Ly6G to stain for neutrophils and anti-DX5 to stain for NK cells (see 
below). The cells were collected by centrifugation as above, resuspended in the FACS stains 
and incubated at 4 
o
C for 30 min in the dark. The cells were collected as above and washed 
once with 200 μl PBS per well. The cells were again collected, resuspended in 100 μl 
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LIVE⁄DEAD® Fixable Aqua Dead Cell Stain (Invitrogen) per well, diluted 1:500 in PBS and 
incubated at 4 
o
C for 30 min in the dark. The cells were collected and washed with PBS as 
above and then were resuspended in 100 μl fixing solution (2 % (v/v) paraformaldehyde in 
PBS) per well, and incubated at room temperature for 30 min in the dark. The cells were 
collected and washed in PBS as above, resuspended in 200 μl FACS buffer per well and 
stored overnight at 4 
o
C. Stained cells were analysed on a BD FACS CantoII flow cytometer 
and these data were analysed using FlowJo software. Ab compensation was performed using 
rat/hamster Ab compensation beads (BD Biosciences). For BAL 10,000 events were analysed 
where possible and 100,000 events were analysed for the spleen and lung samples. 
Antibody Source Dilution 
rat-anti-CD3 APC-Cy7 BD Biosciences (560590) 1:50 
rat-anti-CD4 APC BD Biosciences (553051) 1:200 
rat-anti-CD8 FITC BD Biosciences (553031) 1:100 
Armenian hamster-anti-CD69 PE BD Biosciences (553237) 1:100 
rat-anti-CD19 PE-Cy7 BD Biosciences (552854) 1:200 
rat-anti-F4/80 APC Serotec (MCA 497 APC) 1:20 
rat-anti-CD11b APC-Cy7 BD Biosciences (557657) 1:100 
rat-anti-Ly6G PE  BD Biosciences (551461) 1:100 
rat-anti-DX5 FITC BD Biosciences (553857) 1:100 
rat-anti-CD44 PE BD Biosciences (553135) 1:100 
 
2.8.6. Virus titre analysis from infected tissue 
Cell suspensions taken from the lung (see 2.8.3) and spleen (see 2.8.4) for viral titre analysis 
were subjected to three rounds of freeze-thawing and were sonicated briefly before titration 
on monolayers of BSC-1 cells as described in 2.6.5. 
2.8.7 Intradermal infection 
Groups of female C57BL/6 mice, aged 6-8 weeks old, were inoculated i.d. with 10 μl 
sucrose-purified recombinant VACV (see 2.6.6) diluted in PBS in both ear pinna whilst under 
anaesthetic (Tscharke & Smith, 1999). The titre of each inoculum was confirmed by plaque 
assay (see 2.6.5). The diameter of the resulting lesions was measured daily using a 
micrometer. 
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2.8.8. Vaccination and challenge experiment 
Groups of female C57BL/6 mice, aged 6-8 weeks old, were vaccinated by i.d. infection in 
both ears, as described in 2.8.7. One month later the animals were challenged i.n. with 5 × 
10
6 
p.f.u. WR per animal, as described in 2.8.1. The animals were weighed daily. The titre of 
both vaccination and challenge inocula were confirmed by plaque assay (see 2.6.5). 
2.8.9. IMV plaque reduction neutralisation assay 
One month post-vaccination animals were sacrificed and the blood was taken. The blood was 
incubated at room temperature for 1 h to allow clotting to occur. The blood cells were then 
collected by centrifugation at 2,500 x g for 30 min. The serum was transferred to a clean 
eppendorf tube and was stored at -80 
o
C. Complement in the serum was inactivated by 
incubation at 56 
o
C for 30 min. Two-fold dilutions of serum were then prepared from 1:25-
1:800, diluted in infection medium. The diluted serum was then incubated for 1 h at 37 
o
C 
with 100 p.f.u. sucrose purified WR per sample. The serum/virus mixes were then titrated in 
duplicate on monolayers of BSC-1 cells (see 2.6.5).  
2.8.10. VACV ELISA 
The VACV ELISA was performed in 96-well immunoplates (Nunc). The plates were coated 
overnight at 4 
o
C with antigen (1:500 dilution of a cell lysate of WR-infected cells (Putz et al, 
2006), or 2 μg/ml BSA) diluted in 50 mM NaHCO3 pH 9.6. The plates were washed three 
times in wash buffer (2 mM Tris-HCl, 154 mM NaCl, 0.2 % (v/v) Tween-20) and then 
blocked for 2 h at room temperature in 5 % (w/v) milk proteins in TBS. Two-fold dilutions of 
serum (1:100-1:12,800) were prepared in 1 % (w/v) milk proteins in TBS + 0.1 % (v/v) 
Tween-20 (TBST). Blocked plates were washed three times as above and were incubated 
with the diluted serum at room temperature for 90 min. The plates were again washed three 
times as above and were incubated at room temperature for 1 h with goat-anti-mouse IgGγ 
specific-alkaline phosphatase conjugate (Sigma) diluted 1:1000 in 1 % (w/v) milk proteins in 
TBST. The plates were washed three times as above and the revelation solution (1 Sigma 
FAST pNPP tablet and 1 Sigma FAST buffer tablet per 10 ml water) was added for 1 h. The 
absorbance was then measured at 405 nm, with 650 nm as a reference. 
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2.8.11 Chromium release cytotoxicity assay 
EL-4 (murine T lymphoma cell line) target cells were infected with WR at 20 p.f.u. per cell 
for 2 h in RPMI infection medium (RPMI + 2.5 % (v/v) FBS + P/S). The cells were collected 
by centrifugation at 250 x g for 5 min, resuspended in 
51
Cr solution supplemented with 30 % 
(v/v) FBS (150 μCi per 3 x 106 cells) and incubated at 37 oC for 2 h. Chromium-loaded cells 
were then washed three times in RPMI-10 by centrifugation at 250 x g for 5 min per wash. 
Finally the cells were resuspended in RPMI-10 at 10
6
 cells/ml. Splenocytes (effector cells) 
from infected mouse spleens were prepared as described in 2.8.4. Two-fold dilutions of 
effector cells were prepared in RPMI-10 to give 100:1 to 2.5:1 effector cell:target cell ratios. 
The effector cells were then incubated with infected target cells for 6 h at 37 
o
C. The cells 
were collected by centrifugation at 250 x g for 5 min and 100 μl supernatant transferred to a 
LUMA plate (PerkinElmer) to quantify the radioactivity of the sample. 
2.8.12 ELISPOT 
Enzyme-linked immunosorbent spot (ELISPOT) plates were coated with IFNγ capture Ab 
overnight at 4 
o
C (Mouse IFNγ ELISPOT set, Beckton Dickenson). The wells were washed 
once in RPMI-10 and then blocked by incubating with RPMI-10 for 2 h at room temperature. 
Whole splenocytes were prepared from infected mouse spleens as described in 2.8.4. Two-
fold dilutions of splenocytes were prepared from 2 × 106 cells/ml to 2.5 × 105 cells/ml in 
RPMI infection medium. The splenocytes were then stimulated overnight by incubation at 37 
o
C with VACV-specific peptide (TSYKFESV or VGPSNSPTF, 2 μg/ml) or with EL-4 cells 
that had been infected for 4 h with 20 p.f.u. per cell WR (50,000 cells per well). The cell 
suspensions were removed and the wells were washed twice with deionised water, allowing a 
3-5 min incubation per wash. The wells were then washed three times with PBST, allowing a 
1-2 min incubation per wash. The plate was incubated with IFNγ detection Ab (Mouse IFNγ 
ELISPOT set, Beckton Dickenson) diluted in PBS + 10 % (v/v) FBS and were incubated at 
room temperature for 2 h. The wells were then washed three times in PBST as above. The 
enzyme conjugate (Mouse IFNγ ELISPOT set, Beckton Dickenson) diluted in PBS + 10 % 
(v/v) FBS was added to wells and the mixture was incubated at room temperature for 1 h. 
Wells were then washed four times in PBST as above, and twice with PBS. 
Aminoethylcarbazole (AEC) substrate reagent (Beckton Dickenson) was added to each well 
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and spots were allowed to develop for 5 min. The substrate reaction was stopped by washing 
wells with deionised water. The plates were air-dried overnight in the dark and the spots were 
enumerated. 
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Chapter 3: Analysis of the VACV WR 022 ORF encoding 
protein C6 
3.1 Bioinformatic analysis of the 022 ORF from VACV strain WR 
ORF 022 of the WR strain of VACV (gene C6L in VACV strain Copenhagen and termed 
protein C6 from here on) is 456 bp in length and is situated at the left end of the genome. It is 
predicted to encode an uncharacterised polypeptide of 151 amino acids with a molecular 
mass of 17.3 kDa and a PI of 4.96. It is not predicted to have any coiled-coil segments and 
does not contain an obvious signal peptide sequence (www.poxvirus.org). Using the viral 
protein localisation algorithm Virus-mPLoc (www.csbio.sjtu.edu.cn/bioinf/virus-multi/), C6 
is predicted to be cytoplasmic as it contains no obvious nuclear localisation sequence (NLS) 
(Shen & Chou, 2010).  
The predicted C6 protein is highly conserved amongst VACV strains (>96 % amino acid 
identity), with differences in amino acid sequence at just six residues (Figure 3.1, highlighted 
in red). C6 is also highly conserved in MVA (97 % identity), except for an additional six 
amino acids present at the C terminus of both the sequenced strains of MVA. These extra 
residues are also present in VACV strain ACAM3000. The high level of conservation of C6 
is also maintained within the OPV family (>88 % identity) with all sequenced OPVs 
encoding a C6 orthologue (Figure 3.2). Notably the C6 orthologue of RPXV strain Utrecht 
and C6 from all sequenced VACV strains are a few amino acids shorter in length compared 
to other OPVs, due to a 5 amino acid deletion at residue 146 close to the C terminus of the 
protein. Outside of the OPV family C6 orthologues are predicted to be encoded by members 
of the Capripoxvirus genus goatpox, sheepox and lumpy skin disease virus, and also by the 
unclassified mule deer poxvirus (www.poxvirus.org). C6 encoded by VACV WR shares 
between 46-50 % similarity and 26-27 % identity with these non-OPV orthologues.  
Structural-based screens of the VACV genome have identified C6 as a member of the VACV 
Bcl-2-like Pfam (Finn et al, 2008) protein family. This family currently consists of 10 
proteins; A46, A52, B14, C1, C6, C16/B22, F1, K7, N1 and N2 (Gonzalez & Esteban, 2010; 
Graham et al, 2008) with low amino acid sequence identity, but for A52, B14 
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 (Graham et al, 2008), K7 (Kalverda et al, 2008; Oda et al, 2009), N1 (Aoyagi et al, 2007; 
Cooray et al, 2007) and F1 (Kvansakul et al, 2008) whose structures have been solved, a high 
level of structural similarity exists and this resembles the fold of the cellular Bcl-2 family of 
apoptotic regulators (Petros et al, 2004). The structure of C6 was modelled using 
MODELLER (Eswar et al, 2006), based on a sequence alignment with the VACV Bcl-2 
family member B14 (Graham et al, 2008) (Figure 3.3). This algorithm predicted the structure 
of C6 to be highly similar to B14, adopting a Bcl-2 fold comprising of seven alpha helices. 
Subjecting this model to the Ramanchandran plot assessor RAMPAGE (Lovell et al, 2002) 
indicated that 95.5 % of the residues were in a favourable region of the plot, supporting the 
validity of this structural prediction. Notably the residues at which the VACV strains differ in 
sequence (Figure 3.1) are mainly found within alpha helices 3 and 4 in the C6 model.   
The cellular Bcl-2 proteins have characterised roles in regulating apoptosis, but despite the 
high level of structural similarity between these cellular proteins and N1, F1, B14 and A52, 
only N1 and F1 are anti-apoptotic (Cooray et al, 2007; Graham et al, 2008). Cellular anti-
apoptotic proteins exert their function via a groove on their surface that interacts with the 
BH3 peptide of pro-apoptotic family members (Youle & Strasser, 2008). This groove  lies 
between alpha helices 2 and 4 of myxoma poxvirus protein M11, as demonstrated in the 
crystal structure of this protein in complex with the BH3 peptide of human Bak-2 (Douglas et 
al, 2007). Alpha helices 2 and 4 are also believed to form the BH3-binding groove in protein 
N1, based on model predictions (Cooray et al, 2007). Residues V64 and F65 in helix 2 of 
B14, as well as Y90 in helix 4 however are predicted to occlude this potential BH3 peptide 
binding groove and explain why this protein in not anti-apoptotic (Graham et al, 2008) 
(Figure 3.3). Similar bulky residues are also present at equivalent positions at the end of 
helices 2 and 4 in A52, which is also not able to inhibit apoptosis (Graham et al, 2008). N1 on 
the other hand is one turn shorter in helix 2 than B14 and A52 and does not have bulky 
residues protruding into the putative BH3 peptide binding groove, a potential explanation for 
how this member of the VACV Bcl-2 family has anti-apoptotic abilities (Figure 3.3). Like 
B14, C6 has an additional turn in helix 2 and at positions equivalent to V64 and F65 there are 
two tyrosine residues (Figure 3.3), which are also bulky and may occlude the putative BH3 
peptide binding groove. From this structural model C6 is therefore not predicted to have anti-
apoptotic ability, but this still remains to be confirmed experimentally. 
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Figure 3.3: C6 predicted structure. The structure of C6 was modelled using MODELLER (Eswar 
et al, 2006) based on a sequence alignment with B14 (Graham et al, 2008). The side chains of the 
bulky residues (highlighted in red in the sequence alignment) predicted to protrude into the groove 
formed by alpha helices 2 and 4 and potentially prevent the binding of a BH3 peptide are shown. The 
structure of N1, which has an open groove, is also shown. The positions of the alpha helices (α) and 
the N (N) and C (C) termini are indicated 
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3.2 Expression of C6 protein 
Peptides derived from C6 are presented to CD8
+
 T cells during VACV infection (Oseroff et 
al, 2005) and therefore it is assumed that this protein is expressed during infection. To 
confirm this expression and to study the potential function of C6 the 022 gene was amplified 
from WR genomic DNA by PCR and inserted into the pcDNA3.1 expression vector with an 
N-terminal FLAG tag. The expression of FLAG-tagged C6 was confirmed by transfection of 
HEK293 cells and immunoblotting with a mouse-anti-FLAG monoclonal Ab (Figure 3.4A). 
This protein resolved to 17-18 kDa on a denaturing protein gel, as expected from C6 size 
predictions. To study C6 expression during virus infection a polyclonal serum was made by 
immunising rabbits with unfolded C6 that had been produced in E. coli. This serum 
recognised a protein that resolved to approximately 15 kDa on a denaturing protein gel from 
lysates of BHK cells infected with WR, but not mock-infected cells (Figure 3.4B). 
Immunoblotting of this lysate with an Ab against the late VACV protein D8 (Niles & Seto, 
1988) served as a control in this experiment to confirm the infection of these cells. The serum 
was also capable of recognising plasmid expressed FLAG-tagged C6, which was slightly 
larger than virus-expressed C6, presumably due to the tag. In addition a protein of 
approximately 15 kDa was recognised by the C6 serum in lysates of BHK cells infected with 
VACV MVA. Again, this protein was slightly larger than WR C6, as MVA C6 is 6 amino 
acids longer.  
Taken together these data indicated that a protein that resolves to approximately 15 kDa is 
expressed from the sequence of VACV WR gene 022 and a serum raised against this protein 
produced in E. coli is able to recognise C6 expressed from VACV strain WR. The predicted 
orthologue of C6 is also expressed by MVA and is recognised by the C6 polyclonal serum 
due to the high sequence conservation of these two proteins. This finding was mirrored very 
recently by Garcia-Arriaza et al who demonstrated that a polyclonal serum raised against 
MVA C6 also recognised C6 expressed by WR (Garcia-Arriaza et al, 2011). 
3.3 Timing of C6 expression 
A transcriptome-based analysis of VACV ORFs characterised C6L as an immediate-early 
transcript, with mRNA detected from as early as 30 min p.i. (Assarsson et al, 2008). To  
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confirm the early expression of C6 at the protein level, BSC-1 cells were infected with WR at 
5 p.f.u. per cell in the presence or absence of AraC and whole cell lysates were prepared at 
various time points p.i. for immunoblotting analysis with the C6 serum (Figure 3.5). 
Expression of C6 protein was detected at two h p.i. with increased levels of protein detected 
at four h. The expression of C6 was affected only minimally by the presence of AraC, an 
inhibitor of viral replication and hence late gene expression. In contrast the expression of the 
late protein D8 was completely inhibited by this compound. These data confirmed expression 
of C6 from an early VACV promoter.    
3.4 Construction of WR C6 recombinant viruses 
To study the role of C6 for virus replication in vitro and assess its contribution to virulence in 
vivo a panel of recombinant viruses were constructed. For a virus lacking the C6L gene 
approximately 300-350 bp flanking the left and right of this gene was amplified by PCR from  
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Figure 3.4: C6 expression by plasmid transfection and infection with VACV strains 
WR and MVA. (A) HEK293 cells were transfected for 24 h with a plasmid expressing 
FLAG-tagged C6 or were mock-transfected using calcium phosphate. (B) BHK cells were 
either mock infected or infected with VACV strains WR or MVA overnight with 2 p.f.u. per 
cell. The cells were harvested in cell lysis buffer, the proteins were separated by SDS-PAGE 
and then immunoblotted with mouse-anti-tubulin and mouse-anti-FLAG antibodies (A) or 
mouse-anti-tubulin, mouse-anti-D8 and rabbit-anti-C6 antibodies (B). The location of 
protein molecular mass markers is indicated (kDa). 
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WR genomic DNA and cloned into a plasmid containing Ecogpt (Boyle & Coupar, 1988) 
fused to EGFP (Z11ΔC6, Figure 3.6A). For the construction of a C6 revertant virus, the C6 
ORF, in addition to the left and right flanking regions was amplified from genomic DNA by 
PCR and inserted into the Z11 plasmid (Z11C6Rev, Figure 3.6A). For in vivo analysis a 
revertant frame-shift plasmid was constructed where the C6 ORF was amplified with an 
additional adenine nucleotide to disrupt the translational initiation codon (i.e. ATAG) and 
hence the C6 protein cannot be expressed (Z11C6FS, Figure 3.6A). For localisation and 
binding partner studies revertant viruses expressing HA-tagged (Z11C6HA, Figure 3.6A) or 
TAP (comprising two Strep epitopes and one FLAG epitope, see Chapter 6)-tagged C6 
(pUC13 C6TAP, Figure 3.6A) were also constructed. Digestion of these plasmids with 
BamHI and NotI for the Z11 derivatives or with BamHI and XbaI for the pUC13 derivative 
indicated all plasmids to contain an insert of the expected size (Figure 3.6B). 
Recombinant viruses were generated using the transient-dominant selection method as 
described in Chapter 2 (Falkner & Moss, 1988). For the C6 deletion virus (vΔC6) CV-1 cells  
AraC - - - - - - -+ +
8h6h4h2h1h0.5h0h
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Figure 3.5: C6 is an early expressed VACV protein. BSC-1 cells were infected in the 
presence or absence of AraC at 5 p.f.u. per cell for 90 min on ice to allow viruses to adhere. 
The cells were then transferred to 37 
o
C and harvested at the indicated times p.i.. The 
proteins were separated by SDS-PAGE and immunoblotted with mouse-anti-tubulin, mouse-
anti-D8 or rabbit-anti-C6 antibodies. The location of protein molecular mass markers is 
indicated (kDa). 
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Z11ΔC6: 0.65 kb
Z11C6Rev: 1.1 kb
Z11C6HA: 1.1 kb
Z11C6FS: 1.1 kb
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Figure 3.6: Plasmids for construction of the WR C6 recombinant viruses. (A) For 
construction of the C6 deletion virus (vΔC6) the left (L) and right (R) flanking regions of C6 
were cloned into the Z11 plasmid containing the Escherichia coli guanylphosphoribosyl
 
transferase (Ecogpt) gene fused in-frame with the enhanced green
 
fluorescent protein 
(EGFP) gene (Z11 ΔC6). For the revertant (vC6Rev), revertant HA-tagged (vC6HA) or 
revertant frame-shift (vC6FS) viruses the C6 ORF, an HA-tagged version of the C6 ORF or 
a frame-shift version of the C6 ORF respectively were cloned between the L and R flanking 
regions in the Z11 plasmid (Z11 C6 rev, Z11 C6HA and Z11 C6FS). For the revertant TAP-
tagged (vC6TAP) virus a TAP-tagged version of the C6 ORF was cloned between the L and 
R flanking regions in the pUC13 plasmid also containing Ecogpt.EGFP (pUC13 C6TAP). 
(B) Digestion with BamHI and NotI for the Z11 derivatives and with BamHI and XbaI for 
the pUC13 derivative indicated all plasmids contained an insert of the correct size as 
indicated in (A).  
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were infected with WR and then transfected with Z11ΔC6. A single recombination event 
between regions of homology in the plasmid and the virus allowed the plasmid, including the 
Ecogpt-EGFP locus, to be recombined into the virus genome (Figure 3.7). These viruses 
could be selected by growth in the presence of MPA, X and HX. MPA is an inhibitor of 
purine metabolism, which blocks the replication of wild type VACV in normal cell lines but 
can be overcome by expression of Ecogpt, in the presence of X and HPX. The presence of 
EGFP allowed plaques formed by these intermediate viruses to be visualised and selected 
with ease. Due to the instability of the resulting intermediate virus, a second recombination 
event, between repeated right of left flanking sequences, occurred when the drug selection 
was removed, resolving the virus and excising the inserted plasmid yielding either a wild-
type virus (vC6WR) or vΔC6 (Figure 3.7). For the revertant viruses CV-1 cells were infected 
with vΔC6 and transfected with Z11C6Rev (for vC6Rev), Z11C6FS (for vC6FS), Z11C6HA 
(for vC6HA) or pUC13 C6TAP (for vC6TAP).  
The genotype of the resolved recombinant viruses was confirmed by PCR analysis using the 
primers that had been used to amplify the flanking regions of the C6 gene. Virus-infected 
cells were subjected to proteinase K digestion and the resulting lysate containing viral DNA 
was used as a template for PCR (Figure 3.8). PCR analysis confirmed that the vΔC6 
recombinant virus did not contain the C6 ORF, as indicated by a product of approximately 
650 bp, indistinguishable from that obtained from the Z11ΔC6 plasmid (Figure 3.8). 
Conversely, PCR analysis of vC6WR, vC6Rev, vC6FS and vC6HA yielded PCR products of 
approximately 1.1 kb, indistinguishable from that obtained from the Z11C6Rev, Z11C6FS 
and Z11C6HA plasmids respectively, thus confirming the presence of the C6 ORF. PCR 
analysis of vC6TAP yielded a PCR product of the slightly larger size of 1.2 kb due to the 
presence of the TAP tag. 
Expression of C6 from the various recombinant viruses was confirmed by infecting RK-13 
cells overnight followed by SDS-PAGE of whole cell lysates and immunoblotting. All the C6 
recombinant viruses expressed D8, but only vC6WR, vC6Rev, vC6HA and vC6TAP viruses 
expressed C6, detected using the C6 polyclonal antiserum (Figure 3.9). In addition C6 from 
vC6HA or vC6TAP were detected using monoclonal antibodies against HA or FLAG, 
respectively. Both HA-tagged and TAP-tagged C6 were detected at lower levels using the 
polyclonal antiserum, indicating either a lower expression, or instability of C6 from these  
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Figure 3.7: Schematic representation of the recombination events occurring during the 
construction of vΔC6. Recombinant viruses were constructed using the transient dominant 
selection method (Falkner & Moss, 1988). A single recombination event between the 
regions of homology in the plasmid and the virus genome allowed the plasmid, including the 
Ecogpt-EGFP locus, to be recombined into the virus genome. Due to the instability of the 
resulting intermediate virus a second recombination event occurs between the repeated left 
(L) or right (R) flanking regions when the drug selection is removed, resolving the virus and 
excising the inserted plasmid, yielding either a wild-type virus or deletion virus.  
 
120 
 
 
 
 
 
 
 
 
viruses, or a diminished recognition of C6 tagged at the C terminus with these epitopes. As 
expected, C6 expression was not detected in whole cell lysates from cells infected with vΔC6 
or vC6FS (Figure 3.9). 
Further to the confirmation of C6 expression, the recombinant viruses to be used in vivo were 
subjected to genomic DNA digestion analysis to confirm that no major genomic 
rearrangements or deletions had occurred during their construction. Viral genomic DNA was 
purified from virion cores, digested with HindIII or XhoI and analysed by pulse-field agarose 
gel electrophoresis. As C6L lies within the HindIII C fragment, which is 22 kb in size, the 
loss of the 456-bp C6L gene is not visible on a 0.9 % agarose gel. Consequently digestion 
with this enzyme produced a similar pattern of DNA fragments in all the C6 recombinant and 
the parental WR strain, suggesting that no major rearrangements or deletions in the genome 
had occurred (Figure 3.10). Digestion of genomic DNA with XhoI confirmed that vΔC6 was 
lacking the C6 ORF, indicated by a difference of approximately 450 bp in the XhoI G 
fragment of vΔC6 compared to WR, vC6WR, vC6Rev and vC6FS, which all contain C6L. 
1 kb
0.6 kb
1 kb
0.6 kb
Figure 3.8: PCR analysis of WR C6 recombinant viruses. The phenotype of the 
recombinant viruses was confirmed by infecting RK-13 cells in a 24 well plate with the 
various recombinant viruses. Twenty four h later the cells were scraped in their medium, 
vortexed and 10 μl was used for a proteinase K digestion. One μl of digested lysate was used 
as a template for a PCR using primers specific for the left and right flanking regions of C6, 
and compared to the PCR product obtained from amplification of the plasmid used to 
construct each virus. The approximate sizes of DNA fragments were deduced from size 
markers run in parallel, as indicated.  
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 All other fragments resolved as expected, again indicating that no major rearrangements or 
deletions in the genome had occurred.     
3.5 Analysis of C6 localisation 
To determine the sub-cellular localisation of C6 during viral infection, HeLa cells were 
infected overnight with the various C6 recombinant viruses and the cells were harvested the 
next morning and carefully separated into nuclear and cytoplasmic fractions. These fractions 
were then analysed for C6 expression by SDS-PAGE and immunoblotting using the C6 
polyclonal antiserum. Successful fractionation of cells was achieved using the method 
employed, with nuclear lamins A + C detected only in the nuclear fraction and α-tubulin 
detected only in the cytoplasmic fraction (Figure 3.11). C6 expression was found to be 
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Figure 3.9: Expression of C6 by recombinant WR viruses. For immunoblotting RK-13 
cells were infected overnight with the indicated viruses at 2 p.f.u. per cell. The cells were 
harvested in cell lysis buffer, the proteins were separated by SDS-PAGE and then 
immunoblotted with mouse-anti-tubulin, mouse-anti-D8, rabbit-anti-C6, rabbit-anti-HA or 
mouse-anti-FLAG antibodies. The location of protein molecular mass markers is indicated 
(kDa).  
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Figure 3.10: Restriction digestion of viral genomic DNA. One μg of genomic DNA 
purified from virion cores was subjected to digestion with the restriction enzymes HindIII or 
XhoI for 6 h. Restriction products were then separated by overnight pulse-field gel 
electrophoresis using a 0.9 % agarose gel. The expected restriction patterns for the WR 
genome with each restriction enzyme and the position of the C6L gene are shown below, 
with the corresponding fragments indicated beside the gels with letters. The location of a 
DNA size marker is indicated in the centre (kb).  
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 predominantly cytoplasmic, but with some protein also detected in the nuclear fraction. 
Addition of the HA tag at the C terminus of C6 did not affect its localisation. 
The localisation of C6 was also studied by immunofluorescence by both transfection with a 
plasmid expressing TAP-C6 and infection with vC6HA (Figure 3.12). Overnight transfection 
of HEK293 cells with a plasmid encoding TAP-C6 indicated both a cytoplasmic and nuclear 
localisation of C6, detected using a rabbit-anti-FLAG polyclonal Ab (Figure 3.12A). 
Infection of HeLa cells for 5 h with vC6HA also showed both a cytoplasmic and nuclear 
localisation of C6 (Figure 3.12B). A significant co-localisation of C6 with the DNA stain 
DAPI was observed in the cell nucleus. Mock-infected and vC6WR-infected cells had only  
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Figure 3.11: Localisation of C6 by cellular fractionation. HeLa cells were prepared in 
14.5-cm dishes and infected overnight at 5 p.f.u. per cell. The cells were harvested in LS 
buffer and fractionated carefully into cytoplasmic and nuclear fractions by dounce 
homogenisation and centrifugation. The proteins were separated by SDS-PAGE and were 
analysed by immunoblotting with mouse-anti-tubulin, mouse-anti-lamin A + C, mouse-anti-
D8, rabbit-anti-C6 or rabbit-anti-HA antibodies. Three-fold more of the total nuclear fraction 
was loaded compared to the total cytoplasmic fraction. The location of protein molecular 
mass markers is indicated (kDa). 
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Figure 3.12: Localisation of C6 by immunofluorescence. (A) HEK293 cells were 
transfected overnight with a plasmid expressing TAP-C6 or empty vector control. Cells were 
then fixed and stained with a rabbit anti-FLAG Ab. The localisation of C6 (red), phase-
contrast and merged images are shown. (B) HeLa cells were infected with the indicated 
viruses for 5 h with 5 p.f.u. per cell. The cells were then fixed and stained with a mouse anti-
HA Ab. The localisation of C6 (green), nuclear and viral DNA stained with DAPI (blue), 
phase-contrast and merged images are shown.  
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background levels of fluorescence using the mouse-anti-HA Ab indicating specificity for C6-
HA. Notably, the distribution of C6 in the cytoplasm of both transfected and infected cells 
was not diffuse, but rather showed an uneven distribution with greater staining in some 
regions of the cytoplasm than others (Figure 3.12).  
An immunofluorescence time course showed expression of C6-HA as early as two h p.i. 
(Figure 3.13), in accordance with immunoblotting data of cells infected with WR (Figure 
3.5). At all time points examined C6 was present in both the cytoplasm and the nucleus, with 
a similar distribution. The staining in the cytoplasm at all time points was again not diffuse, 
but rather C6 localised to an unknown sub-cellular structure. 
Although both immunoblotting and immunofluorescence data agree both a cytoplasmic and 
nuclear localisation for C6, the relative distribution of protein in these two compartments is 
different. By immunoblotting both wild-type and HA-tagged C6 were predominantly 
cytoplasmic (Figure 3.11), whereas by immunofluorescence the localisation of C6 was more 
evenly distributed, regardless of the tag (Figures 3.12 and 3.13). One difference between 
these two experiments is the time of infection. Although a time course for 
immunofluorescence was performed this was only carried out up until 8 h p.i., whereas the 
cellular fractionation and immunoblotting analysis was carried out after an overnight 
infection. An overnight transfection with TAP-C6, however, still showed strong nuclear 
staining of C6 suggesting that the length of expression may not explain this difference 
(Figure 3.12A). Nevertheless it is still plausible that the presence of another viral protein may 
affect the localisation of C6 after longer periods of infection. 
Although an obvious NLS is not present in the sequence of C6 (see 3.1) experiments were 
performed to confirm whether C6 was actively transported into the nucleus. HeLa cells were 
infected with vC6HA for 4 h and then incubated for a further 4 h in the presence of 20 ng/ml 
leptomycin B (LMB). LMB is an inhibitor of the nuclear export protein CRM1 (Kudo et al, 
1999) and therefore proteins that are actively transported in and out of the nucleus 
accumulate in the nucleus in the presence of this compound. The localisation of C6 was 
unaltered by the presence of LMB (Figure 3.14A), whereas the cellular protein p65 (an NF-
κB component), which is actively shuttled between the nucleus and cytoplasm and has a  
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Figure 3.13: Time course of C6 localisation by immunofluorescence. HeLa cells were 
infected with 5 p.f.u. per cell of vC6HA for the times indicated. Cells were then fixed and 
stained with a mouse anti-HA Ab. The localisation of C6 (green), nuclear and viral DNA 
stained with DAPI (blue), phase-contrast and merged images are shown.  
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Figure 3.14: Localisation of C6 in the presence of leptomycin B. HeLa cells were 
infected with 5 p.f.u. per cell of vC6HA for 4 h for C6 localisation (A), or mock-infected for 
p65 localisation (B). The cells were then incubated in the presence or absence of 20 ng/ml 
leptomycin B (LMB) for a further 4 h. The cells were fixed and infected cells stained with a 
mouse anti-HA Ab (A) and mock-infected cells stained with a mouse-anti-p65 Ab (B). The 
localisation of C6 or p65 (green), nuclear and viral DNA stained with DAPI (blue), phase-
contrast and merged images are shown.  
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predominantly cytoplasmic localisation (Birbach et al, 2002), was found to be nuclear in the 
presence of this compound (Figure 3.14B). These data indicated that C6 is not actively 
transported into the nucleus using the conventional importin/exportin system, but given its 
small size, is likely to do so by passive diffusion.    
3.6 Dimerisation of C6 
VACV Bcl-2-like family members N1 (Bartlett et al, 2002), B14 and A52 (Graham et al, 
2008) have the ability to form homo-dimers. To test the ability of C6 to homo-dimerise an 
HEK293 T-REx cell line engineered to inducibly express C6-TAP (see Chapter 6) and HA-
tagged C6 expressed from vC6HA were utilised. HEK293 T-REx C6-TAP cells were 
incubated for 24 h in the presence of 2 μg/ml doxycycline to induce the expression of TAP-
C6 and then infected overnight with either vC6HA, or a recombinant WR virus expressing C-
terminally HA-tagged B14 (vB14HA) as a control (Chen et al, 2008). An IP assay was then 
performed on cleared cell lysates using either a mouse-anti-HA Ab coupled to protein G 
sepharose beads (Figure 3.15A) or anti-FLAG agarose beads (Figure 3.15B). TAP-tagged C6 
expressed from the cell line was found to co-immunoprecipitate with HA-tagged C6 
expressed from the virus, but not with HA-tagged B14 (Figure 3.15A). Conversely when 
immunoprecipitating TAP-C6 from the cell line using the FLAG agarose beads virally 
expressed C6-HA was found to co-immunoprecipitate, whereas B14-HA did not, indicating a 
specificity of this interaction (Figure 3.15B).  These data demonstrated that C6, like some 
other members of the VACV Bcl-2-like family, is able to homo-dimerise and this can occur 
in the context of a viral infection. 
Additional evidence for C6 homo-dimerisation was obtained by a LUMIER assay. HEK293 
cells were co-transfected with plasmids expressing LUC-tagged C6 and either FLAG-C6 or 
TAP-C6. The cleared cell lysates were then incubated with anti-FLAG agarose beads and the 
bound proteins eluted in a buffer containing 250 ng/ml FLAG peptide. The luminescence in 
this eluted sample was normalised to the total luminescence of the sample before IP. FLAG-
GFP was used as a negative control and data for the other FLAG-tagged proteins were 
normalised to this protein and expressed as a fold binding relative to this. Both FLAG- and 
TAP-tagged C6 showed a 20-25 fold binding to LUC-C6 indicating the ability of C6 to 
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 dimerise (Figure 3.16). Whether or not C6 dimers can be detected in virus-infected cells was 
not addressed and whether dimerisation is important for C6 function is currently not known. 
3.7 Summary 
Protein C6 encoded by gene 022 of the WR strain of VACV is an uncharacterised protein that 
is highly conserved amongst VACV strains (including MVA) and other OPVs. An orthologue 
of this protein is also predicted in the genomes of the more distantly related capripoxviruses 
and also in the uncharacterised mule deer poxvirus.  Although the structure of this protein has 
not been solved, structural based alignments predict C6 to be a member of the VACV Bcl-2-
like Pfam (Finn et al, 2008) protein family (Gonzalez & Esteban, 2010; Graham et al, 2008). 
Given the role of other members of this family in innate immune evasion and the high 
conservation of C6 in all sequenced OPVs this protein was chosen for further investigation. 
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Figure 3.15: Dimerisation of C6 by immunoprecipitation assay. HEK293 T-REx TAP-
C6 cells were incubated for 24 h in the presence of 2 μg/ml doxycycline to induce the 
expression of TAP-C6. The cells were then infected overnight at 5 p.f.u. per cell with either 
vC6HA or vB14HA. The cells were harvested in IP buffer (see Materials and Methods) and 
the cleared lysates were incubated with either a mouse-anti-HA Ab coupled to protein G 
sepharose beads (A) or FLAG agarose beads (B) to immunoprecipiatate the epitope-tagged 
proteins. Whole cell lysates (INPUT) and immunoprecipitated proteins (IP) were separated 
by SDS-PAGE and analysed by immunoblotting with mouse-anti-D8, mouse-anti-FLAG or 
rabbit-anti-HA antibodies. The location of protein molecular mass markers are indicated 
(kDa). 
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Transcriptome analysis suggested C6 to be an immediate-early gene (Assarsson et al, 2008) 
and this was confirmed by both immunoblotting and immunofluorescence analysis of 
infected cells. C6 was found to be localised to both the cytoplasm and the nucleus of infected 
and transfected cells and its nuclear accumulation was unaffected by the nuclear export 
inhibitor LMB. 
To study C6 both in vitro and in vivo a panel of recombinant viruses were constructed using 
the transient-dominant selection method (Falkner & Moss, 1988). This included a C6 deletion 
virus, a revertant virus, a frame-shift virus and two epitope-tagged C6 viruses. The successful 
construction of a virus lacking the C6 ORF indicated that C6 was a non-essential viral 
protein. Genomic DNA was purified from the recombinant viruses that were to be used for in 
vivo experiments and subjected to digestion with two restriction enzymes, followed by 
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Figure 3.16: Dimerisation of over-expressed C6 by LUMIER assay. HEK293 cells were 
co-transfected with a plasmid expressing renilla luciferase(LUC)-tagged C6 and with 
plasmids expressing either FLAG-GFP, C6-FLAG or C6-TAP. The cells were harvested in 
IP buffer and the cleared lysates were incubated with FLAG agarose beads. The proteins 
bound to the beads were eluted in a buffer containing 250 ng/ml FLAG peptide. The 
luminescence in the samples was measured after elution from the beads and was normalised 
to the total luminescence in the whole cell lysate. Data are from one representative 
experiment of three and are presented as a fold binding normalised to the FLAG-GFP 
control.  
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agarose gel electrophoresis. All of the viruses showed the expected sizes of restriction 
fragments indicating that no major genomic rearrangements or deletions had occurred during 
their construction.  
Co-IP and LUMIER assays using C6 tagged with two different epitopes/molecules 
demonstrated that C6 was able to dimerise, consistent with other members of the Bcl-2-like 
family N1 (Bartlett et al, 2002), B14 and A52 (Graham et al, 2008). The functional relevance 
of this dimerisation ability in the context of viral infection is currently unknown.     
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Chapter 4: Characterisation of C6 as an inhibitor of 
innate immune signalling 
4.1 Inhibition of IFNβ induction by protein C6 
Given the role of other Bcl-2-like VACV proteins in innate immune evasion, namely the 
inhibition of NF-κB by A46, A52 (Bowie et al, 2000), B14 (Chen et al, 2008) and N1 
(Cooray et al, 2007; DiPerna et al, 2004) and the inhibition of the IRF3 intracellular immune 
signalling pathway by K7 (Schroder et al, 2008), it was hypothesised that C6 may function in 
a similar manner. IFNs play a very important role in the cellular defence against viruses, 
particularly IFNβ which is produced early in response to infection. The promoter of the IFNβ 
gene contains binding sites for the NF-κB, IRF3 and AP-1 transcription factors (Thanos & 
Maniatis, 1995; Visvanathan & Goodbourn, 1989) and therefore those Bcl-2 family members 
that inhibit the activation of these transcription factors ultimately reduce the induction of 
IFNβ.  
To test the potential effect of C6 on IFNβ induction a dual luciferase reporter gene assay was 
performed in human HEK293ET cells. Unlike HEK293 cells that do not exhibit IFNβ 
induction when incubated with the dsRNA mimic poly I:C in the culture medium, the 
HEK293ET cell line is able to respond to RNA in this manner (Ryzhakov & Randow, 2007). 
The mechanism by which this occurs is not currently known, but it is believed to be via the 
cytoplasmic RNA sensors, as these cells, like HEK293T cells, do not express TLR3. These 
cells were transfected in 96-well plates with an IFNβ-promoter firefly luciferase reporter 
plasmid, where the expression of firefly luciferase is under the control of the IFNβ promoter, 
a renilla luciferase reporter plasmid whose expression is under the control of the thymidine 
kinase (TK) promoter and therefore acts as a transfection control, and 100, 200 or 300 ng of a 
plasmid expressing TAP-C6.  Twenty four h later the cells were stimulated by incubation for 
9 h in the presence of 20 μg/ml poly I:C in the overlay and then harvested for measurement of 
firefly and renilla luciferase activity. The firefly luciferase activity was normalised to renilla 
luciferase activity to account for transfection efficiency, and these data normalised to the un-
stimulated EV control to give a fold induction relative to the control. Incubation of 
HEK293ET cells with poly I:C led to a 50-fold induction of the IFNβ-promoter and this was 
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inhibited in a concentration-dependent manner by the presence of C6 (Figure 4.1A). This 
inhibition was highly statistically significant (P<0.001) when analysed using the Student‟s T-
test. 
To understand whether the inhibition of IFNβ induction by C6 was specific to signalling 
downstream of RNA, other stimuli known to induce IFNβ promoter activity were tested by 
reporter gene assay. Transfection of cells with the dsDNA mimic poly dA:dT for 24 h led to a 
3-fold induction from the IFNβ promoter, which was again inhibited in a concentration-
dependent manner by C6 (Figure 4.1B). As with poly I:C, this inhibition was highly 
statistically significant (P<0.001). In HEK cells poly dA:dT is bound by RNA pol III and 
transcribed into RNA, which is sensed by RIG-I (Ablasser et al, 2009; Chiu et al, 2009), a 
cytoplasmic RNA sensor that signals via the canonical and non-canonical IKK complexes to 
induce IFNβ production (Sasai et al, 2006; Yoneyama et al, 2004).  Consistent with the 
ability of C6 to inhibit the induction of IFNβ in response to poly dA:dT transfection, C6 was 
also found to be inhibitory following the infection of HEK293ET cells with Newcastle 
disease virus (NDV) with statistical significance (Figure 4.1C). NDV is an RNA virus of the 
Paramyxoviridae family and like poly dA:dT, is sensed by RIG-I (Kato et al, 2005). 
In addition to inhibiting IFNβ induction in human cells, the ability of C6 to inhibit innate 
immune signalling in murine cells was also tested. Murine NIH3T3 cells were transfected 
with the same IFNβ reporter and renilla luciferase plasmids as described above and either 100 
or 200 ng of a plasmid expressing TAP-C6. After 24 h the cells were stimulated by 
transfection with 800 ng poly I:C per well for a further 24 h. This stimulation induced a 
robust induction from the IFNβ promoter, which was again inhibited by the presence of C6 
with high statistical significance (P<0.01) (Figure 4.1D). Poly I:C delivered to the cytoplasm 
by transfection is recognised by the cytoplasmic RNA sensor MDA-5 (Andrejeva et al, 2004; 
Kang et al, 2004; Kang et al, 2002). These data indicated that C6 was able to inhibit IFNβ 
induction downstream of both RIG-I and MDA-5, indicating that its method of inhibition was 
likely at a point of a signalling pathway common to these receptors. These data also indicated 
that the inhibitory function of C6 was conserved in both human and murine cells. 
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Figure 4.1: C6 inhibits IFNβ induction in human and murine cells. (A, B, C) 
HEK293ET cells were transfected in 96-well plates with 60 ng of IFNβ-promoter firefly 
luciferase reporter plasmid, 10 ng of renilla luciferase transfection control plasmid, 100, 200 
or 300 ng of a C6 expression plasmid (C6) or empty vector control (EV) per well. After 24 h 
cells were stimulated for 9 h with 20 µg/ml poly(I:C) (A), transfected for 24 h with 800 ng 
poly(dA-dT) per well (B), or mock-infected or infected for 16 h with NDV (C). (D) Mouse 
NIH3T3 cells were transfected as above and stimulated by transfection for 24 h with 800 ng 
poly(I:C) per well. All cells were harvested in passive lysis buffer and the firefly luciferase 
activity was measured and normalised to the renilla luciferase activity. Data are from one 
representative experiment of at least three, with each being performed in triplicate. Data are 
represented as mean ± standard deviation (SD) normalised to the un-stimulated EV control. 
* P<0.05, ** P<0.01, *** P<0.001 analysed using the Student‟s T-test.   
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The inhibitory action of C6 was evident using a plasmid expressing TAP-C6. As recombinant 
viruses had been constructed with C-terminally tagged C6 (vC6HA and vC6TAP) for 
identification of novel binding partners, it was important to determine that epitope-tagging 
C6 in this manner would not affect its function. HEK293 cells were transfected with the 
IFNβ-promoter firefly luciferase reporter plasmid, the renilla luciferase transfection control 
and 250 ng of plasmids encoding un-tagged (Figure 4.2A), N- and C-terminally TAP-tagged 
C6 (Figure 4.2A), N- and C-terminally histidine (HIS)-tagged C6 (Figure 4.2B), frame-shift 
C6 (Figure 4.2B) and C-terminally HA-tagged C6 (Figure 4.2C). The cells were stimulated 
by co-transfection with a plasmid expressing the adaptor molecule TRIF lacking the RIP 
domain, as the RIP domain induces cellular apoptosis (Kaiser & Offermann, 2005) 
(TRIFΔRIP, Figures 4.2A & B) or with 40 μg/ml poly I:C in the overlay (Figure 4.2C). These 
stimuli induced a robust induction from the IFNβ promoter that was inhibited by C6 
regardless of the tag or its location. As expected, the plasmid encoding frame-shift C6, which 
does not express C6 protein, was incapable of inhibiting IFNβ induction (Figure 4.2B).    
4.2 Conservation of IFNβ inhibition by protein C6 expressed from MVA 
Protein C6 from VACV strains WR and MVA (encoded by gene 019) show 97 % amino acid 
sequence identity, but differ in their C termini where an additional six amino acids are present 
in 019, but not C6 (Figure 4.3A). MVA is a highly passaged and attenuated VACV strain. 
This attenuation is due to the deletion of large regions of non-essential genes from the 
genome (Meyer et al, 1991). In addition a number of proteins with a role in innate immune 
evasion have insertions or deletions within their coding sequence rendering them non-
functional, including the soluble receptors for IFNγ, IFNα/β, TNF and CC chemokines 
(Blanchard et al, 1998) and MVA gene 183R, encoding an orthologue of B14 (McCoy et al, 
2010), a protein which when expressed full length has anti-NF-κB signalling activity (Chen et 
al, 2008).  
To determine whether the additional six C-terminal amino acids in 019 rendered it non-
functional, 019 was amplified from MVA genomic DNA by PCR and cloned into the 
pcDNA4/TO N-terminal TAP vector yielding a plasmid that expressed TAP-019. This 
plasmid was then analysed by IFNβ reporter gene assay in HEK293 cells stimulated by co- 
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Figure 4.2: C6 epitope-tagged at either terminus inhibits IFNβ induction. (A, B) 
HEK293 cells were transfected in 96-well plates with 60 ng of IFNβ-promoter firefly 
luciferase reporter plasmid, 10 ng of renilla luciferase transfection control plasmid, 250 ng 
of un-tagged (C6) or TAP-tagged C6 (A), or frame-shifted C6 (C6 FS) or HIS-tagged C6 (B) 
or empty vector control (EV) expression plasmid and 70 ng of TRIFΔRIP expression 
plasmid per well. After 24 h the cells were harvested in passive lysis buffer and the firefly 
luciferase activity was measured and normalised to the renilla luciferase activity. (C) 
HEK293ET cells were transfected in 96-well plates with 60 ng of IFNβ-promoter firefly 
luciferase reporter plasmid, 10 ng of renilla luciferase transfection control plasmid, 250 ng 
of HA-tagged (C6-HA) or empty vector control (EV) expression plasmid. After 24 h the 
cells were stimulated by incubation with 40 μg/ml poly I:C in the overlay for 8 h. Data are 
from one representative experiment of at least three, each performed in triplicate. Data are 
represented as mean ± SD fold induction normalised to the un-stimulated (EV) control of 
each plasmid. ** P<0.01, *** P<0.001, analysed using the Student‟s T-test.  
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Figure 4.3: Conservation and functionality of C6 encoded by MVA. (A) Amino acid 
sequence alignment of the C6 protein from VACV strains WR and MVA. (B) HEK293 cells 
were transfected in 96-well plates with 60 ng of IFNβ-promoter firefly luciferase reporter 
plasmid, 10 ng of renilla luciferase transfection control plasmid, 100 or 250 ng of TAP-C6 
from WR (WR C6) or TAP-019 from MVA (MVA C6) and 70 ng of TRIFΔRIP expression 
plasmid per well. After 24 h the cells were harvested in passive lysis buffer and the firefly 
luciferase activity was measured and normalised to the renilla luciferase activity. Data are 
from one representative experiment of at least three, each performed in triplicate. Data are 
represented as mean ± SD fold induction normalised to the un-stimulated control (EV) of 
each plasmid. ** P<0.01, analysed using the Student‟s T-test.  
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transfection with a plasmid expressing TRIFΔRIP. Both C6 and 019 inhibited IFNβ promoter 
activity in this assay with high statistical significance (P<0.01) indicating the conservation of 
function of this protein in MVA, despite the additional residues at the C terminus (Figure 
4.3B). 
The inhibition of IFNβ induction by C6 was also demonstrated to be conserved in the MPXV 
orthologue of this protein by collaborators in Professor Andrew Bowie‟s laboratory at Trinity 
College Dublin (Unterholzner et al, 2011). This protein differs from VACV C6 by just a few 
amino acids (Figure 3.2). The conservation of function in MPXV is also interesting as this is 
an emerging zoonotic pathogen (Parker et al, 2007). 
4.3 C6 does not inhibit NF-κB signalling 
As discussed in 4.1 the IFNβ promoter contains binding sites for the transcription factors NF-
κB, IRF3 and AP1. To better understand how C6 might inhibit IFNβ promoter activity it was 
tested in an NF-κB reporter gene assay. HEK293 cells were transfected with an NF-κB-
promoter firefly luciferase reporter plasmid, a renilla luciferase transfection control and 100 
ng of a plasmid expressing C6, B14 or an empty vector control. After 24 h the cells were 
stimulated for 8 h with TNFα (50 ng/ml) or IL-1β (100 ng/ml). The binding of TNFα 
(DiDonato et al, 1997) and IL-1β (Woronicz et al, 1997) to their respective receptors induces 
independent signalling cascades which converge on the canonical IKK complex, consisting of 
the kinases IKKα, IKKβ (Zandi et al, 1997) and the regulatory subunit NEMO (Rothwarf et 
al, 1998). Activation of this complex leads to phosphorylation of IκBα and the subsequent 
release of NF-κB allowing it to translocate to the nucleus and bind to the promoter of NF-κB-
responsive genes, such as IFNβ. Stimulation of HEK293 cells with TNFα induced an 
approximate 40-fold induction of NF-κB reporter activity, whilst stimulation with IL-1β 
induced a more modest 15-fold induction (Figure 4.4A). In both cases the presence of C6 was 
found not to affect this activation whereas protein B14 was a potent inhibitor, as expected 
(Chen et al, 2008). 
The ability of C6 to inhibit NF-κB activity was also tested by immunoblotting the lysates of 
cells that had been stimulated with TNFα for total IκBα and its phosphorylated form. When 
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Figure 4.4: C6 does not inhibit NF-κB signalling. (A) HEK293 cells were transfected in 
96-well plates with 60 ng of NF-κB-promoter firefly luciferase reporter plasmid, 10 ng of 
renilla luciferase transfection control plasmid and 100 ng of a C6, B14 or empty vector 
control (EV) expression plasmid per well. After 24 h the cells were stimulated for 8 h with 
TNFα (50 ng/ml) or IL-1β (100 ng/ml). The cells were harvested in passive lysis buffer and 
the firefly luciferase activity was measured and normalised to the renilla luciferase activity. 
Data are from one representative experiment of at least three, each performed in triplicate. 
Data are represented as mean ± SD normalised to the un-stimulated control (Mock) of each 
plasmid. ** P<0.01, *** P<0.001 analysed using the Student‟s T-test. (B) HEK293 cells 
were transfected with a TAP-C6, FLAG-B14 or empty vector (EV) control expression 
plasmid for 24 h. The cells were stimulated with 100 ng/ml TNFα and  harvested at the 
indicated times. The whole cell lysates were analysed by immunoblotting with rabbit-anti-
IκBα, mouse-anti-phospho-IκBα (P-IκBα), mouse-anti-FLAG or mouse-anti-tubulin 
antibodies. The location of protein molecular mass markers is indicated (kDa).  
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 the canonical IKK complex becomes activated due to upstream signalling events, the IKK 
kinases cooperate to phosphorylate IκBα leading to its ubiquitination and subsequent 
degradation by the proteasome, thus releasing the NF-κB transcription factor (Beg et al, 
1993). After incubation of HEK293 cells in the presence of TNFα for 15 min, a substantial 
decrease in total IκBα was observed in the empty vector control-transfected cells (Figure 
4.4B). This was accompanied by the appearance of the phosphorylated form of this protein, 
with the highest levels detected after 60 min of stimulation. In contrast, levels of total IκBα 
were higher in cells expressing B14 and phosphorylated IκBα was only weakly detected. This 
is consistent with work published by our laboratory characterising the binding of B14 to 
IKKβ, inhibiting its kinase function and hence preventing the phosphorylation of IκBα (Chen 
et al, 2008). Both IκBα phosphorylation and degradation were observed in the presence of 
C6, confirming reporter gene assay data showing that C6 does not have a role in inhibiting 
NF-κB activation. 
A third assay, namely a p65 translocation assay analysed by immunofluorescence, was also 
performed to assess the effect of C6 on NF-κB signalling. HeLa cells were transfected 
overnight with a plasmid expressing TAP-C6, FLAG-B14 or empty vector control and then 
stimulated with TNFα or IL-1β for 30 min. The cells were stained for the FLAG epitope of 
C6 and B14 and for endogenous p65, one of the subunits of the NF-κB heterodimer. In 
resting cells p65 was mainly cytoplasmic, regardless of the presence of C6 or B14 (Figure 
4.5). When empty vector control – transfected cells were stimulated with either TNFα or IL-
1β p65 was observed in the nucleus, co-localised with the DNA stain DAPI, suggesting 
translocation of this protein had occurred. This translocation induced by either stimulus was 
not affected by the presence of C6, but was prevented in both cases in cells expressing 
FLAG-B14, where p65 remained cytoplasmic.  
These data indicated that C6 did not inhibit NF-κB signalling in a reporter gene assay (Figure 
4.4A) and did not inhibit the translocation of p65 to the nucleus (Figure 4.5), whereas B14 
had an inhibitory function in both of these assays. In addition, IκBα degradation was 
observed in the presence of C6 after stimulation of cells with TNFα and higher levels of 
phosphorylated IκBα were detected than cells expressing B14 (Figure 4.4B). Taken together, 
these data therefore indicated that C6 did not inhibit NF-κB signalling pathways.   
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Figure 4.5: C6 does not inhibit p65 translocation. HeLa cells were transfected overnight 
with a plasmid expressing TAP-C6, FLAG-B14 or empty vector (EV) control. The cells 
were stimulated with TNFα (100 ng/ml) or IL-1β (250 ng/ml) for 30 mins, fixed and stained 
with rabbit anti-FLAG and mouse-anti-p65 antibodies. The localisation of C6 or B14 
(green), endogenous p65 (red), nuclear DNA stained with DAPI (blue) and merged images 
are shown.  
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 4.4 Inhibition of IRF3 activation by protein C6 
In addition to testing the potential effect of C6 on the NF-κB signalling pathway, the effect of 
this protein on IRF3 signalling was also tested. To assess IRF3-specific promoter activity an 
ISG56.1-promoter firefly luciferase reporter plasmid was utilised. Transcription of this gene 
is highly dependent on, and specific for the IRF3 transcription factor (Grandvaux et al, 2002). 
HEK293ET cells were transfected with this reporter plasmid, the renilla luciferase 
transfection control and 100 ng of a C6, B14 or empty vector control expression plasmid. 
After 24 h cells were stimulated by transfection for 24 h with 800 ng poly I:C or poly dA:dT 
per well. Transfection with either of these stimuli induced an approximate 5-6 fold increase 
in IRF3 promoter activity, which was unaffected by the presence of B14 (Figure 4.6). In 
contrast the presence of C6 significantly reduced IRF3 induction in response to either 
stimulus (P<0.01). 
The effect of C6 on IRF3 signalling was also tested at the mRNA and protein level by qRT-
PCR and ELISA, respectively. HEK293ET cells were transfected in triplicate in 24-well 
plates with 1.5 μg of a TAP-C6, FLAG-GFP or empty vector control (EV) expression 
plasmid per well. After 24 h cells were stimulated by infection with NDV. For qRT-PCR 
analysis the cells were harvested 6 h p.i., the RNA was extracted, cDNA was synthesized and 
this was then used for qRT-PCR analysis using primers specific for human CCL-5, an IRF3-
dependent gene (Lin et al, 1999a). Infection with NDV induced a relative 300-fold increase in 
CCL-5 mRNA, which was reduced by 50 % in cells expressing C6 (Figure 4.7A). Such an 
inhibition was not observed in the presence of GFP. For protein expression experiments the 
cell supernatants were harvested 24 h p.i. and were analysed for CXCL-10, a protein with 
IRF3-dependent expression (Ohmori & Hamilton, 1993), by ELISA. Approximately 120 
pg/ml of CXCL-10 was detected in the supernatants of empty vector control – transfected 
cells infected with NDV (Figure 4.7B). In the presence of C6 however, CXCL-10 production 
was significantly reduced, a phenomenon that was again not observed in the presence of GFP. 
Taken together these data demonstrated that C6 was an inhibitor of IRF3 activation. This 
inhibition was observed by reporter gene assay using the promoter of the IRF3-dependent 
gene ISG56.1 fused to firefly luciferase, as well as by qRT-PCR and ELISA where C6 was  
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able to inhibit the expression of an IRF3-dependent gene and protein in cells that had been 
infected with NDV. Further to this, collaborators in Andrew Bowie‟s laboratory 
demonstrated the ability of C6 to inhibit IRF3 translocation to the nucleus following the 
stimulation of cells with SeV (Unterholzner et al, 2011), a paramyxovirus that like NDV is 
sensed by RIG-I and induces IRF3 signalling and IFNβ production (Li et al, 2005). 
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Figure 4.6: C6 inhibits IRF3 induction. HEK293ET cells were transfected in 96-well 
plates with 60 ng of ISG56.1-promoter firefly luciferase reporter plasmid, 10 ng of renilla 
luciferase transfection control plasmid and 100 ng of a C6, B14 or empty vector control 
(EV) expression plasmid per well. After 24 h the cells were stimulated by transfection for 24 
h with 800 ng poly(I:C) or poly(dA-dT) per well. The cells were harvested in passive lysis 
buffer and the firefly luciferase activity was measured and normalised to the renilla 
luciferase activity. Data are from one representative experiment of at least three, each 
performed in triplicate. Data are represented as mean ± SD normalised to the un-stimulated 
control (Mock) of each plasmid. ** P<0.01, analysed using the Student‟s T-test.  
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4.5 C6 inhibits IRF3 signalling downstream, or at the level of the non-
canonical IKK complex 
To gain an understanding of how C6 blocked the activation of IRF3, experiments were 
performed to determine the level at which it inhibited the IRF3 signalling cascade. The IRF3 
translocation data from Professor Bowie‟s laboratory indicated that C6 was not inhibiting 
IRF3 activation in the nucleus, as its translocation was prevented in the presence of this 
protein (Unterholzner et al, 2011). This implied that C6 was abrogating IRF3 signalling 
within the cytoplasm of stimulated cells. The reporter gene assay data presented in Figure 4.1 
demonstrated that C6 was able to inhibit IFNβ induction downstream of various stimuli that 
are sensed by different PRRs, suggesting C6 was unlikely to inhibit the receptors themselves. 
Further to this, C6 was found to inhibit the activation of IFNβ following the over-expression 
of TRIFΔRIP (Figure 4.2), therefore indicating that C6 acted downstream of this adaptor 
protein.   
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Figure 4.7: C6 inhibits IRF3-dependent gene expression and protein production. 
HEK293ET cells were transfected in triplicate in 24-well plates with 1.5 μg of a C6, GFP or 
empty vector control (EV) expression plasmid per well. After 24 h the cells were stimulated 
by infection with NDV for 6 h (A) or 24 h (B). (A) Following stimulation RNA was 
extracted from the cells, cDNA was synthesized and used for qRT-PCR analysis in duplicate 
using primers specific for human CCL-5. Data are represented as mean ± SD stimulation 
relative to sample one of the mock-treated EV control. (B) Following stimulation the culture 
supernatant was analysed for human CXCL-10 protein in duplicate by ELISA. Data are 
represented as mean ± SD. * P<0.05, analysed using the Student‟s T-test.  
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To further narrow down the point at which C6 inhibited IRF3 signalling, reporter gene assays 
were performed where IRF3 or IFNβ activation were induced by the over-expression of 
various proteins characterised to have a role in the IRF3 signalling cascade. In agreement 
with data presented in Figure 4.2, C6 was found to inhibit IRF-3 as well as IFNβ activation in 
cells over-expressing the TLR adaptor protein TRIF (Figure 4.8A). C6 was also able to 
inhibit IRF3 activation induced by the RIG-I adaptor molecule MAVS in a concentration-
dependent manner. Moving further downstream in the signalling cascade C6 was found to 
inhibit IRF3-dependent transcription following the over-expression of the kinases TBK1 and 
IKKε (Figure 4.8B), both of which activated IRF3, albeit weaker than the adaptor molecules 
shown in Figure 4.8A. Finally, the over-expression of IRF3 itself was used to stimulate IFNβ 
induction, however C6 was found not to inhibit in this instance (Figure 4.8C).  
In conclusion, these data demonstrated that C6 could inhibit IRF3 activation downstream of 
the adaptors TRIF and MAVS, as well as the kinases of the non-canonical IKK complex, but 
acted upstream of IRF3, as inhibition was no longer observed following the over-expression 
of this molecule. This implied that the likely level of inhibition of C6 was downstream, or at 
the level of the non-canonical IKK complex (Figure 4.8D). 
4.6 C6 inhibits signalling downstream of IFNα but not IFNγ  
Following the expression and secretion of IFNs in response to infection, these molecules act 
in a paracrine and autocrine manner to induce the expression of ISGs, causing an antiviral 
state in the cell. The binding of IFNs to their respective receptors induces intracellular 
signalling cascades involving the JAK kinases and STAT transcription factors, which 
ultimately translocate to the nucleus and bind to the promoters of IFN responsive genes, thus 
regulating their transcription (reviewed in (Takaoka & Yanai, 2006). The binding of the type 
I IFNs, IFNα and IFNβ to the IFNα/β receptor ultimately regulates the transcription of genes 
with an ISRE in their promoter. To investigate whether C6 was able to abrogate IFN 
signalling HEK293 cells were transfected with an ISRE-promoter firefly luciferase reporter 
plasmid, a renilla luciferase transfection control and 100 or 200 ng of a C6, B14 or empty 
vector control expression plasmid. After 24 h cells were stimulated for 8 h with 250 U/ml 
IFNα. IFNα treatment induced an approximate 120-fold activation of the ISRE reporter in  
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Figure 4.8: C6 inhibits IRF3 induction downstream, or at the level of the non-canonical 
IKK complex. HEK293 cells were transfected in 96-well plates with 60 ng of ISG56.1- (A, 
B) or IFNβ- (C) promoter firefly luciferase reporter plasmid, 10 ng of renilla luciferase 
transfection control plasmid, 100 ng or 200 ng of a C6 or empty vector control (EV) 
expression plasmid and 70 ng of TRIFΔRIP or MAVS (A), 200 ng of TBK1 or IKKε (B) or 
200 ng of IRF3 (C) expression plasmid per well. After 24 h the cells were harvested in 
passive lysis buffer and the firefly luciferase activity was measured and normalised to the 
renilla luciferase activity. Data are from one representative experiment of at least three, each 
performed in triplicate. Data are represented as mean ± SD normalised to the un-stimulated 
EV control. n.s. Not significant, * P<0.05, ** P<0.01, analysed using the Student‟s T-test. 
(D) Summary of C6 inhibition in schematic form with green ticks indicating inhibition by 
C6 observed and the red cross indicating no inhibition by C6 after over-expression of this 
protein. 
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empty vector-transfected cells, which was reduced to less than 50-fold in cells transfected 
with a plasmid expressing C6 (Figure 4.9B). The same effect was not observed when cells 
were transfected with a plasmid expressing B14, as observed previously (Chen et al, 2008).  
To understand if the inhibition of ISRE activation downstream of IFNα was the only IFN-
induced signalling pathway that C6 had an effect on, signalling downstream of IFNγ was also 
tested. When IFNγ binds to the IFNγ receptor STAT1 is activated, translocates to the nucleus 
and regulates the transcription of genes with a GAS element in their promoter. To investigate 
IFNγ signalling HEK293 cells were transfected with a GAS-promoter firefly luciferase 
reporter plasmid, renilla luciferase transfection control and 200 ng of a C6, B14 or empty 
vector control expression plasmid. After 24 h cells were stimulated for 8 h with 1000 ng/ml 
IFNγ. Unexpectedly, this treatment did not induce any activation of the GAS reporter and 
thus HeLa cells were tested instead. In these cells treatment with 1000 ng/ml IFNγ induced an 
approximate 50-fold activation of the GAS reporter and this was unaffected by the presence 
of C6 or B14 suggesting that neither of these proteins were able to inhibit signalling 
downstream of IFNγ (Figure 4.9B).  
These data indicated that C6 specifically inhibited signalling downstream of the type I IFNs 
and was unlikely to act on a protein that is common to both type I and type II IFN signalling 
pathways, for example STAT1, but was more likely to act on a protein unique to IFNα/β 
signalling. Incubation of cells with IFNλ also activates the transcription of genes with an 
ISRE in their promoter (Meager et al, 2005). It would therefore be interesting to determine 
whether C6 is able to inhibit ISRE-reporter plasmid activity downstream of these type III 
IFNs. If so, these data may indicate where C6 is likely to inhibit these signalling pathways. 
The mechanism by which C6 inhibits type I IFN signalling is currently unknown. 
4.7 Summary  
Given the role of many of the other VACV Bcl-2-like family members in evasion of innate 
immune signalling it was hypothesised that C6 may too have an immunodulatory function. 
To this end, C6 was found to inhibit IFNβ reporter activity in a concentration-dependent 
manner downstream of a number of stimuli, including infection with NDV. This inhibition  
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was observed in both human and murine cells, and was unaffected by a number of epitope 
tags, located at either the N or C terminus of the C6 protein. The conservation of IFNβ 
inhibition was found in MVA 019 and MPXV, orthologues of protein C6.  
Signalling downstream of the TLRs and RLRs activates multiple transcription factors 
including NF-κB, IRF3 and AP1. These transcription factors cooperate in activating the 
transcription of the IFNβ gene. The ability of C6 to inhibit IFNβ induction was not due to an 
effect on NF-κB because C6 was found not to inhibit NF-κB induction by reporter gene 
assay, analysing IκBα phosphorylation and degradation by immunoblotting, or p65 
translocation to the nucleus by immunofluorescence. Instead, C6 was found to have an 
inhibitory role on the IRF3 signalling pathway. Reporter gene assay data obtained using the 
ISG56.1 promoter reporter plasmid, which has an IRF3 binding site indicated that C6 
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Figure 4.9: C6 inhibits signalling downstream of IFNα but not IFNγ. (A) HEK293 cells 
were transfected in 96-well plates with 60 ng of ISRE-promoter firefly luciferase reporter 
plasmid, 10 ng of renilla luciferase transfection control plasmid and 100 ng or 200 ng of a 
C6, B14 or empty vector control (EV) expression plasmid. After 24 h the cells were 
stimulated for 8 h with 250 U/ml IFNα. (B) HeLa cells were transfected in 96-well plates 
with 60 ng of GAS-promoter firefly luciferase reporter plasmid, 10 ng of renilla luciferase 
transfection control plasmid and 200 ng of a C6, B14 or empty vector control (EV) 
expression plasmid. After 24 h the cells were stimulated for 8 h with 1000 ng/ml IFNγ. The 
cells were harvested in passive lysis buffer and the firefly luciferase activity was measured 
and normalised to the renilla luciferase activity. Data are from one representative experiment 
of at least three, each performed in triplicate. Data are represented as mean ± SD normalised 
to the un-stimulated control (Mock) of each plasmid. * P<0.05, analysed using the Student‟s 
T-test.  
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inhibited its activation downstream of both poly I:C and poly dA:dT in a concentration-
dependent manner, whereas B14 did not. Further to this, C6 was found to inhibit the 
transcription of CCL-5 and production of CXCL-10, both IRF3 specific genes, following 
infection of HEK293ET cells with NDV. The point at which C6 inhibited IRF3 signalling 
was also determined by over-expressing known proteins in the signalling pathway to drive 
activation of the ISG56.1 reporter plasmid. C6 was found to inhibit downstream, or at the 
level of the non-canonical IKK complex because it was able to inhibit IRF3 induction 
following over-expression of the kinases TBK1 and IKKε, but not the induction of IFNβ 
downstream of IRF3 itself.  
Finally, in addition to the role of C6 in inhibiting IFNβ induction, this protein was found to 
inhibit signalling downstream of the IFNAR, reducing the activation of an ISRE reporter 
plasmid following the treatment of cells with IFNα. This inhibition was specific to signalling 
downstream of IFNα, as no such inhibition was observed on the activation of a GAS reporter 
plasmid following the treatment of cells with IFNγ. The mechanism by which C6 exerts this 
inhibitory action is currently unknown and warrants further investigation. 
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Chapter 5: Characterisation of the binding of C6 to the 
non-canonical IKK complex adaptor proteins TANK, 
SINTBAD and NAP1 
5.1 C6 binds the non-canonical IKK complex adaptor protein TANK 
Given that C6 was able to inhibit IRF3 signalling, and the level of this inhibition was 
determined to be at, or downstream of the non-canonical IKK complex, a LUMIER assay was 
used to screen for the binding of C6 to known components of this complex. HEK293 cells 
were co-transfected with a plasmid expressing a LUC – tagged prey protein, namely the two 
kinases of the non-canonical IKK complex IKKε and TBK1, and the three adaptor proteins 
TANK, SINTBAD and NAP1, and a plasmid expressing a FLAG-tagged bait protein. The 
cells were harvested 48 h later and cleared lysates were used for the LUMIER assay (see 
Chapter 2), and also separated by SDS-PAGE and analysed by immunoblotting for the 
expression of the FLAG-tagged protein.  
In all instances the LUC-tagged prey proteins were found to co-immunoprecipitate with their 
respective positive control FLAG-tagged bait proteins, which was TBK1 for the adaptor 
proteins and TANK for the kinases (Figure 5.1). Expression of all FLAG-tagged proteins was 
detected by immunoblotting, except for FLAG-TBK1, a problem which was observed on a 
number of occasions, but given that all three LUC-tagged adaptor proteins were found to be 
co-immunoprecipitated in cells transfected with a plasmid expressing this protein, this 
problem was likely to be a detection issue rather than a problem with expression. TAP-C6 
was found to co-immunoprecipitate LUC-TANK, but not LUC-tagged SINTBAD, NAP1 or 
IKKε, suggesting an interaction between these two proteins. A weak interaction was detected 
between TAP-C6 and LUC-TBK1, however this was probably background levels of binding, 
possibly mediated via the interaction of C6 with TANK.  
To determine whether the interaction of C6 with TANK could be observed during the context 
of a viral infection HEK293 cells were either co-transfected with a plasmid expressing a 
LUC-tagged prey protein and FLAG-GFP, or transfected with a plasmid expressing a LUC- 
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Figure 5.1: C6 interacts with TANK in a LUMIER assay. HEK293 cells were co-
transfected with a plasmid expressing a renilla luciferase (LUC) – tagged prey protein and a 
plasmid expressing a FLAG-tagged bait protein (TAP-C6 for C6). The cells were harvested 
48 h later in IP buffer and cleared lysates were incubated with FLAG agarose beads. A 
proportion of the whole cell lysate was analysed for total luminescence and also separated 
by SDS-PAGE and analysed by immunoblotting for the expression of the FLAG-tagged 
protein. The FLAG agarose beads were washed three times in IP buffer and the bound 
proteins were eluted using 150 ng/ml FLAG peptide. The luminescence after 
immunoprecipitation was measured and normalised to the total luminescence of the sample. 
A fold binding was calculated by normalising to a FLAG-GFP control. The location of 
protein molecular mass markers is indicated (kDa).    
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tagged prey protein and then infected with vC6TAP, or vΔC6 as a control. After the 
LUMIER assay was performed an equivalent level of background binding of the LUC-tagged 
prey proteins was observed in the cells transfected with FLAG-GFP, or infected with vΔC6, 
and thus only data for FLAG-GFP are presented in Figure 5.2. In agreement with LUMIER 
data obtained by over-expression of TAP-C6, LUC-TANK was co-immunoprecipitated with 
C6-TAP expressed by vC6TAP (Figure 5.2). No such binding was observed for the other 
proteins in the non-canonical IKK complex, or the proteins of the canonical IKK complex, 
namely IKKα, IKKβ and the regulatory subunit NEMO. All LUC-tagged proteins had been 
tested previously for binding to positive control FLAG-tagged molecules indicating their 
functionality in this assay (data not shown). The expression of FLAG-GFP or C6-TAP was 
confirmed in all samples by immunoblotting (Figure 5.2).  
The binding of C6 to TANK in the context of a viral infection was also confirmed using 
conventional immunoprecipitation assays. HEK293 cells were transfected for 24 h with a 
plasmid expressing TANK and then infected for 4 h with 5 p.f.u. per cell of vC6WR, or vΔC6 
as a control. Cleared lysates were incubated with the rabbit-anti-C6 serum coupled to protein 
G sepharose beads to immunoprecipitate C6 from the infected cells. Over-expressed TANK 
was found to co-immunoprecipitate with un-tagged C6 expressed from vC6WR but not in 
cells infected with vΔC6, indicating the specificity of this interaction (Figure 5.3A). In a 
converse experiment HEK293 cells were transfected with a plasmid expressing TANK and 
then infected with vC6HA, or vB14HA as a control and subjected to an immunoprecipitation 
with a goat-anti-TANK Ab coupled to protein G sepharose beads. In this instance C6-HA, but 
not B14-HA was found to co-immunoprecipitate with TANK, again indicating the specificity 
of the interaction (Figure 5.3B). 
Taken together these data indicated that both over-expressed C6 and C6 expressed at natural 
levels from cells infected with VACV WR could interact with over-expressed TANK, and 
this was demonstrated following the immunoprecipitation of TANK or C6. 
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Figure 5.2: Virally expressed C6 interacts with TANK in a LUMIER assay. HEK293 
cells were co-transfected with a plasmid expressing a LUC – tagged prey protein and a 
plasmid expressing FLAG-GFP or empty vector control. Thirty two h later empty vector-
transfected wells were infected overnight with vC6TAP at 2 p.f.u. per cell. The cells 
transfected with FLAG-GFP were mock-infected overnight. The cells were harvested in IP 
buffer and cleared lysates were incubated with FLAG agarose beads. A proportion of the 
whole cell lysate was analysed for total luminescence and also separated by SDS-PAGE and 
analysed by immunoblotting for the expression of the FLAG-tagged protein. The FLAG 
agarose beads were washed three times in IP buffer and the bound proteins were eluted 
using 150 ng/ml FLAG peptide. The luminescence after immunoprecipitation was measured 
and normalised to the total luminescence of the sample. A fold binding was calculated by 
normalising to a FLAG-GFP control. The location of protein molecular mass markers is 
indicated (kDa).    
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Figure 5.3: C6 interacts with over-expressed TANK in the context of a viral infection. 
HEK293 cells were transfected with a plasmid expressing TANK for 24 h and then infected 
for 4 h at 5 p.f.u. per cell with the viruses indicated. The cells were harvested in IP buffer 
and cleared lysates were incubated with either rabbit-anti-C6 serum coupled to protein G 
sepharose beads (A) or goat-anti-TANK Ab coupled to protein G sepharose beads (B). The 
whole cell lysates (INPUT) and immunoprecipitated proteins (IP) were separated by SDS-
PAGE and analysed by immunoblotting with goat-anti-TANK, rabbit-anti-C6 or rabbit-anti-
HA antibodies. The location of protein molecular mass markers is indicated (kDa).    
 
155 
 
5.2 C6 interacts with the N-terminal coiled-coil region, but not full length 
hTANK by LUMIER 
To further characterise the interaction of C6 with TANK, a series of truncation mutants were 
designed with Dr. Felix Randow (MRC laboratory of Molecular Biology, Cambridge) based 
on the human sequence of TANK (hTANK). TANK is an adaptor molecule that has been 
described to interact with a number of proteins including TBK1 (Pomerantz & Baltimore, 
1999), IKKε (Nomura et al, 2000), TRAF2 and TRAF3 (Cheng & Baltimore, 1996), NEMO 
(Chariot et al, 2002), IRF3 (Guo & Cheng, 2007) and it also has the ability to homo-dimerise 
(Chin et al, 1999). The structure of this protein has not been solved, but several domains have 
been predicted based on its amino acid sequence and biochemical analysis (see Figure 1.4). 
At the N terminus there is a coiled-coil domain, a domain with an important role in protein-
protein interactions (Figure 5.4A). Between residues 135 and 173 there is the TBD, an α-
helical region responsible for interactions with the kinases TBK1 and IKKε (Ryzhakov & 
Randow, 2007). At the C terminus of the protein there is a zinc-finger domain, a region 
which in addition to the N terminus is required for binding to NEMO (Bonif et al, 2006). 
Based on these domains a set of 7 truncation mutants were constructed with an N-terminal 
renilla luciferase tag, for use in LUMIER assays. The expression of the truncation mutants 
was confirmed by immunoblotting. HEK293 cells were transfected with the LUC – tagged 
hTANK truncation mutants. The cells were harvested 24 h later, the cleared lysates were 
separated by SDS-PAGE and these were analysed by immunoblotting with mouse-anti-renilla 
luciferase and mouse-anti-tubulin antibodies. All of the truncation mutants were expressed 
(indicated by the white arrows, Figure 5.4B), although the expression of 1-135, 1-173 and to 
some extent 1-69 was found to be weaker than the other mutants. The mouse-anti-renilla 
luciferase Ab was found repeatedly to react non-specifically with proteins of approximately 
80 kDa and 100 kDa. 
The interaction of TAP-C6 with the hTANK truncation mutants was then tested by LUMIER 
assay in HEK293 cells. Somewhat surprisingly, unlike full length murine TANK (mTANK), 
which had been previously identified as a binding partner for C6 (Figures 5.1, 5.2 and 5.3), 
full length hTANK did not co-immunoprecipitate with C6 (Figure 5.5A). This molecule 
however did show strong binding to TBK1 indicating that this protein was expressed and had 
folded correctly, or at least sufficiently to bind TBK1. This result was unexpected because  
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Figure 5.4: Human TANK truncation mutants. (A) Schematic representation of hTANK 
and the truncation mutants with the locations of the coiled-coil domain (CC), TBK1-binding 
domain (TBD) and Zinc finger domain (Zn) indicated. (B) Expression of truncation mutants. 
HEK293 cells were transfected with LUC – tagged hTANK truncation mutants. The cells 
were harvested 24 h later in cell lysis buffer and cleared lysates were separated by SDS-
PAGE and analysed by immunoblotting with mouse-anti-renilla luciferase and mouse-anti-
tubulin antibodies. The location of the LUC – tagged proteins is indicated with a white 
arrow. The location of protein molecular mass markers is indicated (kDa).    
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Figure 5.5: C6 interaction with hTANK truncation mutants. (A) HEK293 cells were co-
transfected with a plasmid expressing a LUC – tagged hTANK prey protein and a plasmid 
expressing a FLAG-tagged bait protein. The cells were harvested 48 h later in IP buffer and 
cleared lysates were incubated with FLAG agarose beads. A proportion of the whole cell 
lysate was analysed for total luminescence. The FLAG agarose beads were washed three 
times in IP buffer and the bound proteins were eluted using 150 ng/ml FLAG peptide. The 
luminescence after immunoprecipitation was measured and normalised to the total 
luminescence of the sample. A fold binding was calculated by normalising to a FLAG-GFP 
control.  (B) Amino acid sequence alignment of hTANK and murine TANK (mTANK).  
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murine and human TANK share high amino acid sequence identity (80 %) (Figure 5.5B). 
Notably there is an N-terminal extension in the sequence of mTANK and a ten amino acid 
deletion in this protein at residue 348 compared to hTANK. These differences may explain 
why C6 is able to interact with mTANK by LUMIER assay and not hTANK.  
Despite the lack of binding of full length hTANK to C6 it was surprising to observe twenty 
fold more luminescence of mutant 1-135 in the immunoprecipitation of this protein with 
TAP-C6 than FLAG-GFP, suggesting a possible interaction between these molecules (Figure 
5.5A). Due to the lack of known binding partners that interact solely with the N-terminal 
region of TANK, mutants 1-69 and 1-135 did not have positive controls for this assay. 
Mutant 1-69 is particularly small and may not fold correctly when fused to the large 36 kDa 
renilla luciferase tag. This could therefore explain the lack of interaction with C6. An 
interaction between TAP-C6 and mutants 1-173 and 1-391 was also observed in this assay. 
Both of these molecules showed positive binding to TBK1 as they included the TBD. Mutant 
70-425 did not show an interaction with C6, but did bind TBK1, which acted as a positive 
control for this molecule. Mutant 174-425 also did not bind C6, and because it did not contain 
the TBD TRAF2 was used as a positive control since the binding of TANK to this molecule 
has been characterised to be between residues 173 and 191 (Cheng & Baltimore, 1996). 
Mutant 174-425 did show some binding to FLAG-TRAF2, although this interaction was 
weak. 
In conclusion these data indicated that C6 interacted with the N terminus of hTANK, as 
truncations removing the C terminus were still able to bind. The smallest region found to bind 
C6 was residues 1-135, which included the coiled-coil domain. When the coiled-coil domain 
was not present, such as in mutant 70-425, C6 was no longer able to interact with hTANK, 
suggesting that this region is essential for binding. The coiled-coil domain alone (mutant 1-
69) was not found to interact with C6, but it is not known if this domain of hTANK folded 
correctly when fused to the large LUC tag.  
The finding that C6 interacted with mTANK and some of the truncation mutants of hTANK, 
but not full length hTANK was unexpected. It is possible that with full length hTANK the 
LUC tag obscures the N-terminal coiled-coil domain in some manner, thus preventing the 
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interaction with C6. Of note, the N terminus of mTANK is 34 amino acids longer than 
hTANK (Figure 5.5B), which may provide a spacer between the LUC tag and the domain 
that interacts with C6. In the context of full length hTANK fused to the LUC tag, it is further 
possible that the C terminus of the protein folds incorrectly, potentially precluding the 
binding of C6 to the coiled-coil domain at the N terminus. This may explain why mutants 
where C-terminal regions of the protein are removed show a positive interaction with C6. 
Supporting this hypothesis, the existence of intramolecular interactions between the N and C 
termini of TANK has previously been suggested (Chin et al, 1999), as has an intramolecular 
interaction within the signalling adaptor TRIF (Tatematsu et al, 2010). Of note mutant 1-391 
is still able to interact with C6, suggesting that any preclusion of binding caused by the C 
terminus of the protein would be due to the Zinc finger region.  
5.3 C6 interacts with hTANK by co-immunoprecipitation assay 
To determine if the presence of the LUC tag was preventing the binding of hTANK to C6, a 
conventional immunoprecipitation assay was performed using FLAG-tagged hTANK. 
HEK293ET cells were transfected with plasmids encoding FLAG-tagged GFP, mTANK, or 
hTANK and TAP-C6. After 48 h the cells were harvested and cleared lysates were subjected 
to immunoprecipitation with Strep agarose beads to purify TAP-C6. Both FLAG-tagged 
murine and human TANK were found to co-immunoprecipitate with C6, although the 
interaction with hTANK appeared weaker (Figure 5.6). FLAG-GFP was not found to co-
immunoprecipitate with C6 in this assay indicating the specificity of the interaction of C6 
with TANK. These data indicated that over-expressed FLAG-hTANK was able to interact 
with C6 and that the LUC-hTANK molecule used in the LUMIER assay was not folded 
appropriately to support this interaction.         
5.4 C6 interacts with the N-terminal coiled-coil region of mTANK 
To confirm those data obtained by LUMIER assay using the hTANK mutants, four LUC-
tagged mTANK truncation mutants were constructed (Figure 5.7A). As with the hTANK 
mutants the expression of the mTANK truncations was confirmed by transfecting HEK293 
cells and immunoblotting cell lysates with a mouse-anti-renilla Ab. All four mutants were 
found to express a protein of the expected size, although as with the hTANK truncations this  
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expression varied between the mutants (Figure 5.7B). The interaction of the mTANK 
truncations with C6 was then tested by LUMIER assay. Consistent with data obtained with 
the hTANK truncations, mTANK truncations including the coiled-coil domain (1-120 and 1-
165) interacted with TAP-C6, but those lacking this domain (120-448 and 162-448) did not 
(Figure 5.8 and data not shown). Truncation 120-448 was presumed to be functional by 
LUMIER assay because it was able to interact with TBK1 as a positive control. These data 
confirm previous findings that C6 binds the N-terminal coiled-coil region of TANK, and that 
this region is essential, because when it is deleted C6 is no longer able to interact. Further 
supporting this hypothesis, in the case of mTANK, C6 was found to interact with the coiled-
coil region expressed alone, encoded by residues 1-120. 
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Figure 5.6: C6 interacts with over-expressed hTANK by conventional IP. HEK293ET 
cells were grown in 10-cm dishes and transfected with 5 μg of plasmids encoding FLAG-
tagged GFP, mTANK or hTANK and 5 μg of TAP-tagged (consisting of FLAG and Strep 
epitopes) C6 as indicated. After 48 h the cells were harvested in IP buffer and cleared lysates 
(INPUT) were subjected to immunoprecipitation (IP) with Streptavidin agarose beads. The 
proteins were separated by SDS-PAGE and detected by immunoblotting with a mouse-anti-
FLAG Ab. The location of protein molecular mass markers (kDa) and TAP-C6 are 
indicated.    
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Figure 5.7: mTANK truncation mutants. (A) Schematic representation of mTANK and 
the truncation mutants with the locations of the coiled-coil domain (CC), TBK1-binding 
domain (TBD) and Zinc finger domain (Zn) indicated. (B) Expression of truncation mutants. 
HEK293 cells were transfected with LUC – tagged mTANK truncation mutants. The cells 
were harvested 24 h later in cell lysis buffer and the cleared lysates were separated by SDS-
PAGE and analysed by immunoblotting with mouse-anti-renilla luciferase and rabbit-anti-
actin antibodies. The location of protein molecular mass markers is indicated (kDa).    
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5.5 C6 is still able to inhibit IFNβ induction in TANK-null cells 
To determine whether the binding of C6 to TANK could explain mechanistically how this 
VACV protein was able to inhibit IRF3 signalling and hence IFNβ induction, TANK-null 
cells were obtained from the laboratory of Dr. Felix Randow to use in a reporter gene assay. 
HCT116 TANK +/+ or TANK -/- cells were transfected with the IFNβ-promoter firefly 
luciferase reporter plasmid, the renilla luciferase transfection control plasmid, 100 ng of a C6 
expression plasmid or empty vector (EV) control and 70 ng of TRIFΔRIP expression plasmid 
to induce IFNβ reporter activation. Over-expression of the adaptor molecule TRIF induced an 
approximate nine-fold activation of the IFNβ promoter in the HCT116 parental cell line 
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Figure 5.8: C6 interaction with mTANK truncation mutants. HEK293 cells were co-
transfected with a plasmid expressing LUC – tagged mTANK prey protein and a plasmid 
expressing a FLAG-tagged bait protein. The cells were harvested 48 h later in IP buffer and 
cleared lysates were incubated with FLAG agarose beads. A proportion of the whole cell 
lysate was analysed for total luminescence. The FLAG agarose beads were washed three 
times in IP buffer and the bound proteins were eluted using 150 ng/ml FLAG peptide. The 
luminescence after immunoprecipitation was measured and normalised to the total 
luminescence of the sample. A fold binding was calculated by normalising to a FLAG-GFP 
control.    
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(HCT116 TANK +/+) and this induction was significantly inhibited by the expression of C6, 
as expected (Figure 5.9). The lack of TANK did not prevent IFNβ induction in the HCT116 
TANK -/- cell line following over-expression of TRIFΔRIP, but this activation was 
significantly (P<0.01) reduced, indicating an important contribution of TANK to this 
signalling pathway, as previously observed in the context of viral infection (Guo & Cheng, 
2007). Interestingly C6 was also found to significantly (P<0.01) inhibit IFNβ activation in the 
TANK-null cell line, indicating that the binding of C6 to TANK was not the cause of IRF3 
signalling abrogation, or this binding alone was not sufficient to explain the inhibition. 
5.6 Renilla luciferase-tagged C6 failed to interact with TANK 
The fact that C6 was able to inhibit IFNβ induction in TANK-null cells suggested that C6 
might interact with other proteins in addition to TANK. Data obtained with the TANK 
truncation mutants identified the coiled-coil region as the binding site for C6 on TANK. This 
region is shared amongst the three non-canonical IKK adaptor proteins TANK, SINTBAD 
and NAP1, with a single coiled-coil domain in TANK and three present in SINTBAD and 
NAP1 (Ryzhakov & Randow, 2007). If C6 had evolved to bind the coiled-coil domain of 
TANK, it may also be able to interact with this region of SINTBAD and NAP1. Given the 
overlapping role of these adaptors in the IRF3 signalling pathway (Guo & Cheng, 2007; 
Ryzhakov & Randow, 2007; Sasai et al, 2006), targeting all three adaptors could be highly 
beneficial to the virus and an effective way of abrogating IRF3 activation.  
LUMIER data obtained in Figures 5.2 and 5.3 indicated that C6 was not able to interact with 
LUC-tagged SINTBAD or NAP1. However, as previously discussed, the renilla luciferase tag 
used in the LUMIER assay is very large and may preclude the binding of some pairs of 
proteins, or may prevent their correct folding. It was observed, for example, that C6 did not 
interact with LUC-hTANK (Figure 5.5A), but did interact with FLAG-hTANK (Figure 5.6), 
perhaps due to the considerably smaller size of the FLAG epitope. In order to screen the 
interaction of C6 against signalling molecules with a smaller tag (the FLAG epitope), C6 was 
renilla luciferase tagged at either the N or the C terminus for use in the LUMIER assay. 
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HEK293 cells were co-transfected with a plasmid expressing LUC-C6 (Figure 5.10A) or C6-
LUC (Figure 5.10B) prey protein and a plasmid expressing a FLAG-tagged bait protein. The 
cells were harvested 48 h later and a LUMIER assay was performed. The homo-dimerisation 
of C6 was used as a positive control in this assay (see Chapter 3) and accordingly both LUC-
C6 and C6-LUC were found to interact with TAP-C6 (Figure 5.10). These data indicated that 
C6 tagged at either end with renilla luciferase was sufficiently folded to support its 
dimerisation. In both cases, however, C6 was found not to interact with any of the non-
canonical IKK complex proteins, including human and murine TANK. The lack of 
interaction with mTANK, which had previously been demonstrated by LUMIER assay using 
LUC-mTANK (Figures 5.1 and 5.2) implied that LUC-tagged C6 was not sufficiently folded  
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Figure 5.9: C6 inhibits IFNβ induction in TANK-null cells. HCT116 TANK +/+ or 
TANK -/- cells were transfected in 96-well plates with 60 ng of IFNβ-promoter firefly 
luciferase reporter plasmid, 10 ng of renilla luciferase transfection control plasmid, 100 ng 
of a C6 expression plasmid (C6) or empty vector control (EV) and either 70 ng of TRIF 
expression plasmid (TRIFΔRIP) or EV per well using JetPrime. Thirty h after transfection 
the cells were harvested in passive lysis buffer and the firefly luciferase activity was 
measured and normalised to the renilla luciferase activity. Data are from one representative 
experiment of at least three, each performed in triplicate. Data are represented as mean ± 
SD. ** P<0.01, analysed using the Student‟s T-test.   
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Figure 5.10: Interaction of LUC-tagged C6 with FLAG-tagged proteins. HEK293 cells 
were co-transfected with a plasmid expressing an N-terminal (A) or C-terminal (B) LUC – 
tagged C6 prey protein and a plasmid expressing a FLAG-tagged (or TAP-tagged in the case 
of C6) bait protein. The cells were harvested 48 h later in IP buffer and cleared lysates were 
incubated with FLAG agarose beads. A proportion of the whole cell lysate was analysed for 
total luminescence. The FLAG agarose beads were washed three times in IP buffer and the 
bound proteins were eluted using 150 ng/ml of FLAG peptide. The luminescence after 
immunoprecipitation was measured and normalised to the total luminescence of the sample. 
A fold binding was calculated by normalising to a FLAG-GFP control.    
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to allow this interaction, or the binding surface was not accessible. These data again highlight 
the limitations of the LUMIER assay and the use of large tags.  
The interaction of C6 with FLAG-Ub was also tested in these assays, because data collected 
by members of the laboratory had shown an interaction between this molecule and other Bcl-
2 family members (unpublished results). C6 LUC-tagged at either end was found to interact 
with FLAG-Ub (Figure 5.10). It is not possible to conclude from this assay whether this 
interaction is non-covalent or whether C6 itself is ubiquitinated and therefore the functional 
relevance of this interaction is currently unknown, but given the importance of ubiquitination 
in innate immune signalling (Chau et al, 2008) and the fact that TANK has been shown to be 
ubiquitinated (Gatot et al, 2007), this finding is very interesting.  
5.7 C6 interacts with NAP1 and SINTBAD in addition to TANK by 
conventional IP 
A number of problems had been encountered using the LUMIER assay to probe for 
interactions between C6 and innate immune signalling molecules, and therefore their 
potential interaction was investigated by conventional IP using signalling proteins tagged 
with the small FLAG epitope. HEK293 cells were transfected with plasmids encoding 
FLAG-tagged NAP1, SINTBAD, TANK or GFP as a negative control and 48 h later the cells 
were infected with vC6HA (2 p.f.u. per cell) for 16 h. The cells were then harvested in IP 
buffer and cleared lysates were subjected to immunoprecipitation with anti-FLAG agarose 
beads. Using this method C6-HA expressed by vC6HA was found to co-immunoprecipitate 
with FLAG-tagged NAP1, SINTBAD and TANK, but not GFP (Figure 5.11A).  
To perform a reciprocal immunoprecipitation assay HEK293 cells were co-transfected with 
the same plasmids as above encoding FLAG-tagged NAP1, SINTBAD, TANK or GFP, in 
addition to TAP-tagged C6. After 48 h the cells were harvested and cleared lysates were 
subjected to immunoprecipitation with Streptavidin agarose beads to purify TAP-C6. In 
agreement with data presented in Figure 5.11A, an interaction was detected between C6 and 
NAP1, SINTBAD and TANK, but not GFP, confirming the specificity of this interaction 
(Figure 5.11B).  
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Figure 5.11: C6 interacts with NAP1, SINTBAD and TANK. (A) HEK293 cells were 
grown in 10-cm dishes and transfected with 10 μg of plasmids encoding FLAG-tagged 
NAP1, SINTBAD, TANK or GFP as indicated. After 48 h the cells were infected with 
vC6HA (2 p.f.u. per cell) for 16 h. The cells were harvested in IP buffer and the cleared 
lysates (input) were subjected to IP with anti-FLAG agarose beads. The proteins were 
separated by SDS-PAGE and detected by immunoblotting as indicated on the right. (B) 
HEK293 cells were grown in 10-cm dishes and transfected with 5 μg of plasmids encoding 
FLAG-tagged NAP1, SINTBAD, TANK or GFP and 5 μg of TAP-tagged (consisting of 
FLAG and Strep epitopes) C6 as indicated. After 48 h the cells were harvested in IP buffer 
and the cleared lysates (input) were subjected to IP with Streptavidin agarose beads. The 
proteins were separated by SDS-PAGE and detected by immunoblotting with antibodies, as 
indicated on the right. The location of protein molecular mass markers is also indicated 
(kDa).    
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Taken together these data indicated that despite the failure to find an interaction between C6 
and SINTBAD and NAP1 by LUMIER assay, these molecules did in fact interact when 
tagged with smaller epitope tags. This interaction was observed with C6 tagged in two 
different ways suggesting the interaction was not an artefact of the epitope tag and was also 
observed in the context of a viral infection where C6 was expressed at natural levels (Figure 
5.11A). Importantly, the interaction was also observed when immunoprecipitating either the 
adaptor proteins or C6, and FLAG-GFP was not found to interact.  
5.8 The expression of C6 did not prevent the non-canonical IKK adaptor 
proteins from binding to TBK1 
To gain a mechanistic understanding of how the interaction between C6 and the non-
canonical IKK adaptor proteins NAP1, SINTBAD and TANK might inhibit IRF3 signalling, 
assays were performed to investigate whether the expression of C6 might prevent the 
interaction of these adaptors with known binding partners. This was achieved using two 
methods; the LUMIER assay and conventional immunoprecipitation assays using the 
inducible HEK293 T-REx TAP-C6 cell line (see Chapter 6).   
TANK is known to interact with both TRAF3 and TBK1, thus forming a trimeric complex 
(Gatot et al, 2007). One possibility is that the binding of TANK to these two proteins links 
signalling upstream of TRAF3 to the non-canonical IKK complex, leading to TBK1 
activation and the subsequent phosphorylation and activation of IRF3. As all three adaptors 
bind constitutively to TBK1 and IKKε, one hypothesis is that C6 may prevent this interaction 
and disconnect the link between upstream signalling molecules and the non-canonical IKK 
complex, preventing the activation of these kinases. To test this hypothesis HEK293 cells 
were co-transfected with a plasmid expressing LUC-TANK prey protein, a plasmid 
expressing a FLAG-tagged TBK1 or IKKε and varying quantities of a plasmid expressing un-
tagged C6. After 48 h the cells were harvested for a LUMIER assay. In the absence of C6 
both TBK1 and IKKε were found to interact with LUC-TANK, as expected (Figure 5.12A). 
The fold binding between TBK1 and TANK was slightly reduced by the presence of C6, 
although increasing quantities did not reduce this interaction further.  The presence of C6 did 
not reduce the interaction of IKKε with TANK until 1500 ng of plasmid was transfected in a 
well of a six-well plate, and again this interaction was not reduced greatly.  
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Figure 5.12: Interaction of TANK with TBK1 and IKKε in the presence of C6. HEK293 
cells were co-transfected (A) or co-transfected in triplicate (B) with a plasmid expressing 
LUC – tagged TANK prey protein, a plasmid expressing a FLAG-tagged bait protein and 
varying quantities of a plasmid expressing un-tagged C6, as indicated. The cells were 
harvested 48 h later in IP buffer and the cleared lysates were incubated with FLAG agarose 
beads. A proportion of the whole cell lysate was analysed for total luminescence. The 
luminescence after immunoprecipitation was measured and normalised to the total 
luminescence of the sample. A fold binding was calculated by normalising to a FLAG-GFP 
control.    
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It was unclear from the data presented in Figure 5.12A whether the observed reduction in fold 
binding was significant, particularly because the LUMIER immunoprecipitation was 
performed from a single transfected well of a six-well plate. To allow for some statistical 
analysis to be performed the experiment was repeated for the TBK1-TANK interaction in 
triplicate. Upon averaging the fold bindings between LUC-TANK and TBK1 from three 
separate LUMIER immunoprecipitation assays no difference was found for these molecules 
in the presence or absence of C6 (Figure 5.12B). A small reduction was observed when cells 
were transfected with 1500 ng of a plasmid expressing C6, but this was not significant due to 
the size of the error bars. 
A major advantage of the LUMIER assay is that to some extent it is a quantitative assay, 
particularly when comparing the interaction of the same molecules in various conditions, 
such as in the presence of varying quantities of C6. A major disadvantage of this assay, 
however, is achieving replicate fold binding data with a small standard deviation. This is 
challenging due to the number of steps in the protocol where variability between 
immunoprecipitations can occur. As such it is unlikely that statistically significant data will 
be achieved when only small differences in fold binding are observed, such as that presented 
in Figure 5.12. An additional disadvantage of this approach is that the cells were co-
transfected with three different plasmids. Inevitably not all cells would be transfected will all 
three and not all cells would express C6. To overcome this non-uniform expression of C6 a 
conventional immunoprecipitation assay was performed using the inducible HEK293 T-REx 
TAP-C6 cell line. The advantage of this cell line was the fact that in the presence of 
doxycycline all cells would express C6.  
To further investigate the interaction of TANK and the other two adaptor proteins with TBK1 
HEK293 T-REx TAP-C6 cells were transfected in duplicate with a V5-TBK1 expression 
plasmid and a plasmid expressing HA- NAP1, - SINTBAD, - TANK or - N1 as a negative 
control. One dish per transfection was transfected in the presence of 2 μg/ml doxycycline to 
induce TAP-C6 expression. The cells were harvested 24 h later and cleared lysates were 
subjected to immunoprecipitation with mouse-anti-HA Ab coupled to protein G sepharose 
beads. In this assay V5-TBK1 was observed to co-immunoprecipitate with HA-NAP1, - 
SINTBAD and - TANK, but not HA-N1, indicating a specificity of the interaction between 
the adaptors and this kinase (Figure 5.13). Of note, N1 had been previously described to  
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interact with TBK1 (DiPerna et al, 2004), but this interaction has not been repeated by 
members of our laboratory. In the presence of C6 the amount of TBK1 co-
immunoprecipitated with the adaptor proteins was highly similar, indicating that the 
interaction of these molecules is not inhibited by the presence of C6, in agreement with data 
obtained by LUMIER assay (Figure 5.12). 
5.9 The expression of C6 did not prevent binding of TANK to TRAF3, 
IRF3 or its homo-dimerisation 
Given that the mechanism of C6 inhibition was unlikely to be due to it preventing the 
interaction between the kinases and the adaptor proteins, the known interaction of TANK 
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Figure 5.13: Interaction of TBK1 adaptor proteins with TBK1 in the presence of C6. 
(A) HEK293 T-REx TAP-C6 cells were grown in 10-cm dishes and transfected in duplicate 
with 5 μg of V5-TBK1 expression plasmid and 5 μg of a plasmid expressing HA- NAP1, - 
SINTBAD, - TANK or - N1 control. One dish per transfection was transfected in the 
presence of 2 μg/ml doxycycline (doxy) to induce TAP-C6 expression. The cells were 
harvested 24 h later in IP buffer and cleared lysates (INPUT) were subjected to IP with 
mouse-anti-HA Ab coupled to protein G sepharose beads. The proteins were separated by 
SDS-PAGE and detected by immunoblotting as indicated on the left. The location of protein 
molecular mass markers is indicated (kDa).    
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with other signalling molecules was tested. TANK was chosen as it was the best 
characterised adaptor molecule of the three. Since C6 was found to interact with the coiled-
coil region of TANK (Figures 5.5 and 5.8), and this domain had been reported to be involved 
in the oligomerisation of TANK (Chin et al, 1999), it was hypothesised that the binding of C6 
to this domain may preclude TANK homo-dimerisation. To test this, HEK293 cells were co-
transfected with a plasmid expressing LUC-TANK prey protein, a plasmid expressing FLAG-
TANK and varying quantities of a plasmid expressing un-tagged C6. The cells were then 
harvested 48 h later and a LUMIER assay was performed. An approximate 180-fold binding 
was observed between LUC- and FLAG-tagged TANK and this was not affected significantly 
by the presence of increasing amounts of C6 (Figure 5.14).  
To confirm the result of the LUMIER assay HEK293 T-REx TAP-C6 cells were transfected 
in duplicate with a V5-TANK expression plasmid and a plasmid expressing HA - TANK or - 
N1 as a negative control. As for the experiment presented in Figure 5.13, one dish per 
transfection was transfected in the presence of 2 μg/ml doxycycline to induce TAP-C6 
expression. The cells were then harvested 24 h later and cleared lysates were again subjected 
to immunoprecipitation with mouse-anti-HA Ab coupled to protein G sepharose beads. In 
agreement with the data obtained by LUMIER assay, the amount of V5-TANK co-
immunoprecipitated with HA-TANK was similar in the presence or absence of C6, indicating 
that TANK homo-dimerisation can occur, and is not reduced by the presence of C6 (Figure 
5.15). V5-TANK was not found to co-immunoprecipitate with HA-N1, as only a band 
corresponding to the Ab heavy chain at approximately 50 kDa (a little smaller than the size of 
V5-TANK) was observed.  
As discussed previously, TANK has been proposed to link upstream signalling events to the 
non-canonical IKK complex by interacting with both TRAF3 and TBK1 to form a complex. 
Although the binding sites for TRAF3 and C6 on TANK do not overlap the structure of 
TANK has not been solved and therefore it is not possible to conclude from the primary 
sequence which domains of this protein would be in close proximity in three dimensional 
space. As such, the binding of C6 to TANK may preclude its interaction with TRAF3 which 
theoretically could then break the link between the non-canonical IKK complex and upstream 
signalling events. To test this hypothesis HEK293 cells were co-transfected with a plasmid 
expressing LUC-TANK prey protein, a plasmid expressing FLAG-TRAF3 bait protein and  
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varying quantities of a plasmid expressing un-tagged C6. The cells were then harvested 48 h 
later for a LUMIER assay. As expected, LUC-TANK was found to interact with FLAG-
TRAF3 by LUMIER assay in the absence of C6, and this interaction was largely unaffected 
by the presence of this VACV protein (Figure 5.16). This interaction was also investigated by 
transfecting HEK293 T-REx TAP-C6 cells in duplicate in the presence or absence of C6 
expression with a V5-TANK expression plasmid and a plasmid expressing FLAG-TRAF3 or 
N1-TAP as a negative control for the FLAG epitope. The cells were harvested 24 h later and 
cleared lysates were subjected to immunoprecipitation with mouse-anti-V5 Ab coupled to 
protein G sepharose beads. FLAG-TRAF3, but not N1-TAP was immunoprecipitated with 
V5-TANK and this interaction was not reduced in the presence of C6 (Figure 5.17). These  
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Figure 5.14: Homo-dimerisation of TANK in the presence of C6. HEK293 cells were co-
transfected with a plasmid expressing LUC – tagged TANK prey protein, a plasmid 
expressing a FLAG-tagged bait protein and varying quantities of a plasmid expressing un-
tagged C6, as indicated. The cells were harvested 48 h later in IP buffer and the cleared 
lysates were incubated with FLAG agarose beads. A proportion of the whole cell lysate was 
analysed for total luminescence. The luminescence after immunoprecipitation was measured 
and normalised to the total luminescence of the sample. A fold binding was calculated by 
normalising to a FLAG-GFP control.    
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data are in agreement with the LUMIER data presented in Figure 5.16 and indicated that the 
binding of C6 to TANK did not prevent this adaptor molecule from interacting with TRAF3.  
Finally, an interaction between TANK and IRF3 had been described previously by Gatot and 
colleagues (Gatot et al, 2007).  The binding of TANK to this transcription factor may bring it 
into proximity of the non-canonical IKK kinases, aiding the phosphorylation and activation 
of IRF3 by these kinases. Preventing the recruitment of IRF3 to this complex by inhibiting its 
interaction with TANK might inhibit IRF3 signalling and be beneficial to a virus. Because a 
FLAG-IRF3 plasmid was not available the interaction of TANK with IRF3 could not be  
37
25
15
10
20
HA
50
V5 (TANK)
FLAG (C6)
INPUT IP: HA
- ++doxy
HA:
50
20
- ++
TANK
Figure 5.15: Homo-dimerisation of TANK in the presence of C6. (A) HEK293 T-REx 
TAP-C6 cells were grown in 10-cm dishes and transfected in duplicate with 5 μg of V5-
TANK expression plasmid and 5 μg of a plasmid expressing HA - TANK or - N1 control. 
One dish per transfection was transfected in the presence of 2 μg/ml doxy to induce TAP-C6 
expression. The cells were harvested 24 h later in IP buffer and the cleared lysates (INPUT) 
were subjected to IP with mouse-anti-HA Ab coupled to protein G sepharose beads. The 
proteins were separated by SDS-PAGE and detected by immunoblotting as indicated on the 
left. The location of protein molecular mass markers is indicated (kDa). The location of co-
immunoprecipitated V5-TANK is indicated by the arrow.   
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investigated by LUMIER assay. Instead, HEK293 T-REx TAP-C6 cells were transfected in 
duplicate in the presence or absence of TAP-C6 with a V5-TANK expression plasmid and a 
plasmid expressing HA – IRF3 or - N1 negative control. The cells were then harvested 24 h 
later for an anti-V5 IP. Only very small amounts of HA-IRF3 were co-immunoprecipitated 
with V5-TANK, but this was a specific interaction as HA-N1 was not co-immunoprecipitated 
in this assay despite being well expressed (Figure 5.18). The interaction of IRF3 with TANK 
was not demonstrated by Gatot et al to be direct, but rather as part of a complex including 
TRAF3, TANK, TBK1 and IRF3. It is not known if TANK and IRF3 therefore interact 
directly and this may explain the weak binding observed in Figure 5.18. The presence of C6 
nevertheless did not prevent this interaction. 
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Figure 5.16: Interaction of TANK with TRAF3 in the presence of C6. HEK293 cells 
were co-transfected with a plasmid expressing LUC – tagged TANK prey protein, a plasmid 
expressing a FLAG-tagged bait protein and varying quantities of a plasmid expressing un-
tagged C6, as indicated. The cells were harvested 48 h later in IP buffer and the cleared 
lysates were incubated with FLAG agarose beads. A proportion of the whole cell lysate was 
analysed for total luminescence. The luminescence after immunoprecipitation was measured 
and normalised to the total luminescence of the sample. A fold binding was calculated by 
normalising to a FLAG-GFP control.    
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5.10 Summary 
C6 was found to inhibit the IRF3 signalling pathway downstream, or at the level of the non-
canonical IKK complex (Chapter 4) and therefore the potential binding of C6 to the known 
proteins of this complex was investigated by LUMIER assay. Using this method TANK was 
identified as an interaction partner for C6 and this was confirmed by conventional 
immunoprecipitation assay in the context of a viral infection. By constructing a set of TANK 
truncation mutants the binding site for C6 on TANK was identified as the N-terminal coiled-
coil domain, because mutants lacking this domain failed to interact with C6 by LUMIER 
assay. In the case of mTANK, the coiled-coil domain alone was sufficient for binding to C6. 
Intriguingly, LUC-tagged full length hTANK was not found to interact with C6 by LUMIER 
assay, but a FLAG-tagged version of this protein was found to interact by conventional IP.  
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Figure 5.17: Interaction of TANK with TRAF3 in the presence of C6. HEK293 T-REx 
TAP-C6 cells were grown in 10-cm dishes and transfected in duplicate with 5 μg of V5-
TANK expression plasmid and 5 μg of a plasmid expressing FLAG-TRAF3 or TAP-N1 
control. One dish per transfection was transfected in the presence of 2 μg/ml doxy to induce 
TAP-C6 expression (indicated by the arrow). The cells were harvested 24 h later in IP buffer 
and cleared lysates (INPUT) were subjected to IP with mouse-anti-V5 Ab coupled to protein 
G sepharose beads. The proteins were separated by SDS-PAGE and detected by 
immunoblotting as indicated on the left. The location of protein molecular mass markers is 
indicated (kDa).  
 
177 
 
 
 
 
 
 
 
To link the binding of C6 to TANK to its ability to inhibit IRF3 signalling, an IFNβ reporter 
gene assay was performed in a TANK-null cell line. C6 was found to inhibit IFNβ induction 
in these cells and thus the binding of C6 to other proteins in this pathway was investigated 
further. To do this, plasmids expressing LUC-C6 and C6-LUC were constructed but these 
failed to interact with TANK, although they were able to dimerise with TAP-C6 suggesting 
they were folded to some degree. Interestingly LUC-tagged C6 was found to interact with 
FLAG-Ub in this assay. Given the possibility of the large luciferase tag precluding the 
interactions of some pairs of proteins, conventional immunoprecipitation assays were 
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Figure 5.18: Interaction of TANK with IRF3 in the presence of C6. (A) HEK293 T-REx 
TAP-C6 cells were grown in 10-cm dishes and transfected in duplicate with 5 μg of V5-
TANK expression plasmid and 5 μg of a plasmid expressing HA – IRF3 or - N1 control. 
One dish per transfection was transfected in the presence of 2 μg/ml doxy to induce TAP-C6 
expression. The cells were harvested 24 h later in IP buffer and the cleared lysates (INPUT) 
were subjected to IP with mouse-anti-V5 Ab coupled to protein G sepharose beads. The 
proteins were separated by SDS-PAGE and detected by immunoblotting as indicated on the 
left. The location of protein molecular mass markers is indicated (kDa).  
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performed with small epitope tags. Using this method NAP1 and SINTBAD, in addition to 
TANK, were found to interact with C6, and this occurred in the context of a viral infection. 
Finally, to provide a mechanistic understanding of how the binding of C6 to the non-
canonical IKK complex adaptor proteins might inhibit IRF3 signalling, LUMIER and 
immunoprecipitation assays were performed to investigate whether C6 expression could 
prevent, or reduce the interaction of these adaptors with other signalling molecules. C6 was 
found not to affect the interaction of any of the three adaptors with TBK1 and did not prevent 
the interaction of TANK with IKKε. In addition an effect of C6 on the interaction of TANK 
with TRAF3, IRF3 or TANK homo-dimerisation was not observed. Further assays are needed 
to fully understand the mechanism of IRF3 inhibition by C6. 
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Chapter 6: An un-biased approach for the identification of 
C6 binding partners  
6.1 Construction of stable inducible cell lines expressing TAP-tagged C6 
Data presented in Chapter 5 identified three novel binding partners for C6 using a directed 
approach based on knowledge of the function of this protein presented in Chapter 4. At the 
same time an un-biased method was also utilised for the discovery of novel binding partners. 
This approach was based on a TAP protocol described by Gloeckner and colleagues 
(Gloeckner et al, 2007). In that study proteins of interest were tagged with a TAP tag 
consisting of two StrepII epitopes and a FLAG epitope in tandem (Figure 6.1A) at either the 
N or C terminus of the protein. A stable HEK293 cell line was then constructed and cell 
lysates were subjected to a double purification protocol, first by incubation with strepactin 
superflow resin and then with FLAG agarose beads. The proteins eluted from the FLAG 
agarose beads were then separated by SDS-PAGE and silver stained so that proteins of 
interest could be identified and sent for mass spectrometry analysis.  
The TAP protocol has a number of advantages for identifying novel protein-protein 
interactions. Firstly this a non-directed and hence non-biased approach, since the purification 
is performed from a large pool of proteins expressed by the cell. Secondly, this approach has 
been demonstrated to yield minimal false positives due to two rounds of purification and the 
choice of the Strep and FLAG epitopes, which both have a high affinity for the resin or beads 
used in this experiment (Gloeckner et al, 2007). Thirdly, the size of the tag is considerably 
smaller than those used in original TAP experiments where two IgG binding domains of 
protein A were fused to a calmodulin binding peptide domain, yielding a tag of 21 kDa 
(Rigaut et al, 1999). A tag of this size may preclude the correct folding of the protein being 
tagged and its presence may prevent potential protein-protein interactions. 
To construct a stable inducible cell line expressing TAP-tagged C6, the C6 ORF was cloned 
using restriction enzyme digestion into pcDNA4/TO vectors previously engineered with 
either an N- or C-terminal TAP tag (designed by Brian Ferguson). This plasmid also 
contained a zeocin resistance cassette. Digestion of the N-terminal tag TAP-C6 plasmid with  
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Figure 6.1: Construction of TAP-tagged C6 cell lines. (A) Tandem affinity purification 
(TAP) tag sequence and schematic. (B) C6 was cloned into the pcDNA4/TO TAP vectors 
using the restriction enzymes XbaI and NotI for N-terminal TAP and KpnI and NotI for C-
terminal TAP. To confirm the presence of the C6 ORF in these plasmids 1 μg of DNA was 
subjected to restriction enzyme digestion with the above enzymes and digestion products 
were separated by agarose gel electrophoresis on a 1 % gel. (C) Stable inducible cell lines 
were constructed by transfection of HEK293 T-REx cells followed by selection of clones in 
the presence of zeocin. The clones were tested for inducible expression of TAP-tagged C6 
by growth for 24 h in the presence of 2 μg/ml doxycycline. Whole cell lysates were 
prepared, the proteins were separated by SDS-PAGE and then immunoblotted with mouse 
anti-tubulin or mouse anti-FLAG antibodies. The location of protein molecular mass 
markers is indicated (kDa).  
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XbaI and NotI, and the C-terminal tag C6-TAP plasmid with KpnI and NotI excised an insert 
of approximately 450 bp, corresponding to the size of C6 (Figure 6.1B). These plasmids were 
then used to transfect HEK293 T-REx cells and stable clones were selected by growth in the 
presence of zeocin. The HEK293 T-REx cell line expresses the tetracycline repressor protein. 
Therefore, to induce expression of C6 from the stably transfected clones the cells were 
incubated in the presence of the tetracycline analogue doxycycline for 24 h. The cells were 
then harvested and the lysates subjected to SDS-PAGE and immunoblotting analysis using an 
anti-FLAG Ab, which binds to the FLAG epitope in the TAP tag. Four clones were selected 
for the TAP-C6 cell line and two were tested for the C6-TAP cell line. Expression of C6 was 
not observed in the absence of doxycycline in any clone, confirming that there was no leaky 
expression of this protein (Figure 6.1C). In the presence of doxycyline a band of 
approximately 20 kDa was observed for all tested clones, which corresponded to the expected 
size of C6 plus the 4.6 kDa TAP tag (Gloeckner et al, 2007). Clone 3 for the TAP-C6 cell line 
and clone 4 for the C6-TAP cell line were found to express slightly higher levels of TAP-
tagged C6 and hence were selected for further analysis, although all clones were found to 
express good levels of this protein.   
6.2 Mass spectrometry analysis of proteins purified with C6 from the 
HEK293 T-REx C6-TAP stable inducible cell line 
As the HEK293 T-REx C6-TAP cell line was constructed first this was the one used for 
tandem affinity purification assay analysis. For a pilot experiment to optimise the TAP 
protocol 20 T175 flasks of HEK T-REx C6-TAP cells were prepared and half were induced 
to express C6-TAP by treatment with 2 μg/ml doxycycline for 24 h. The cells were then 
harvested and cleared lysates were subjected to a tandem affinity purification experiment, 
with samples taken at multiple steps during purification to analyse C6 expression and the 
efficiency of binding to and elution from the beads. These protein samples were subjected to 
SDS-PAGE using an Invitrogen NuPAGE 4-12% Bis-Tris polyacrylamide gel and 
immunoblotting analysis using an anti-FLAG Ab.  
A band corresponding to the size of C6-TAP was present in the whole cell lysate (INPUT) 
from cells incubated in the presence of doxycycline but not in its absence, indicating 
expression of C6-TAP from the stable inducible cell line (Figure 6.2). Some C6-TAP was  
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detected in the streptactin bead flow-through suggesting that not all C6 had been captured by 
these beads. This was a step in the protocol that required optimisation and was later solved by 
incubating the whole cell lysate with more streptactin beads.  Some C6-TAP was also 
associated with the streptactin beads following elution in the presence of des-thiobiotin. 
Again, this step required optimisation and two rounds of elution with des-thiobiotin was 
sometimes found to enhance the dissociation of C6 at this step. No C6-TAP was found in the 
FLAG bead flow-through indicating the efficient capture of this protein by the beads at this 
step. As with the strepactin beads a proportion of C6-TAP was still associated with the FLAG 
beads after elution in the presence of FLAG peptide and this was not improved by incubation 
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Figure 6.2: Immunoblot analysis of the tandem affinity purification assay using 
HEK293 T-REx C6-TAP cell line. Fractions of the tandem affinity purification assay were 
separated by SDS-PAGE and analysed by immunoblotting using a mouse-anti-FLAG Ab. 
Five times more Strep flow-through was loaded than INPUT sample. For the beads, the 
remaining protein associated with the beads after washing was eluted by boiling for 5 mins 
in the presence of protein sample loading buffer. One-fifth of the total final elution volume 
was used for immunoblotting analysis. The location of protein molecular mass markers is 
indicated (kDa).    
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with a higher concentration of FLAG peptide, or two rounds of elution. A similar pattern of 
proteins was found in the final elution to those still associated with the FLAG beads. The 
band at approximately 20 kDa was presumed to be C6, and given data presented in Chapter 1 
the band of approximately 40 kDa was thought to correspond to dimeric C6. A number of 
larger proteins were also present which could have been multimeric forms of C6, or C6 
associated with potential interaction partners, because the NuPAGE buffer used for loading 
the samples in the Invitrogen NuPAGE 4-12% Bis-Tris polyacrylamide gels was not found to 
be as efficient at reducing samples as the protein sample buffer containing BME.  
Following the optimisation of the TAP protocol the experiment was repeated and the proteins 
in the final elution and associated with both sets of beads were separated by SDS-PAGE as 
described above and the proteins were stained using the Invitrogen SilverQuest silver staining 
kit. Four main bands were identified that corresponded to proteins purified from cells 
incubated in the presence of doxycycline but not in its absence, as indicated by the black 
arrows in Figure 6.3. Three of these bands were present in the final elution and one was 
found still associated with the FLAG beads, presumably because this particular protein had 
not eluted well during the final incubation in the presence of FLAG peptide. These four bands 
were carefully excised and the proteins were identified by LC-MS/MS mass spectrometry at a 
service in Imperial College. The band at approximately 20 kDa was identified as VACV 
protein C6, indicating that C6 had been purified from the HEK293 T-REx cell line using this 
protocol. Unfortunately, only keratin contamination that appears in all mass spectrometry 
analysis was identified in the remaining three bands, presumably because the proteins present 
in these slices were below the limit of mass spectrometry detection and identification. 
6.3 Mass spectrometry analysis of proteins purified with C6 from vC6TAP-
infected cells 
Two major disadvantages of using a stable inducible cell line for TAP experiments involving 
a viral protein are that the protein is expressed out of the context of other viral proteins, and 
protein-protein interaction analysis may be limited by the cell line chosen, for example by the 
lack of expression of the potential interaction partners in particular cell lines. To avoid these 
potential problems a recombinant virus expressing C6-TAP was constructed (see Chapter 3). 
This virus allowed protein-protein interaction analysis to be performed in multiple cell lines 
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Figure 6.3: Tandem affinity purification assay using HEK293 TRex C6-TAP cell line. 
Twenty T175 flasks of HEK T-REx C6-TAP cells were prepared and half were induced to 
express C6-TAP by treatment with 2 μg/ml doxycycline (doxy) for 24 h. The cells were then 
harvested and cleared lysates were subject to a tandem affinity purification experiment. 
Proteins were separated by SDS-PAGE and stained using the Invitrogen SilverQuest silver 
staining kit. The bands of interest (indicated by arrows) were excised and sent for LC-
MS/MS mass spectrometry analysis. The proteins that were identified are indicated. The 
location of protein molecular mass markers is also indicated (kDa).    
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 where the expression of C6 would be in the context of a viral infection. This method would 
also potentially identify novel interactions between viral proteins. 
To ascertain whether the pattern of bands observed in the final elution from the cell line 
would be similar to that obtained using the C6-TAP virus, 30 T175 flasks of HEK293 cells 
were prepared, half of which were infected overnight with 2 p.f.u. per cell of vΔC6 and the 
other half with vC6TAP. The cells were then harvested and the cleared lysates were subjected 
to a TAP experiment. The proteins in the final elution were separated by SDS-PAGE and 
stained using the Invitrogen SilverQuest silver staining kit as described above for the 
HEK293 T-REx C6-TAP cell line. Using this protocol a large number of proteins were 
purified with C6-TAP that were not purified from cells infected with the vΔC6 control, and 
this exceeded the number observed from the cell line (Figure 6.4A). This may have been 
because more C6-TAP was expressed from 15 flasks infected with vC6TAP than 10 flasks of 
the HEK293 T-REx C6-TAP cell line, or it could have been due to the presence of other viral 
proteins. As a direct comparison of expression from the virally-infected cells and the cell line 
was not made, it is not possible to conclude why more proteins were purified with virally 
expressed C6-TAP. Importantly however, proteins of a similar size to those sent for mass 
spectrometry analysis from the C6 cell line were also purified from vC6TAP infected cells 
(black arrows, Figure 6.4A). 
To determine whether the pattern of proteins observed from infected HEK293 cells was 
unique to these cells or whether the pattern from other infected human cells might be similar, 
the tandem affinity purification assay was repeated using HCT116 cells. Whilst investigating 
the interaction of C6 with endogenous TANK, NAP1 and SINTBAD it was noted that TANK 
and NAP1 were more easily detected by immunoblotting from HCT116 lysates than HEK293 
lysates, perhaps indicating that in this cell line the endogenous expression levels were higher 
(data not shown). The overall pattern of proteins purified with C6-TAP from vC6TAP-
infected HCT116 cells was found to be highly similar to that from vC6TAP-infected 
HEK293 cells and, importantly, the amount of protein purified was higher, as indicated by 
the darker silver stained bands (Figure 6.4B). Although the pattern of proteins was similar, 
one notable difference was the relative intensities of the bands in the final elution, which 
seemed to differ between the two cell lines. For example, the protein of approximately 37 
kDa which was hypothesised to be dimeric C6 was more abundant in infected HCT116 cells  
186 
 
 
  
250
150
100
75
50
37
25
20
15
10
250
150
100
75
50
37
25
20
15
10
Final elution
HEK293 HCT116
Final elutionA B
Figure 6.4: Tandem affinity purification assay following infection of cells with 
vC6TAP. Thirty T175 flasks of HEK293 (A) or HCT116 (B) cells were prepared, half of 
which were infected overnight with 2 p.f.u. per cell vΔC6 and the other half with vC6TAP. 
The cells were harvested and cleared lysates were subjected to a tandem affinity purification 
experiment. The proteins in the final elution were separated by SDS-PAGE and stained 
using the Invitrogen SilverQuest silver staining kit. The location of protein molecular mass 
markers is indicated (kDa). The black arrows indicate the size of the bands sent for mass 
spectrometry analysis from the HEK 293 T-REx cell line (Figure 6.3).   
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than HEK293 cells. A prominent protein of approximately 50 kDa was also visible in the 
HCT116 cell final elution that was present in much smaller quantities in the HEK293 cell 
elution. This band was of particular interest as it corresponded to the size of TANK. Given 
this finding and the fact that there was more protein overall in the final elution of the infected 
HCT116 cells, the experiment was repeated using these cells to send for LC-MS/MS mass 
spectrometry analysis.  
For the mass spectrometry analysis 15 T175 flasks of HCT116 cells were infected overnight 
with vC6TAP and 15 were infected with a recombinant virus expressing TAP-tagged N1 
(vN1TAP, Carlos Maluquer de Motes, unpublished results). The final elution was then sent to 
an LC-MS/MS mass spectrometry service at the University of Cambridge where the proteins 
were separated by SDS-PAGE and the gel cut into 16 equal slices per lane for identification 
of proteins in the individual slices. A small proportion of the final elution was retained, 
separated by SDS-PAGE and silver stained to visualise the proteins that had been purified 
with C6-TAP and not N1-TAP (Figure 6.5).  
As with mass spectrometry analysis from the HEK293 T-REx cell line, the protein of 
approximately 20 kDa from vC6TAP-infected HCT116 cells was identified as VACV protein 
C6 (Figure 6.5). In addition to C6, 6 other proteins were identified as potential interacting 
partners. At the top of the gel a large protein of 450 kDa was identified as DNA-PKcs. This 
protein has a characterised role in DNA repair (Finnie et al, 1995), and more recently has 
been described as a DNA sensor as part of a complex with Ku70 and Ku80, with roles in the 
detection of foreign DNA and activation of IRF3 signalling ((Zhang et al, 2011), B. Ferguson 
et al, submitted). The proteins of 200 kDa, 70 kDa and 37 kDa were identified as Ub protein 
ligase E3 component n-recognin (UBR)1, heat shock protein (Hsp)70 and UBR2 
respectively. These proteins form a complex that has a role in the N-end rule pathway of 
protein degradation (Nillegoda et al, 2010). This complex is responsible for the addition of a 
Ub moiety at the N terminus of target proteins marking them for degradation by the 
proteasome. This complex is important for the degradation of mis-folded cellular proteins and 
also viral proteins such as Sindbid virus RNA polymerase (de Groot et al, 1991) and HIV-1 
integrase (Mulder & Muesing, 2000). A protein of approximately 150 kDa was identified as 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, 
member 1 (SMARCC1), also known as BAF155. This protein is a member of the SWI/SNF  
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Figure 6.5: Potential C6 interaction partners identified by mass spectrometry. Thirty 
T175 flasks of HCT116 cells were prepared, half of which were infected overnight with 2 
p.f.u. per cell of vC6TAP and the other half with vN1TAP. The cells were harvested and 
cleared lysates were subjected to a tandem affinity purification experiment. The final elution 
was sent for separation by SDS-PAGE and subsequent LC-MS/MS mass spectrometry 
analysis following the cutting of each lane of the gel into 16 equal slices. A proportion of the 
final elution was also separated by SDS-PAGE and stained using the Invitrogen SilverQuest 
silver staining kit. The proteins that were identified in the vC6TAP lane and not the 
vN1TAP lane, and their expected sizes (kDa), are indicated on the left. The location of 
protein molecular mass markers is indicated on the right (kDa). DNA-PKcs: DNA-protein 
kinase catalytic subunit, UBR: Ub protein ligase E3 component n-recognin, SMARCC1: 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, 
member 1, Hsp70: heat shock protein 70, TROVE2: TROVE domain family member 2.    
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family whose members possess ATPase and helicase activities and have roles in 
transcriptional regulation by chromatin remodelling (Wang et al, 1996).  Gastric cancer MDR 
protein variant, or TROVE domain family member 2 (TROVE2), a protein of approximately 
60 kDa was also identified as a potential C6 binding partner. TROVE2 is a ribonucleoprotein 
with the ability to bind several small cytoplasmic Y RNAs, potentially stabilising them from 
degradation (Deutscher et al, 1988). Finally a protein of 36 kDa was identified as VACV 
protein I1. I1 is a late expressed protein found in the virion core with DNA binding ability 
(Klemperer et al, 1997). Importantly, the identification of VACV I1 supports the use of this 
method for identifying novel viral protein-viral protein interactions. Further, this interaction 
was not identified in a large yeast two-hybrid screen of vaccinia virus protein-protein 
interactions (McCraith et al, 2000). 
Given its mass the protein of approximately 37 kDa was hypothesised to be dimeric C6. This 
hypothesis was supported by the fact that C6 was shown to co-immunoprecipitate with 
another molecule of C6 (Chapter 3) and a protein of approximately 37 kDa was identified by 
a FLAG Ab from a previous TAP assay (Figure 6.3). Nevertheless mass spectrometry 
analysis did not identify protein C6 in the gel slice containing proteins of this mass (Figure 
6.5). A potential reason for this is that dimeric C6 may be a very small component of the 
protein band observed at approximately 37 kDa. Indeed, VACV protein I1 is 36 kDa and may 
represent the majority of protein in the band of this size. Supporting this hypothesis is the fact 
that the protein samples are prepared with Nu-PAGE buffer that contains some reducing 
agent and thus prevents proteins from resolving by PAGE as complexes. Further, the protein 
band corresponding to dimeric C6 in immunoblotting data presented in Figure 6.3 is less 
strong than the band for monomeric C6, indicating substantially less dimeric C6 in this gel.   
Interestingly, TANK, NAP1 and SINTBAD were not identified by mass spectrometry as 
interacting partners of C6. Given that confirming an endogenous interaction between C6 and 
these signalling adaptor molecules was problematic it may be that these proteins are not 
expressed at sufficient levels for identification by mass spectrometry. As a direct interaction 
between C6 and TANK, NAP1 or SINTBAD has not been demonstrated, it is possible that 
these proteins interact as part of a complex and again sufficient amounts of this complex may 
not have been purified for successful mass spectrometry analysis. It is also possible that the 
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interaction is weak or transient, or it may only occur at certain time points p.i., for example 
very early.  
6.4 An interaction between C6-TAP and DNA-PKcs could not be confirmed 
by conventional IP 
Following the identification of potential interaction partners by tandem affinity purification 
and mass spectrometry analysis it is important to confirm these interactions by other methods. 
To confirm the interaction between C6 and DNA-PKcs HCT116 cells were infected 
overnight with vC6TAP, or vN1TAP as a negative control. The cells were harvested and 
cleared lysates were subjected to IP with Streptactin beads to purify the TAP-tagged protein. 
Using this method DNA-PKcs was co-immunoprecipitated with both C6TAP and N1TAP, 
suggesting that this result may have been a false positive (Figure 6.6A). To further investigate 
this a reciprocal IP assay was performed where lysates of HCT116 cells infected with 
vC6TAP or vN1TAP were incubated with a DNA-PKcs Ab coupled to protein G sepharose 
beads. DNA-PKcs was immunoprecipitated from these lysates in the presence of the DNA-
PKcs Ab, but not by the protein G sepharose beads alone (Figure 6.6B). In addition Ku70, a 
known interaction partner of DNA-PKcs (Gottlieb & Jackson, 1993) was co-
immunoprecipitated in this assay, but neither C6 nor N1 were co-purified. Taken together 
these data indicated that DNA-PKcs did not interact specifically with C6 and may have been 
purified non-specifically during the TAP assay. By conventional IP DNA-PKcs was found to 
co-immunoprecipitate with both C6-TAP and N1-TAP, but it was not identified in the N1 
lane by mass spectrometry. A potential explanation for this is that it was present, but was 
below the limit of detection.  
6.4 An interaction between C6-TAP and SMARCC1 was confirmed by 
conventional IP 
To confirm the interaction between C6 and SMARCC1 HEK293 cells were infected 
overnight with vC6TAP or vN1TAP. The cells were then harvested and cleared lysates were 
subjected to IP with protein G sepharose beads coupled with rabbit-anti-SMARCC1 Ab or 
with anti-FLAG agarose beads. Endogenous SMARCC1 was detected in the cell lysate using  
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Figure 6.6: C6-TAP does not interact with DNA-PKcs. HCT116 cells were infected 
overnight with vC6TAP or vN1TAP (2 p.f.u. per cell). The cells were harvested in TAP IP 
buffer and cleared lysates (INPUT) were subjected to IP with Streptactin beads (A) or 
protein G sepharose beads coupled (+ Ab) or not coupled (- Ab) to mouse-anti-DNA-PKcs 
Ab. The proteins were separated by SDS-PAGE and detected by immunoblotting as 
indicated on the left. The location of protein molecular mass markers is indicated on the 
right (kDa).    
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the rabbit-anti-SMARCC1 Ab, and this Ab was also suitable to IP SMARCC1 (Figure 6.7). 
SMARCC1 was not immunoprecipitated with the rabbit-anti-HA control Ab demonstrating 
the specificity of this IP. Although SMARCC1 was found to co-immunoprecipitate with C6-
TAP purified using FLAG agarose beads and not N1-TAP, C6-TAP was not co-
immunoprecipitated with SMARCC1 purified using the SMARCC1 Ab coupled to protein G 
beads. These data confirmed the mass spectrometry data, but an interaction was not observed 
when purifying SMARCC1 rather than C6. A different SMARCC1 Ab may need to be tested 
to observe this interaction.  
6.5 An interaction between C6-TAP and UBR1 was confirmed by 
conventional IP 
In a similar experiment to the one described in section 6.4, UBR1 was found to co-
immunoprecipitate with C6-TAP purified from the lysate of HEK293 cells infected with 
vC6TAP (Figure 6.8). This interaction was specific as UBR1 was not observed to interact 
with N1-TAP expressed by vN1TAP. A reciprocal IP experiment was performed purifying 
UBR1 from lysates using a rabbit-anti-UBR1 Ab coupled to protein G sepharose beads. A 
small amount of UBR1 was immunoprecipitated in this assay, but C6 was not co-
immunoprecipitated. These data confirmed the mass spectrometry data, but in order to 
observe the interaction in the reciprocal IP, again, another Ab more suitable for the IP of 
UBR1 may be required.   
6.6 Summary  
As a non-biased approach to identify novel C6 interaction partners, cell lines expressing 
TAP-tagged C6 were constructed by stable transfection of HEK293 T-REx cells. The 
HEK293 T-REx C6-TAP cell line was used for a TAP assay and 4 protein bands from an 
SDS-PAGE protein gel were sent for LC-MS/MS mass spectrometry analysis. The band of 20 
kDa was identified as VACV protein C6, but only keratin contamination was identified in the 
other three bands.  
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To identify novel interaction partners using other cell types and in the context of a viral 
infection, the recombinant virus expressing C6-TAP (vC6TAP, see Chapter 3) was used to 
infect HEK293 or HCT116 cells and a TAP assay was performed. The pattern of proteins 
observed in the final elution was highly similar between the two cell types, but the relative 
abundance of each protein differed somewhat. Proteins in the final elution of the TAP 
experiment performed from lysates of HCT116 cells infected with vC6TAP were analysed by 
mass spectrometry and compared to proteins purified by this method from cells infected with 
vN1TAP. From this experiment DNA-PKcs, UBR1, UBR2, Hsp70, TROVE2 and VACV 
protein I1 were identified as potential C6 binding partners. The interaction of C6 with UBR1 
and SMARCC1 was confirmed by conventional IP, but the interaction between C6 and DNA-
PKcs was found to be non-specific, because this protein also co-immunoprecipitated with 
N1-TAP. DNA-PKcs was therefore likely to be a false positive hit and thus highlights the 
importance of confirming mass spectrometry data by another method such as a conventional 
IP assay. Further assays need to be performed to confirm the interaction of C6 with the other 
identified proteins and to understand the biological relevance of these interactions. 
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Figure 6.7: C6-TAP interacts with SMARCC1. HEK293 cells were infected overnight 
with vC6TAP or vN1TAP (2 p.f.u. per cell). The cells were harvested in TAP IP buffer and 
cleared lysates (INPUT) were subjected to IP with protein G sepharose beads coupled with 
rabbit-anti-SMARCC1 or rabbit-anti-HA (control) Ab or with anti-FLAG agarose beads, as 
indicated. The proteins were separated by SDS-PAGE and detected by immunoblotting as 
indicated on the left. The location of protein molecular mass markers is indicated on the 
right (kDa).    
 
194 
 
 
  
INPUT
IP:
FLAG
IP:
UBR1
20
15
250
FLAG
UBR1
Figure 6.8: C6-TAP interacts with UBR1. HEK293 cells were infected overnight with 
vC6TAP or vN1TAP (2 p.f.u. per cell). The cells were harvested in TAP IP buffer and 
cleared lysates (INPUT) were subjected to IP with protein G sepharose beads coupled with 
rabbit-anti-UBR1 Ab or with anti-FLAG agarose beads, as indicated. The proteins were 
separated by SDS-PAGE and detected by immunoblotting as indicated on the left. The 
location of protein molecular mass markers is indicated on the right (kDa).    
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Chapter 7: Contribution of C6 to VACV virulence  
7.1 Deletion of C6 has no effect on viral replication or spread in vitro  
Before investigating the role of C6 during infection in vivo, the recombinant viruses were 
analysed in vitro to ascertain whether the deletion of C6 had an effect on viral replication and 
spread. The effect of C6 on viral spread was tested using three cell lines of different animal 
origin; African green monkey kidney BSC-1 cells, rabbit kidney RK-13 cells and human 
osteosarcoma TK143 cells. These cells were infected at low p.f.u. per cell with the C6 
recombinant viruses (vC6WR, vΔC6, vC6Rev and vC6FS) for 72 h and the size of the 
resulting plaques was measured by microscopy. The plaque size of the viruses expressing or 
lacking C6 was found to be similar in all of the cell types tested suggesting that the deletion 
of C6L had no effect on viral spread in vitro (Figure 7.1). 
In addition to analysing the plaque size of the C6 recombinant viruses, single- and multi-step 
growth curves were generated using BSC-1 cells. For the single-step growth curve to analyse 
viral replication, the cells were infected in duplicate with 10 p.f.u. per cell and the virus was 
harvested at 12 h and 24 h p.i., with careful separation of the intracellular and extracellular 
viral components, and was titrated on monolayers of BSC-1 cells. The production of both 
intracellular (predominantly IMV, Figure 7.2A) and extracellular (predominantly EEV, 
Figure 7.2B) virus was found to be similar amongst the four recombinant viruses indicating 
that the deletion of C6L did not affect viral replication in vitro.  
For the multi-step growth curve to analyse viral spread, the cells were infected in duplicate 
with 0.01 p.f.u. per cell and the virus was harvested at 24 h, 48 h and 72 h p.i., again with 
careful separation of intracellular (Figure 7.2C) and extracellular (Figure 7.2D) viral 
components, and was titrated. As with the single-step growth curves, the multi-step growth 
curves for both IMV and EEV were found to be similar, demonstrating that the lack of C6 did 
not affect viral spread, in agreement with data presented in Figure 7.1.    
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7.2 Purification of C6 recombinant viruses for in vivo characterisation 
Other members of the VACV Bcl-2 family have been characterised as virulence factors in 
vivo. This includes proteins A46 (Stack et al, 2005), A52 (Harte et al, 2003), B14 (Chen et al, 
2006a), K7 (S. Lucas and A. Fahy, unpublished data) and N1 (Bartlett et al, 2002), where in 
all cases deletion of the encoding gene from WR led to the attenuation of the virus in at least 
one model of murine infection. Outside of the Bcl-2 family other VACV immunomodulatory 
proteins have also been demonstrated to be virulence factors in vivo, for example proteins 
C16 (Fahy et al, 2008), E3 (Brandt & Jacobs, 2001) and B8 (Symons et al, 2002) to name but 
a few. To test the contribution of C6 to VACV virulence vC6WR, vΔC6, vC6Rev and vC6FS 
recombinant viruses (see Chapter 3) were amplified to high titre in RK-13 cells and partially 
purified for in vivo experiments by sedimentation of cytoplasmic extracts through two 
sucrose cushions (see Chapter 2 for methods details). These viruses were titrated at least three 
times on monolayers of BSC-1 cells and the titres were found to be similar for all four viruses 
(Figure 7.3A). The expression of C6 from these partially purified viruses was confirmed by  
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Figure 7.1: Plaque size analysis of C6 recombinant viruses in vitro. Six-well plates of 
BSC-1 (African green monkey), RK-13 (rabbit) and TK143 (human) cells were infected for 
72 h at 50 p.f.u. per well. The cells were stained with crystal violet and the plaque size was 
measured using Axiovision 4.6 software and a Zeiss Axiovert 200M microscope. Results are 
expressed as the mean plaque radius (μM) ± SD.  
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infecting BSC-1 cells overnight and subjecting whole cell lysates to immunoblotting analysis. 
As expected, both vC6WR and vC6Rev expressed C6 but vΔC6 and vC6FS did not, while all 
viruses expressed D8 to equivalent levels (Figure 7.3B). 
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Figure 7.2: Replication and spread of C6 recombinant viruses in vitro. For construction 
of single- (A and B) and multi-step (C and D) growth curves T25 flasks of BSC-1 cells were 
infected in duplicate at 10 p.f.u. per cell and 0.01 p.f.u. per cell, respectively, for 90 min. 
The unbound virus was then washed off and cells were harvested at the time points indicated 
with careful separation of intracellular (A and C) and extracellular virus (B and D) 
components. The harvested viruses were titrated in duplicate on confluent monolayers of 
BSC-1 cells. Results are expressed as the mean titre per sample ± SD.  
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Virus Titre (p.f.u./ml)
vC6WR 1.43 × 1010
vΔC6 1.25 × 1010
vC6Rev 1.59 × 1010
vC6FS 1.41 × 1010
α tubulin
D8
C6
25
15
50
37
A
B
Figure 7.3: Partially purified recombinant viruses. Recombinant viruses were purified for 
in vivo experiments by sedimentation through two sucrose cushions. (A) Viral titres were 
calculated by plaque assay on confluent monolayers of BSC-1 cells. Data are from one 
representative experiment of three. (B) The expression of C6 was confirmed by infecting 
BSC-1 cells overnight with 5 p.f.u. per cell of recombinant virus. The cells were then lysed, 
the proteins were separated by SDS-PAGE and immunoblotted with mouse anti-tubulin, 
mouse anti-D8 or rabbit anti-C6 antibodies. The location of protein molecular mass markers 
is indicated (kDa).  
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7.3 A virus lacking C6 is attenuated in the VACV i.n. model of murine 
infection  
To assess the contribution of C6 to VACV virulence the C6 recombinant viruses were first 
tested in the i.n. model of murine infection. Groups of ten female BALB/c mice were infected 
i.n. with 5 × 10
3
 p.f.u. of virus per animal and their weights and signs of illness were 
monitored daily. Infection with vC6WR induced weight loss in these animals starting 
between days 4 and 5 p.i., with the maximal weight loss observed at days 7-8, followed by a 
period of recovery (Figure 7.4A). Between days 6 and 12 p.i. the mice that were infected with 
a virus lacking C6 expression (vΔC6 and vC6FS) lost significantly less weight than those 
animals that had been infected with a virus expressing C6 (vC6WR and vC6Rev). The 
maximal weight loss of these animals was also smaller (approximately 15 % for vΔC6 and 
vC6FS, and 20 % for vC6WR and vC6Rev) and this was reached one day earlier (day 7 for 
vΔC6 and vC6FS compared to day 8 for vC6WR and vC6Rev) indicating that these animals 
recovered from infection sooner.  
Importantly, the weight loss observed in mice infected with vC6WR and vC6Rev was 
similar, supporting data presented in Figure 3.10 demonstrating that no major rearrangements 
or deletions of the genome had occurred during transient-dominant selection. Furthermore, 
the weight loss observed in animals infected with vΔC6 was similar to those infected with 
vC6FS, again indicating that these viruses are phenotypically alike and that the attenuation 
observed in the absence of the C6 ORF was due to the lack of expression of the C6 protein 
and not due to the lack of the DNA sequence or a non-coding RNA. 
In agreement with the weight loss data, mice infected with a virus lacking the expression of 
C6 showed significantly fewer signs of illness between days 5 and 12 p.i. (Figure 7.4B). 
Further, the maximum signs of illness score was lower for those animals infected with vΔC6 
or vC6FS, peaking at day 7 p.i., corresponding to the maximal weight loss of these animals 
(Figure 7.4A). For the animals infected with a virus retaining C6 expression the maximum 
signs of illness score was higher and recorded at days 8-9 p.i. (Figure 7.4B), again coinciding 
with the maximal weight loss of these animals (Figure 7.4A). Taken with the weight loss 
measurements, these data indicated that a virus lacking C6 expression was attenuated in vivo, 
and this protein was therefore a virulence factor. 
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Figure 7.4: Virulence of C6 recombinant viruses in the murine i.n. model of infection. 
Female BALB/c mice (n=10) were infected with 5 × 10
3
 p.f.u. of the indicated viruses and 
their weights (A) and signs of illness (B) were monitored daily. Data are from one 
representative experiment of two. Weight data (A) are expressed as the percentage ± 
standard error of the mean (SEM) of the mean weight of the same group of animals on day 
0. Signs of illness data (B) are expressed as the mean score ± SEM. The horizontal bar 
indicates the days on which the weight loss or signs of illness induced by vΔC6 and vC6FS 
were statistically different (P<0.05) from both vC6WR and vC6Rev, analysed using the 
Student‟s T-test.  
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7.4 Mice infected with vΔC6 have more neutrophils and macrophages in 
the spleen early after infection  
To gain a mechanistic understanding of why animals infected i.n. with vΔC6 lost 
significantly less weight than animals infected with the wild-type or revertant virus, BAL 
fluid, the lungs and the spleen were harvested from these animals at various time points p.i.. 
These samples were analysed for levels of cytokines and chemokines and for measurement of 
infiltrating immune cells by flow cytometry. 
As C6 was found to be an inhibitor of the IRF3 signalling pathway, and in vitro the ectopic 
expression of this protein was able to suppress the production of CXCL-10 in response to 
NDV infection (Chapter 4), it was hypothesised that in the absence of C6 an enhanced 
production of CXCL-10 might be observed in the lungs mice infected i.n.. The BAL fluid 
was harvested from groups of 5 mice on days 2, 4, 7 and 12 p.i., the cells were collected by 
centrifugation and the supernatant was analysed for CXCL-10 (Figure 7.5A) and the NF-κB-
dependent cytokine IL-6 as a negative control (Figure 7.5B) by ELISA. Small amounts of 
both CXCL-10 and IL-6 were detected in the BAL fluid of mice that had been infected i.n. 
with 5 × 10
3
 p.f.u. of virus, but no differences were observed between infection with vC6WR, 
vΔC6 or vC6Rev. The highest levels of these proteins were measured at early time points p.i. 
(days 2 and 4), diminishing at later time points (days 7 and 12), as expected for a cytokine 
and chemokine that play a crucial role in the early inflammatory innate immune response. 
These inflammatory mediators function to recruit immune cells to the site of infection, and 
thus if C6 had had an effect on the production of these proteins in the lungs of infected 
animals this may have impacted on the total number of infiltrating cells. Although there was a 
trend for more cells infiltrating the airways of the lungs of animals infected with vΔC6 at 
early time points p.i. this was not statistically significant and the error bars were large (Figure 
7.5C). 
To determine whether the lack of C6 expression had an effect on the types of cells that were 
infiltrating the lungs, the cells that had been isolated from the BAL fluid were stained for 
lymphocyte markers and analysed by flow cytometry. To analyse T cell populations CD3
+
 
cells were gated and analysed further for CD4 and CD8 expression, as well as the expression 
of the early activation marker CD69 (Testi et al, 1988). At days 2 (Figure 7.6A), 4 (Figure  
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Figure 7.5: BAL fluid cytokine, chemokine and cell analysis. Female BALB/c mice were 
infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per virus 
were sacrificed and BAL fluid taken on the days indicated. Quantities of CXCL-10 
chemokine (A) and IL-6 cytokine (B) in the BAL fluid were measured by ELISA. Data from 
a single experiment and are presented as mean ± SEM. The total number of viable cells in 
the BAL fluid were enumerated by the trypan blue exclusion method (C). Data are from a 
single experiment and are presented as mean number of infiltrating cells ± SEM.  
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7.6B) and 12 (Figure 7.6C) p.i. no significant differences were observed in the proportion of 
cells that were CD4
+
 or CD8
+
, or the proportion of these cells that were activated from 
animals that had been infected with vΔC6 compared to vC6WR or vC6Rev. For all three 
viruses the proportion of T cells that were CD4
+
 compared to C8
+ 
was higher on days 2 and 4 
p.i., but by day 12 this proportion was observed to be more equivalent, with slightly more 
cells expressing the CD8 marker. In addition, the percentage of activated CD8
+
 cells had 
increased greatly by this time point. Data for day 7 p.i. were unfortunately not available due 
to a technical problem with the staining for CD3. Finally, the cells in the BAL fluid were also 
stained for CD19, a marker of B cells (Stamenkovic & Seed, 1988), but no significant 
differences were observed in the number of these cells in mice infected with the three C6  
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Figure 7.6: Flow cytometry analysis of cells in the BAL fluid. Female BALB/c mice were 
infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per virus 
were sacrificed and broncho-alveolar lavage (BAL) fluid taken on the days indicated. The 
cells were stained for CD3, CD4, CD8, CD69 (activated) (A, B and C) and CD19 (B cells) 
(D), and were analysed by flow cytometry. Data are from a single experiment and are 
presented as mean percentage of CD3-positive cells (A, B, C) or mean percentage total cells 
(D) ± SEM.  
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recombinant viruses (Figure 7.6D). Due to the lack of cells, flow cytometry analysis of 
myeloid and NK cells in the BAL fluid was not possible. 
To understand whether differences in the burden of virus in the lungs might account for the 
reduced weight loss in animals infected with vΔC6, virus isolated from lung homogenates 
was titred by plaque assay on BSC-1 cells. At days 2, 4 and 7 p.i. virus was detectable in the 
lungs of infected mice, but no differences were observed between the titres obtained for the 
three recombinant viruses (Figure 7.7). No virus was detected in the lung at day 12 p.i., 
presumably because it had been cleared by this time point, and no virus was detected in the 
spleen of these animals at any time point tested (data not shown). 
The cells isolated from lung homogenates at the various time points p.i. were stained for both 
lymphoid and myeloid cell markers. As observed for the BAL fluid, the proportion of CD4
+
 
and CD8
+ 
cells, as well as their activation state (CD69
+
) was similar between mice infected 
with the three C6 recombinant viruses at all time points tested (Figures 7.8A, B and C). Also 
in concordance with analysis of the T cells in the BAL fluid, the proportion of CD4
+ 
cells was  
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Figure 7.7: Viral titres in the lungs of i.n.-infected mice. Female BALB/c mice were 
infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per virus 
were sacrificed and the lungs were taken on the days indicated. The lungs were homogenised 
and virus titres were deduced by plaque assay in duplicate on confluent mono-layers of 
BSC-1 cells. Data are from a single experiment and are presented as the mean viral titre ± 
SEM .  
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higher at early time points p.i. but equal to the proportion of CD8
+ 
cells by day 12 p.i.. No 
differences in the proportion of B cells between the viruses were also observed (Figure 7.8D). 
To analyse myeloid and NK cells in the lungs of infected mice the cells were stained for 
Ly6G (Fleming et al, 1993) to identify neutrophils (Figure 7.9A), DX5 (Arase et al, 2001) to 
identify NK cells (Figure 7.9B) and F4/80 (Austyn & Gordon, 1981) to stain for macrophages 
(Figure 7.9C). Macrophages were also stained for CD11b (Springer et al, 1979) but data 
obtained were similar to that obtained with an Ab against F4/80 (data not shown). At all the 
time points tested, no significant differences in the percentage of the various myeloid or NK 
cells was observed in the lungs of mice infected with the three C6 recombinant viruses.      
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Figure 7.8: Lung lymphocytes flow cytometry analysis. Female BALB/c mice were 
infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per virus 
were sacrificed and the lungs were taken on the days indicated. The lungs cells were stained 
for CD3, CD4, CD8, CD69 (activation marker) (A, B and C) and CD19 (B cells) (D), and 
analysed by flow cytometry. Data are from a single experiment and are presented as the 
mean percentage of CD3-positive cells (A, B, C) or mean percentage of total cells (D) ± 
SEM .  
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The spleen was also harvested from the animals used in the experiments above to analyse 
both lymphoid and myeloid cell populations. No differences were observed in the proportion 
of T cells that were CD4
+
 or CD8
+
, or activated at days 2 (Figure 7.10A), 4 (Figure 7.10B) or 
12 (Figure 7.10C) p.i., or the percentage that were B cells (Figure 7.10D). In contrast to data 
obtained from the lung and BAL, CD4
+ 
cells were the more abundant type of T lymphocyte 
in the spleen at all time points tested. A difference was observed, however, in the percentage 
of neutrophils (Figure 7.11A) and macrophages (Figure 7.11C) in the spleen at day 2 p.i. 
where animals infected with vΔC6 had significantly higher numbers of these cell types. No  
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Figure 7.9: Lung myeloid and NK cell flow cytometry analysis. Female BALB/c mice 
were infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per 
virus were sacrificed and the lungs were taken on the days indicated. The lungs cells were 
stained for Ly6G (neutrophils, A), DX5 (NK cells, B), and F4/80 (macrophages, C), and 
analysed by flow cytometry. Data are from a single experiment and are presented as mean 
percentage of total cells ± SEM .  
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significant difference was observed in the proportion of NK cells in the spleen (Figure 
7.11B). 
Taken together these data indicated that although no differences were observed in the type of 
lymphoid cells in the BAL, lung or spleen, or the proportion of myeloid and NK cells 
measured in the lungs, more neutrophils and macrophages were observed in the spleens of 
vΔC6-infected animals at day 2 p.i.. These innate immune effector cells have crucial roles at 
very early time points p.i.. Increased numbers of these cells may aid in the clearance of a viral 
infection and could in some part explain why a virus lacking C6 is attenuated in the i.n.  
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Figure 7.10: Spleen lymphocytes flow cytometry analysis. Female BALB/c mice were 
infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per virus 
were sacrificed and the spleen was taken on the days indicated. The spleen cells were stained 
for CD3, CD4, CD8, CD69 (activation marker) (A, B and C) and CD19 (B cells) (D), and 
were analysed by flow cytometry. Data are from a single experiment and are presented as 
mean percentage of CD3-positive cells (A, B, C) or mean percentage total cells (D) ± SEM .  
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model of infection. It would be very interesting to investigate whether the proportion of these 
cells would also be increased in the lung and BAL fluid of animals infected with vΔC6 at day 
2 p.i..  
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Figure 7.11: Spleen myeloid and NK cell flow cytometry analysis. Female BALB/c mice 
were infected i.n. with 5 × 10
3
 p.f.u. of the C6 recombinant viruses and five animals per 
virus were sacrificed and the spleen was taken on the days indicated. The spleen cells were 
stained for Ly6G (neutrophils, A), DX5 (NK cells, B), and F4/80 (macrophages, C), and 
were analysed by flow cytometry. Data are from a single experiment and are presented as 
mean percentage of total cells ± SEM . ** P<0.01, *** P<0.001, analysed using the 
Student‟s T-test.   
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7.5 A virus lacking C6 is attenuated in the VACV i.d. model of murine 
infection  
The contribution of C6 to VACV virulence was also tested in the murine i.d. model of 
infection. Groups of ten female C57BL/6 mice were infected with 10
4
 p.f.u. of the C6 
recombinant viruses per ear, in both ears, and the resulting lesions were measured daily with 
a micrometer. Measurable lesions were detectable from day 5 p.i., reaching their maximal 
size between days 11 to 14 p.i. and having completely healed by one month p.i. (Figure 7.12). 
Between days 5 and 23 p.i. the lesions caused by infection with vΔC6 or vC6FS were 
significantly smaller than those induced by vC6WR and vC6Rev. In addition, the lesions 
induced by the viruses lacking C6 expression had a smaller maximal size and began healing 3 
days sooner (day 11 for vΔC6 and vC6FS compared to day 14 for vC6WR and vC6Rev) than 
the lesions caused by the viruses expressing C6. Similar to the results obtained in the i.n. 
model of infection, the size of the lesions induced by infection with the viruses expressing C6 
was similar, as were the lesion sizes induced by infection with the viruses lacking C6 
expression, again indicating that the attenuation observed was attributable to the lack of C6 
protein expression and not due to the aberration of other viral genes. 
7.6 Vaccination of animals with a virus lacking C6 expression provides 
enhanced protection against a lethal dose of virus 
The strength and type of innate immune response mounted against a pathogen impacts greatly 
on the adaptive response that follows. As such, proteins that are known to dampen the innate 
response may have a negative impact on the adaptive immune response and thus may reduce 
the efficacy of vaccination. VACV was used as a vaccine in the eradication campaign against 
smallpox (Fenner et al, 1988) and is being investigated as a vector for the immunisation 
against a wide range of pathogens and cancer (Gomez et al, 2008). To investigate whether the 
deletion of C6 from WR had an effect on its efficacy as a vaccine, groups of 5 female 
C57BL/6 mice were vaccinated i.d. with 10
4
 p.f.u. of the C6 recombinant viruses in both ears. 
One month later the animals were challenged i.n. with a lethal dose (5 × 10
6 
p.f.u. per animal) 
of WR and their weights were monitored daily. The onset of weight loss in response to a 
lethal dose of virus post-vaccination occurred much sooner than that observed during a 
primary VACV infection and recovery began at just 2 days p.i. (Figure 7.13). Between days 2  
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and 4 p.i. the weight loss observed when mice were vaccinated with a virus lacking C6 
expression was found to be significantly less than that of mice that had been vaccinated with 
a virus expressing C6 (Figure 7.13). These data indicated that although all mice were 
protected against the lethal challenge, better protection was afforded by the viruses lacking 
C6 expression and that this virus was therefore a better vaccine. As observed in both the i.n. 
and i.d. models of infection, the viruses lacking and retaining C6 expression were grouped 
together.    
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Figure 7.12: Virulence of C6 recombinant viruses in the murine i.d. model of infection. 
Female C57BL/6 mice (n=10) were infected i.d. with 10
4
 p.f.u. of the indicated viruses in 
both ears and the resulting lesions were measured daily with a micrometer. Data are from a 
representative experiment of two and are expressed as the mean lesion size ± SEM. The 
horizontal bar indicates the days on which the lesion size caused by vΔC6 and vC6FS were 
statistically different (P<0.05) from both vC6WR and vC6Rev.   
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7.7 The enhanced protection observed after vaccination of mice with a 
virus lacking C6 expression was not attributable to an enhanced Ab 
response 
To understand how mice infected with a virus lacking C6 expression were better protected 
against a lethal dose of VACV, the blood was taken from mice one month post-vaccination 
for serum Ab analysis. Antibody neutralisation was first analysed by an IMV plaque 
reduction neutralisation assay. Somewhat surprisingly, antibodies in the serum of animals 
that had been vaccinated with either vΔC6 or vC6FS were found to have a significantly lower 
ND50 than the antibodies in the serum of animals that had been vaccinated with vC6WR or 
vC6Rev, indicating a poorer neutralisation capacity (Figure 7.14A). In each assay a positive 
control serum was included from a human vaccinated multiple times (GLS03). The ND50  
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Figure 7.13: Challenge study following i.d. infection of mice with the C6 recombinant 
viruses. Female C57BL/6 mice (n=5) were infected i.d. with 10
4
 p.f.u. of the indicated 
viruses in both ears. One month later the animals were challenged i.n. with 5 × 10
6 
p.f.u. WR 
per animal and their weights were monitored daily. Data are from a representative 
experiment of two and are expressed as the percentage ± SEM of the mean weight of the 
same group of animals on day 0. The horizontal bar indicates the days on which the weight 
loss of the vΔC6- and vC6FS-vaccinated animals was statistically different (P<0.05) from 
both vC6WR- and vC6Rev-vaccinated animals.   
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Figure 7.14: Antibody analysis of mice one month post - i.d. infection. Groups of female 
C57BL/6 mice (n=5) were infected i.d. with 10
4
 p.f.u. of the indicated viruses in both ears. 
One month later animals were sacrificed and their blood was taken. Blood serum was 
analysed for Ab neutralisation by an IMV plaque reduction neutralisation assay (A) and Ab 
binding to VACV epitopes by ELISA (B). Data are from a total of three experiments and are 
presented as ND50 values (A) or end point titres (B) with the median indicated by a 
horizontal line. Neutralisation data were analysed by a Mann-Whitney test and indicated that 
the Ab neutralisation from animals vaccinated with vΔC6 or vC6FS were statistically 
different (P<0.05) from animals vaccinated with vC6WR.  
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data obtained from this serum were similar between assays, confirming reproducibility 
between experiments. 
To determine whether the antibodies from animals vaccinated with a virus lacking C6 
expression had a poorer neutralisation capacity because the titres of VACV-specific 
antibodies were lower, an ELISA was performed against whole cell lysates of cells that had 
been infected with WR. The end point titre of WR-specific antibodies was found to be similar 
between the vaccinated animals, indicating that the poorer neutralisation was not due to the 
presence of fewer VACV-specific antibodies (Figure 7.14B). 
Given that the enhanced protection of vΔC6 as a vaccine could not be explained by enhanced 
VACV-specific Ab titres or enhanced Ab neutralisation it was hypothesised that the increased 
protection might be T cell-mediated. To investigate this, spleens were harvested from mice 
one month post-vaccination and the cells were analysed by flow cytometry. The overall 
proportion of T cells (CD3
+
) and B cells (CD19
+
) in the spleens of vaccinated animals was 
found to be similar (Figure 7.15A). In addition, the proportion of T cells that were CD4
+
 or 
CD8
+
, or were expressing CD44, a marker of T cell long-term activation and memory 
(Baaten et al, 2010) was also found to be equivalent (Figure 7.15B). These data indicated that 
the enhanced protection could not be attributed to differences in the relative quantities of 
these cell types or their activation. 
To test the ability of the T cells from vaccinated animals to kill VACV-infected cells, a 
chromium release cytotoxicity assay was performed. One month post-vaccination spleens 
were harvested from groups of 5 animals for cytotoxicity analysis, whilst another 5 animals 
per group were challenged i.n. with 5 × 10
6 
p.f.u. WR per animal and sacrificed 8 days later 
for subsequent T cell cytotoxicity analysis. The percentage specific lysis of WR-infected EL-
4 cells by splenic T cells isolated from vaccinated animals was not found to be significantly 
different between the four C6 recombinant viruses, either before (Figure 7.16A), or after 
challenge (Figure 7.16B). As expected, the percentage specific lysis was higher after 
challenge than before challenge, and T cells from mock-infected animals did not have any 
lytic activity. 
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Figure 7.15: Spleen lymphocyte analysis one month post-i.d. infection by flow 
cytometry. Female C57BL/6 mice (n=5) were infected i.d. with 10
4
 p.f.u. of the indicated 
viruses in both ears. One month p.i. the animals were sacrificed and the spleen was taken. 
The spleen cells were stained for CD3 (T cells) and CD19 (B cells) (A), and also CD4, CD8 
and CD44 (activated) (B), and were analysed by flow cytometry. Data are from a 
representative experiment of two and are presented as the mean percentage of of total cells 
(A) or CD3-positive cells (B) ± SEM .  
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Figure 7.16: Splenic T cell cytotoxicity before and after challenge of i.d.-infected mice.  
Female C57BL/6 mice (n=10) were infected i.d. with 10
4
 p.f.u. of the indicated viruses in 
both ears. One month p.i. 5 animals per group were sacrificed and the spleen taken for 
cytotoxicity analysis. The other 5 animals per group were challenged i.n. with 5x10
6 
p.f.u. 
WR per animal and sacrificed 8 days later for splenic T cell cytotoxicity analysis. Specific 
lysis of EL-4 cells by T cells was assessed by 
51
Cr-release assay. Data are from a single 
experiment and are presented as the mean ± SD.  
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IFNγ produced by T cells is a very important cytokine for the immune defence against viral 
infection (Schroder et al, 2004). To analyse IFNγ release by T cells from vaccinated animals 
in response to exposure to VACV-specific antigens, an ELISPOT assay was performed. One 
month post-vaccination the mice were sacrificed and the spleen was harvested. The 
splenocytes were stimulated overnight with a CD8-specific peptide characterised to be 
immunogenic in C57/BL6 mice (TSYKFESV, (Tscharke et al, 2005)) or as a negative control 
a CD8-specific peptide characterised to be immunogenic in BALB/c mice (VGPSNSPTF, 
(Tscharke et al, 2006)), or they were incubated with EL-4 cells that had been mock-infected 
or infected with WR. As expected, minimal IFNγ release was observed from splenic T cells 
that were stimulated with the BALB/c-specific peptide or mock-infected EL-4 cells. The 
release of IFNγ in response to VACV-specific antigens was not enhanced in vΔC6-
vaccinated animals, again providing no mechanistic explanation for the improved protection 
observed with this virus (Figure 7.17).  
7.8 Summary 
Prior to the characterisation of the C6 recombinant viruses in vivo, the effect of C6 deletion 
from WR on virus replication and spread was assessed in vitro. C6 was found not to 
contribute to replication or spread in cell culture as the viruses lacking C6 expression 
replicated to equivalent titres in both a single- and multi-step growth curve, performed using 
BSC-1 cells and formed similar size plaques in three cell types of different species origin. In 
contrast, a virus lacking C6 was attenuated in both the murine i.n. and i.d. models of infection 
in vivo. Mice infected i.n. with either vΔC6 or vC6FS lost significantly less weight and 
showed fewer signs of illness than mice infected with vC6WR or vC6Rev, and the lesions 
induced by i.d. infection of the viruses lacking C6 expression were significantly smaller and 
healed quicker. 
Although C6 inhibited CXCL-10 production in response to NDV infection in vitro, no 
difference in the amount of this chemokine in the BAL fluid of i.n.-infected mice was 
observed in vivo at the times points measured. No difference was also observed in the total 
number of infiltrating cells in the lungs, or the types of immune cells measured in either the 
BAL fluid or the lung tissue. Interestingly, although the populations of T cells and NK cells 
in the spleen were unaltered between mice that had been infected with the various C6  
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recombinant viruses, more neutrophils and macrophages were present at 2 days p.i. with 
vΔC6. These data indicated that the presence of C6 had a negative effect on the number of 
these myeloid cells in the spleens of infected animals. As these cells are crucial for the early 
immune response against viral infection this finding might contribute to the attenuated 
phenotype observed in the absence of C6 expression.  
In addition, a virus lacking C6 expression provided enhanced protection against a lethal 
challenge of mice with WR. This protection could not be attributed to enhanced titres of WR-
specific antibodies in the serum, or enhanced Ab neutralisation capacity. In fact, antibodies 
isolated from vΔC6- or vC6FS-vaccinated animals had poorer neutralisation abilities against 
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Figure 7.17: ELISPOT analysis of IFNγ-producing splenic T cells one month post-i.d. 
infection.  Female C57BL/6 mice (n=5) were infected i.d. with 10
4
 p.f.u. of the indicated 
viruses in both ears. One month p.i. the animals were sacrificed and the spleen taken for 
ELISPOT analysis. The splenocytes were stimulated with TSYKFESV peptide (+ve) or 
VGPSNSPTF peptide (-ve) or were incubated with EL-4 cells that had been mock-infected 
or infected with WR. Data are from one representative experiment of two and are presented 
as the mean spots per million splenocytes ± SEM.  
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IMV WR. Given these data it was hypothesised that the enhanced protection afforded by 
vΔC6 would be due to an enhanced T cell response and/or memory. No differences in the 
types of T cells, including memory T cells were observed in the spleen one month post-
vaccination of mice with the various C6 recombinant viruses and the splenic T cells from 
vΔC6-vaccinated animals were found not to have enhanced killing capacity or release of 
IFNγ in response to VACV antigens.  Further analysis of the immune response to infection 
with vΔC6 needs be undertaken to fully understand this phenotype. 
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Chapter 8: Discussion 
8.1 Basic characterisation of VACV WR protein C6 
To establish a productive infection pathogens must counteract the innate immune response. 
Viruses have evolved many mechanisms to achieve this and studying these not only enhances 
our knowledge of viral pathogenesis but also adds to our understanding of the immune 
system and how it functions. As such this continues to be a field of active research. VACV 
strain WR ORF 022 encodes protein C6, a predicted member of the VACV Bcl-2 family of 
proteins, whose other characterised members have roles in innate immune modulation. 
Together with the fact that C6 was identified from a screen performed in Prof. Bowie‟s lab at 
Trinity College Dublin of VACV proteins with the ability to inhibit IFNβ induction in HEK 
cells, this protein was selected for further investigation. 
Orthologues of C6 were found to be highly conserved amongst the OPVs and counterparts 
were even identified in some Capripoxvirus genus members. The high conservation of C6 
suggested an important function for this protein. An orthologue of C6 is also expressed by 
MVA, which differs from WR C6 by an additional 6 amino acids at the C terminus. These 
residues did not prevent this protein from inhibiting IFNβ however (Figure 4.3). This is in 
agreement with the work of Garcia-Arriaza et al who found that human macrophages and 
monocyte-derived macrophages infected with a strain of MVA lacking C6 expression (MVA-
BΔC6) produced more IFNβ than wild-type MVA-B (Garcia-Arriaza et al, 2011). The ability 
of MVA C6 to inhibit ISRE induction or bind to UBR1 or SMARCC1 was not addressed in 
this study and would be interesting future work to understand whether all functions of this 
protein are conserved. Given that enhanced expression of IFIT1 and IFIT2, two IFNα/β-
inducible genes, was measured in human macrophages infected with MVA-BΔC6 compared 
to wild-type MVA-B, MVA C6 may also have an immunomodulatory role downstream of the 
IFNAR (Garcia-Arriaza et al, 2011).  
MVA is a highly attenuated virus that has been passaged more than 500 times in CEFs. Large 
portions of the genome are missing and many immune modulators have been found to be 
deleted or are no longer functional, for example protein 183, the MVA counterpart of VACV 
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WR B14 (McCoy et al, 2010). The recombinant WR virus lacking C6 (vΔC6) showed no 
defect in replication or spread in vitro (Figures 7.1 and 7.2) and therefore it is interesting that 
it is retained in the MVA genome. It is possible that in the absence of other genes, MVA C6 
may contribute to viral replication. This however is unlikely as another highly attenuated 
VACV strain being tested in vaccine trials, NYVAC, lacks C6 and MVA-BΔC6 was found to 
replicate to identical titres as MVA-B, at least for a multistep growth curve (Garcia-Arriaza et 
al, 2011). A single-step growth curve for these viruses was not constructed by the authors. 
MVA does not replicate in mammalian cells and is normally grown in avian cells such as 
CEFs and DF1 cells. It is possible that the immunomodulatory function of C6 is highly 
beneficial to the virus in these cells in vitro, or another uncharacterised role for this protein 
provides some essential function. 
The structural model of C6, predicted using MODELLER and based on a structural alignment 
between C6 and B14, demonstrated that C6 folds favourably as a Bcl-2 scaffold and is highly 
similar structurally to B14 (Figure 3.3). Like other members of this family C6 is an inhibitor 
of innate immune signalling. The amino acid sequence identity of this family of VACV Bcl-2 
proteins is less than 20 % (Graham et al, 2008), demonstrating that structure is more highly 
conserved than sequence. The Bcl-2 fold may provide a stable structure or platform for 
protein-protein interactions.  
The expression of C6 was observed from 2 h p.i. and occurred without the need for DNA 
replication, confirming it as an early gene (Figure 3.5). This in agreement with a recent study 
using WR and also MVA, where the orthologue of C6 is also expressed early and without the 
need for replication (Garcia-Arriaza et al, 2011). Many other innate immune modulators, 
including other members of the VACV Bcl-2 family are expressed early and this is consistent 
with a role for C6 as an immunomodulator. Viral detection by PRRs may occur very early 
after infection, or even at the point where the virus encounters the cell membrane and thus the 
rapid expression of proteins that can dampen the immune response is critical to the virus. 
Protein VH1 for example is packaged into virions and is able to de-phosphorylate STATs and 
prevent the expression of ISGs prior to viral gene transcription (Najarro et al, 2001). It may 
be interesting to put the expression of an immune modulator such as C6 under the control of a 
late VACV promoter and determine in vivo whether this virus is attenuated, and if so to what 
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extent compared to the knockout virus. This would give an indication to the importance of the 
early expression of a protein that counteracts the innate immune response.   
Although lacking an obvious NLS, C6 was found to be both cytoplasmic and nuclear (Figure 
3.11 and 3.12). TANK, SINTBAD and NAP1 are cytoplasmic proteins and therefore it would 
be interesting to investigate whether co-localisation of C6 and these proteins occurs in 
infected cells. Within the cytoplasm C6 is not diffuse, but rather localises to punctuate 
structures. It is unclear whether these structures are cellular organelles and therefore 
immunofluorescence experiments could be repeated with markers of organelles, such as 
MitoTracker for mitochondria, to look for co-localisation. The function of nuclear C6 is not 
yet known, although this may have something to do with the nuclear protein SMARCC1 that 
was identified by mass spectrometry as a potential binding partner for C6 (Figure 6.5). A 
recent study using a polyclonal antiserum raised against MVA C6 for immunofluorescence 
found C6 expressed by either WR or MVA to be localised to a distinct structure in the 
cytoplasm, which the authors suggested to be a viral factory, although co-localisation with 
DAPI was not presented (Garcia-Arriaza et al, 2011). A possible explanation for the 
difference in localisation observed is that Garcia-Arriaza et al used chicken DF1 cells for 
localisation studies whereas human HeLa and HEK293 cells were used in this study. Further, 
Garcia-Arriaza et al did not present data on C6 localisation by any method other than 
immunofluorescence.  
Like A52, B14 and N1, C6 was also shown by both conventional IP assays (Figure 3.15) and  
LUMIER (Figure 3.16) to have dimerisation abilities. Whether dimers form in cells during 
the course of an infection or whether dimerisation is required for C6 function is currently 
unknown and warrants further investigation. In the case of B14, dimerisation is not required 
for function and in fact the dimerisation interface formed by alpha helices 1 and 6 is also the 
interface for binding to IKKβ (Benfield et al, 2011). The same interface is also used by N1 
for dimerisation (Cooray et al, 2007) and by K7 for binding to DDX3 (Oda et al, 2009). This 
hydrophobic interface may provide a favourable platform for binding to cellular proteins and 
in the absence of ligand, dimersation occurs to prevent the exposure of hydrophobic residues 
to the solvent. Recent studies using a mutant N1 that is unable to dimerise found that this 
protein no longer inhibited NF-κB activation and was attenuated in vivo (Maluquer de Motes 
et al, 2011). What is not clear from this study is whether dimerisation is required for N1 
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function, or whether N1, like B14 and K7 uses the alpha helix 1-6 interface to interact with a 
cellular protein. In this case the mutation introduced in N1 may not only prevent 
dimerisation, but may also prevent binding to an unidentified cellular protein involved in the 
NF-κB pathway.  
Whilst data presented in this study indicate an interaction between C6 molecules it cannot be 
ruled out that this is via an intermediate cellular protein and thus indirect. In order to confirm 
that C6 forms dimers mutations would need to be designed that interfere with the dimer 
interface and prevent an interaction from occurring, akin to what has been demonstrated for 
N1 (Maluquer de Motes et al, 2011), or an immunoprecipitation assay could be performed 
using C6 protein expressed and purified from bacteria. 
Although the VACV Bcl-2 proteins have a similar fold and many have the ability to homo-
dimerise they do not seem to form hetero-dimers. This was demonstrated for C6 and B14 in 
this study (Figure 3.15), and has also been shown for C6 and N1 (C. Maluquer de Motes, 
unpublished results). Of note, although dimerisation using the interface of helices 1 and 6 is 
conserved in A52, B14 and N1, the rotation of the individual monomers at this interface 
differs between the proteins by up to 57 ° (Graham et al, 2008), potentially explaining the 
lack of hetero-dimerisation. 
Recently a role for the cellular Bcl-2 proteins in inflammation has been discovered. The pro-
apoptotic Bcl-2 protein BID was found to interact with NOD1, NOD2 and the canonical IKK 
complex, influencing both NF-κB and MAPK signalling (Yeretssian et al, 2011). A further 
link between mechanisms of apoptosis and immunity was demonstrated by Ferrer et al. In 
that study the induction of Noxa-mediated apoptosis induced by MVA infection was found to 
be dependent on viral recognition by the cytosolic RIG-I-like helicases and subsequent 
activation of IRF3, leading to the upregulation of Noxa itself (Ferrer et al, 2011). 
8.2 Functional characterisation of C6 
C6 was identified in a functional screen of VACV proteins that could inhibit IFNβ induction 
(Unterholzner et al, 2011) and this ability was confirmed in this study (Figure 4.1). IFNs play 
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a crucial role in the defence against viral infection and therefore viruses have evolved 
numerous mechanisms to inhibit their production or counteract their functions (Fensterl & 
Sen, 2009). Many NF-κB-specific inhibitors expressed from VACV have been described 
(Bowie et al, 2000; Chen et al, 2008; DiPerna et al, 2004; Gedey et al, 2006; Myskiw et al, 
2009; Shisler & Jin, 2004), but C6 did not inhibit NF-κB (Figure 4.4 and 4.5) and instead 
inhibited the activation of IRF3 (Figure 4.6), consistent with its ability to inhibit IFNβ 
induction. The site of action of C6 was found to be quite downstream in the signalling 
pathway (downstream of the non-canonical kinases, but upstream of IRF3, Figure 4.8), likely 
explaining how this protein is able to inhibit IRF3 activation downstream of various stimuli. 
In addition, work performed in Prof. Bowie‟s laboratory found C6 to inhibit non-canonical 
IKK-dependent, but not -independent activation of IRF7, further explaining its ability to 
inhibit IFNβ induction (Unterholzner et al, 2011). The inhibition of IFNβ induction by C6 is 
supported by a recent study demonstrating that human macrophages and monocyte-derived 
DCs upregulate the expression of and secrete more IFNβ in response to infection with MVA-
BΔC6 compared to wild-type MVA-B, suggesting that C6 acts to dampen this production 
(Garcia-Arriaza et al, 2011).  
A number of the other characterised IRF3 inhibitors expressed by VACV act upstream in the 
signalling pathway. Both C16 (which binds the Ku complex, N. Peters, manuscript in 
preparation) and E3 (which inhibits the activation of DAI (Wang et al, 2008), and the RLRs 
and PKR (Chang et al, 1992) and also RNA polymerase III-mediated dsDNA-sensing 
(Valentine & Smith, 2010)) act on the PRRs themselves and A46 binds to PRR adaptors. This 
means that these proteins inhibit signalling downstream of specific stimuli only. K7, however 
is a broader inhibitor of IFNβ induction and is believed to exert its effects by binding to 
DDX3. It is currently unclear which signalling pathways converging on the non-canonical 
IKK complex DDX3 plays a role in, but as K7 can inhibit IRF3 activation downstream of 
multiple TLRs and RLRs it is presumed to contribute to a number of pathways.  
An important question therefore is why does VACV require so many proteins that apparently 
inhibit the activation of the same transcription factors and genes? There are a number of 
potential explanations for this, although testing them experimentally is currently challenging. 
First VACV is known to activate multiple signalling pathways and is recognised by 
numerous PRRs including MDA5, NALP3 (Delaloye et al, 2009), IFI16 (Unterholzner et al, 
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2010) and DNA-PK (B. Ferguson et al, submitted), and therefore all arms of the innate 
immune response need to be inhibited. Secondly there appears to be a lot of redundancy in 
the innate immune response, particularly amongst adaptor proteins and this may explain why 
VACV targets immune signalling pathways at multiple points. Further, the position in the 
pathway where the protein acts determines which downstream signalling events are inhibited 
and thus which transcription factor activation is prevented. For example B14 is a potent 
inhibitor of NF-κB activation as it inhibits the canonical IKK complex where multiple 
signalling pathways converge downstream of various PRRs (Chen et al, 2008). On the other 
hand, A52 binds IRAK2 and TRAF6 (Harte et al, 2003), thus inhibiting NF-κB activation 
downstream of certain PRRs only, but allowing this protein to also inhibit MAPK activation 
(Maloney et al, 2005). Thirdly the innate response is activated shortly after infection, at 
which point the level of expression of a single immunomodulator may not be sufficient to 
completely inhibit NF-κB and IRF3 activation. Finally the importance of the 
immunomodulators may be very cell-type specific, depending on the PRRs activated by the 
virus in that particular cell.  
The finding that C6 binds to TANK, SINTBAD and NAP1 (Figure 5.11) corroborates data 
demonstrating that C6 inhibits IRF3 activation downstream of multiple stimuli, as the 
pathways activating IRF3 converge on the non-canonical IKKs via these adaptor proteins. It 
is interesting however that C6 inhibited IRF3 activation after the over-expression of either 
TBK1 or IKKε (Figure 4.8). Although it is not understood mechanistically how the over-
expression of these kinases drives IRF3 reporter activity, it is presumed that the high 
concentration of protein allows auto-phosphorylation of the kinases and activation to occur, 
with the subsequent phosphorylation of IRF3. These data might therefore indicate that the 
adaptors in fact act downstream of the non-canonical IKKs or rather as a large multi-protein 
signalling complex linking upstream and downstream signalling. TANK, for example has 
been described to interact with IRF3 and IRF7 (Gatot et al, 2007) and thus may be required to 
bring these transcription factors in the vicinity of the activated non-canonical IKKs for their 
phosphorylation to occur. If the presence of C6 prevents the formation of this multi-protein 
complex in some manner, then despite the kinases being activated they may not be brought in 
proximity of the IRFs and thus C6 still inhibits the pathway. Analysis of whether TBK1 and 
IKKε are phosphorylated in the presence of C6 has not been performed and could be an 
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informative experiment. In addition, although IRF3 does not translocate to the nucleus in the 
presence of C6 (Unterholzner et al, 2011), its phosphorylation status is yet to be investigated. 
In vitro, C6 inhibited IRF3-dependent gene expression and protein production in response to 
infection with NDV (Figure 4.7). In both cases this inhibition was not complete, but this may 
be explained by insufficient concentrations of C6 and/or the NF-κB dependency of both 
CXCL-10 (Ohmori & Hamilton, 1993) and CCL5 (Danoff et al, 1994) in addition to IRF3. 
This experiment however was performed by over-expressing C6 out of the context of a viral 
infection. Attempts were made to measure IFNβ and IRF-3-dependent gene expression 
following the infection of cells with the recombinant C6 viruses however little or no 
induction of these genes was observed, seemingly because WR expresses sufficient 
immunomodulatory proteins to prevent their activation. Indeed Delaloye et al noted that 
although pro-inflammatory cytokines, chemokines and IFNβ were readily detectable in 
response to MVA infection in macrophages, such a response to VACV WR was not detected 
and they attributed this finding to the presence of immune modulators in the WR genome 
(Delaloye et al, 2009). A recent study also found that myxoma virus-infected DCs produced 
IFN, whereas in an identical experiment using VACV WR no IFN induction was detected 
(Dai et al, 2011). The recent study from Garcia-Arriaza et al found that human macrophages 
infected with MVA-BΔC6 had increased expression of CCL5 compared to MVA-B, 
supporting the role of C6 as an IRF3 inhibitor (Garcia-Arriaza et al, 2011).  
In vivo small amounts of CXCL-10 and IL-6 were found in the BAL of i.n.-infected animals 
but no differences were observed between viruses that did or did not express C6 (Figure 7.5). 
IL-6 is an NF-κB-dependent gene and thus acted as a negative control in this assay, however 
CXCL-10 is both IRF3- and NF-κB-dependent, and given that an effect in vitro was observed 
in the presence of C6, an effect in vivo may also have been expected. A possible explanation 
for the in vivo data is that any differences expected in the absence of C6 may have been 
masked by the presence of other viral immunomodulators. Further, human macrophages 
infected with MVA-BΔC6, despite showing increased expression of IFNβ and other IRF3-
dependent genes, did not show increased expression of CXCL-10 (Garcia-Arriaza et al, 
2011). Other IRF3-dependent genes that are less dependent on NF-κB may need to be 
measured in vivo to observe differences between viruses lacking or retaining C6 expression.  
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As C6 inhibits IFNβ induction in vitro the production of IFNβ protein was also measured in 
the BAL of infected mice by ELISA, but none was detected. Cytokine and chemokine levels 
in the BAL were found to be very low and higher levels may be measureable from 
homogenised lungs. As the production of these inflammatory mediators occurs very soon 
after infection it may also be worthwhile investigating their production at earlier time points 
p.i. such as at 2, 6, 12 or 24 h. In cell culture, differences with MVA-BΔC6 were observed at 
6 h p.i. for example (Garcia-Arriaza et al, 2011). In order to test a broader range of IRF3-
dependent gene induction qPCR could be performed on infected tissue such as the lungs and 
trachea for the i.n. model of infection, or the ear following i.d. infection and the differences 
between an infection with a virus expressing or lacking C6 could be assessed.  
In this study the ability of C6 to inhibit IFNβ induction has been largely attributed to its 
ability to inhibit IRF3, and not NF-κB activation. The absence of anti-NF-κB activity by C6 
is supported by findings that human macrophages infected with MVA-BΔC6 failed to show 
enhanced expression of IL-8, an NF-κB-, but not IRF3-dependent gene (Mukaida et al, 1990), 
compared to a wild-type MVA-B infection (Garcia-Arriaza et al, 2011).  The IFNβ promoter 
however, in addition to NF-κB and IRF3 binding sites also has an AP-1 binding site and it is 
currently unknown whether C6 has any effect on the activation of this transcription factor. 
Reporter gene assays were performed with an AP-1-specific reporter, however the fold 
induction obtained following the treatment of cells with various stimuli was found to be poor 
and inconsistent. An alternative would be to assess AP-1-specific gene activation by qPCR, 
perform an AP-1-specific electrophoretic mobility shift assay, or assess the phosphorylation 
of the MAPKs in the presence and absence of C6. It remains possible therefore that C6 may 
inhibit IFNβ induction by more than one method. Opposing the possibility that C6 inhibits 
AP-1 activation is the finding that MVA-BΔC6 infection did not induce enhanced IL-8 
activation, as expression of this cytokine is also dependent on AP-1 in addition to NF-κB 
(Yasumoto et al, 1992). 
In addition to inhibiting IRF3 activation, C6 was also observed to inhibit an ISRE-specific 
reporter following the stimulation of cells with the type I IFN IFNα (Figure 4.9A). This 
finding is supported by the work of Garcia-Arriaza et al where it was observed that human 
macrophages infected with MVA-BΔC6 showed enhanced expression of IFIT1 and IFIT2, 
two IFNα/β-inducible genes, compared to infection with wild-type MVA-B (Garcia-Arriaza 
227 
 
et al, 2011). Thus far TANK, SINTBAD and NAP1 have not been characterised to contribute 
to the JAK-STAT signalling pathway downstream of the IFNAR. Consequently C6 may have 
a second function in inhibiting this pathway independent of its binding to the three non-
canonical IKK adaptor proteins. However, given that IRF3 and ISGF3 have largely 
overlapping DNA recognition sequences (Fujii et al, 1999) it would be interesting to 
investigate whether IRF3 contributes to the activation of ISRE-dependent ISGs downstream 
of the type I IFNs. For example, the transcription of type I IFN-dependent genes, such as 
IFIT1 and IFIT2 could be measured in TBK1-null, or IRF3-null MEFs following the 
treatment of cells with IFNα and compared to wild-type cells.  If IRF3 activation contributes 
to both IFNβ induction and ISRE induction this may explain how C6 inhibits both pathways.  
The mechanism by which C6 inhibits ISRE induction is currently unknown, but is specific 
for the type I IFN signalling pathway because no effect was observed in GAS-specific 
reporter activity following the stimulation of cells with IFNγ (Figure 4.9B). As such it is 
unlikely that C6 acts on a molecule common to both pathways such as STAT1, but rather on 
a molecule unique to the pathway downstream of the IFNAR. The signalling pathway 
downstream of type III IFNs binding the type III IFN receptor is considered indistinguishable 
from that downstream of type I IFNs (Fensterl & Sen, 2009), therefore it is expected that C6 
would also inhibit ISRE activation following the treatment of cells with a type III IFN, 
although this remains to be tested. Assays assessing the levels of STAT phosphorylation and 
subsequent translocation may indicate whether C6 is inhibiting this pathway within the 
cytoplasm or further downstream in the nucleus. Although many VACV proteins have been 
identified to inhibit the production of IFNs, or to bind and neutralise the activation of secreted 
IFNs, only VH1 has been identified to inhibit IFN-induced intracellular signalling (Najarro et 
al, 2001).  It has been observed that VACV also has the ability to block the transcription of some 
STAT1-independent genes by a currently unknown mechanism (Mann et al, 2008) and it is 
plausible that C6 may contribute to this ability.   
8.3 Identification of TANK, SINTBAD and NAP1 as C6 binding partners 
Although TANK, SINTBAD and NAP1 were found to interact with C6 and it is presumed 
that this binding mechanistically explains how this VACV protein is able to inhibit IRF3 
activation this hypothesis remains to be confirmed experimentally. Cells deficient is all three 
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adaptor proteins are currently not available, but would be very useful to test whether C6 is 
still able to inhibit IRF3 in their absence. It is possible that the activation of IRF3 is 
completely abrogated in the absence of these three adaptors as it is currently unclear whether 
some redundancy between these molecules and DDX3, or other unidentified adaptor proteins 
exists. In the absence of null cell lines an alternative would be to knockdown the expression 
of these proteins by RNAi, which may be challenging for three proteins simultaneously.   
The binding of C6 to three non-canonical IKK adaptors is presumably an effective method 
for the virus to inhibit IRF3 activation by these kinases. It is currently not clear exactly which 
signalling pathways each adaptor is critical for and to what extent their functions are 
redundant, but clearly some non-redundant functions exist as the activation of IFNβ by TRIF 
over-expression was reduced in HCT116 cells lacking TANK (Figure 5.9). Thus by targeting 
all three adaptors the virus has evolved a method to inhibit IRF3 activation downstream of a 
number of stimuli. This is the first viral protein described to target these three adaptor 
molecules and this highlights an important role for these proteins in the host defence against 
viral infection. The severe acute respiratory syndrome (SARS) coronavirus M protein was 
recently described to inhibit type I IFN induction by preventing the formation of a ternary 
complex consisting of TRAF3, TANK and TBK1, and was found to physically associate with 
RIG-I, TRAF3, TBK1 and IKKε (Siu et al, 2009). In this study the M protein inhibited ISRE 
induction following the treatment of cells with dsRNA, or overexpression of RIG-I, MDA5, 
MAVS, TBK1 and IKKε, but not following the overexpression of IRF3 or IRF7, indicating 
that this protein exerts its function at a point in the signalling pathway similar to that of C6. 
These data further support an important role for this signalling pathway in host antiviral 
defence.   
Mechanistically it is still not clear how the binding of C6 to TANK, SINTBAD and NAP1 
inhibits IRF3 activation. An attractive hypothesis is that like SARS coronavirus M protein, 
C6 prevents the formation of a multimeric cellular signalling complex. This was tested by 
both LUMIER assay and conventional IP assays in the presence of over-expressed C6, but no 
disruption of complex formation was observed (Figures 5.12-5.18). However, there may be 
technical reasons for this (below) and no conclusions could be made from these experiments. 
One major limitation of these types of experiments is that all molecules are over-expressed 
outside the context of a viral infection. It is possible that the levels of over-expressed C6 were 
229 
 
not sufficient to interfere with the interaction between over-expressed cellular signalling 
molecules. For example in Figure 5.17 the expression level of TAP-C6 from the HEK293 T-
Rex TAP-C6 cell line was significantly lower than over-expressed FLAG-TRAF3 or N1-
TAP, all probed using an anti-FLAG monoclonal Ab.  
It is unlikely that C6 requires other viral proteins to exert its function because C6 inhibits 
IFNβ (Figure 4.1) and IRF3 (Figure 4.6) activation in a reporter gene assay when it is over-
expressed in the absence of a viral infection. It is possible however that the IRF3 signalling 
pathway needs to be activated, for example by infecting the cells with VACV, or NDV, or by 
treating them with poly I:C for C6 to exert its function. Clearly over-expressed C6 interacts 
with over-expressed TANK, NAP1 and SINTBAD without the need for activating the IRF3 
pathway, but activation may induce protein conformational changes and/or post-translational 
modifications that are required to observe the mechanism of C6 inhibition. C6 may indeed 
affect the post-translational modifications of signalling proteins and this remains to be 
investigated. Infecting cells with VACV or NDV to stimulate the pathway may complicate 
the experiment due to the presence of other immunomodulatory viral proteins, although 
infection with vΔC6 may act as a good control for experiments using wild-type VACV WR 
infection.  
It was not tested in this study whether the presence of C6 interfered with the interaction 
between TANK and NEMO, which would be particularly interesting as the N-terminal region 
where C6 interacts with TANK is important for its binding to NEMO. Although this binding 
has previously been shown to have a role in NF-κB activation rather than IRF3 signalling 
(Chariot et al, 2002), more recent work has indicated that cross-talk between the canonical 
and non-canonical IKKs exists and that the canonical IKKs play an important role in TBK1 
and IKKε activation (Clark et al, 2011). Whether this involves TANK is currently unclear 
and as yet no interaction between NEMO and NAP1 or SINTBAD has been described. Given 
that SINTBAD and NAP1 also contain N-terminal coiled-coil regions it is an attractive 
hypothesis that C6 interacts with these molecules using the same domain, perhaps preventing 
them from interacting with a common binding partner, for example the non-canonical IKKs. 
However it is entirely possible that C6 binds to the three adaptors using different domains 
and potentially different mechanisms to inhibit IRF3 activation.    
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There are still many unanswered questions with regards to the signalling pathways that 
converge on the non-canonical IKKs and subsequently activate IRF3, some of which may be 
answered by understanding the mechanism by which viral proteins like C6 exert their 
immunomodulatory functions. Currently crystal structures for TANK, NAP1 and SINTBAD 
are not available, only a small peptide of TANK in complex with TRAF3 (Li et al, 2002). 
Producing soluble C6 and the adaptor proteins in E. coli has proved difficult, however co-
expressing them may prove fruitful. It is currently not known if the interaction between C6 
and these adaptors is direct and producing bacterially expressed proteins would help answer 
this question. In addition both TBK1 (Chien et al, 2006) and IKKε (Boehm et al, 2007) are 
oncogenic kinases and have been linked to cancer. It is currently unclear whether TANK, 
SINTBAD or NAP1 are involved in this process but if they are, inhibiting their activity by 
over-expressing C6 may provide some therapeutic benefit. 
Despite the lack of binding between LUC-tagged C6 and the non-canonical IKK adaptor 
proteins, an interaction was observed with Ub (Figure 5.10). UBR1, a Ub ligase was 
identified as a potential C6 binding partner by mass spectrometry (Figure 6.5) and therefore it 
could be hypothesised that C6 is itself ubiquitinated, and potentially by UBR1. Prelimary 
data however suggests that the interaction between Ub and C6 is non-covalent and therefore 
it is unlikely that C6 is post-translationally modified in this way (C. Maluquer de Motes, 
unpublished results). A second hypothesis is that the interaction between C6 and TANK is 
not direct but is via Ub moieties on TANK. In support of this hypothesis TANK was found to 
be ubiquitinated between residues 71 and 110, which coincides with the region of TANK 
necessary for its interaction with C6 (Gatot et al, 2007). Ubiqutination of NAP1 and 
SINTBAD has not been described, although both proteins are able to interact with Ub 
(Thurston et al, 2009).  
8.4 A non-biased approach for identifying C6 binding partners 
The construction of a recombinant virus expressing TAP-tagged C6 has proved a very useful 
tool for identifying novel binding partners of this viral protein – both cellular partners and 
viral. In this study novel interaction partners were identified from the human HCT116 cell 
line and at only one time point p.i.. It would be interesting to continue this work further using 
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different cell lines from different species and with harvesting of the cells at various time 
points p.i. to ascertain whether the pattern of co-immunoprecipitated proteins differed.  
Multiple novel binding partners for C6 were identified by mass spectrometry with very 
different cellular functions. Two of these; SMARCC1 (Figure 6.7) and UBR1 (Figure 6.8) 
were confirmed as interaction partners by conventional IP assay. It seems therefore that C6 is 
likely to have multiple functions during viral infection. Whilst this is very common for small 
RNA viruses with a highly limited coding capacity it is interesting that VACV, a large DNA 
virus with considerably larger coding capacity should express proteins with multiple binding 
partners and functions. Another example of a VACV protein with multiple functions is Bcl-2 
family member N1, which is both anti-apoptotic (Cooray et al, 2007) and abrogates NF-κB 
signalling (DiPerna et al, 2004). It is possible that new functions for already characterised 
VACV proteins will be discovered in the future.  
The Ub N-end rule of protein degradation, which UBR1, UBR2 and Hsp70 contribute to, is 
involved in the degradation of a number of viral proteins and potentially contributes to the 
host defence against viral infection. As preliminary data demonstrated C6 to interact with Ub, 
but it was not covalently linked to this moiety, an alternative hypothesis is that C6 binds to 
UBR1 and/or other members of the N-end rule pathway and hijacks them to degrade cellular 
proteins to the benefit of the virus, for example those important for an antiviral innate 
immune response. Few cellular targets of the N-end rule pathway have been identified, for 
example RGS4 and RGS5, which are negative regulators of specific G proteins whose 
functions include cardiac growth and angiogenesis (Lee et al, 2005), but these proteins have 
not currently been linked to the immune response. Although there are numerous examples of 
viral proteins that interfere with the host Ub system, mimicking its functions to degrade 
proteins to the advantage of the virus (recently reviewed in (Isaacson & Ploegh, 2009; 
Viswanathan et al, 2010)), such as the orthopoxvirus ankyrin-F-box-like and BTB-kelch-like 
protein families that interact with the cellular Cullin-1- and Cullin-3-containing Ub-protein 
ligases, respectively (Shchelkunov, 2010), none have been described that target UBR1 and 
the N-end rule of protein degradation. Thus VACV may have evolved a novel mechanism to 
modulate the Ub system through C6.  
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SMARCC1 is a core component of the SWI/SNF complex that remodels chromatin and 
controls the expression of numerous genes (Wang et al, 1996). This complex is important 
during development and a number of components have also been linked to cancer 
(Klochendler-Yeivin et al, 2002). The SWI/SNF complex also plays a crucial role in the 
immune response. It is involved in IFNβ induction, the expression of IFNα target genes, CD4 
T cell repression and T cell activation (Chi, 2004). C6 is able to inhibit both IFNβ induction 
and ISRE induction downstream of IFNα, and its binding to SMARCC1 may mechanistically 
explain these functions. Inhibition of IFNβ induction by C6 has been attributed in this study 
to its ability to inhibit the IRF3 innate immune signalling pathway. As C6 was not able to 
inhibit IFNβ induction downstream of IRF3 over-expression, it is presumed that this viral 
protein does not exert its effects in the nucleus. Indeed, in the presence of C6 IRF3 
translocation to the nucleus in response to SeV infection was inhibited (Unterholzner et al, 
2011). It is possible however that over-expressing IRF3, or a constitutively active form of the 
protein (Unterholzner et al, 2011) circumvents the need for the SWI/SNF complex at the 
IFNβ promoter, or the reporter plasmid does not require this complex for expression of the 
luciferase gene. These dependencies may also be cell-type specific. Again, it therefore 
remains possible that C6 inhibits IFNβ induction by multiple methods.  
In addition the SWI/SNF complex has also been linked to the AP-1 transcription factor. 
Increased expression of the SWI/SNF complex resulted in enhanced AP-1 activity, 
production of AP-1-dependent cytokines such as IFNγ, IL-4 and IL-17 and proliferation of 
peripheral T cells (Jeong et al, 2009). These finding were in T cells, which are not readily 
infected with VACV (Zhao et al, 2009), however whether the SWI/SNF complex affects AP-
1 activity and subsequent pro-inflammatory and antiviral cytokine production in other cells 
remains to be tested.  
Given the important roles of the SWI/SNF complex in the immune system this is potentially a 
good candidate for exploitation by viruses. Indeed, the HIV integrase was shown to directly 
bind SWI/SNF component BAF47
 
(Kalpana et al, 1994). Currently it is not clear what 
advantage this provides the virus but it has been suggested that HIV-1 may exploit the 
SWI/SNF complex during the process of viral integration into the host genome. SMARCC1 
is a core component of the SWI/SNF complex, functioning as a scaffold protein that controls 
the stability of the complex by directly interacting with the other major components. An 
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alteration in the expression or activity of SMARCC1 causes changes in the overall level of 
the SWI/SNF complex and its activity (Sohn et al, 2007), making this protein a good target 
for modulation by a virus. 
Ro ribonucleoprotein (RNP) complexes are small cytoplasmic particles that were initially 
identified as major targets of autoantibodies in patients with systemic lupus erythematosus 
and Sjögren‟s syndrome (Youinou et al, 1994). The human Ro RNP is composed of one 
molecule of a small non-coding Y RNA and two proteins; Ro60 (TROVE2) and La. 
TROVE2, to which C6 may bind to, has been described to be necessary for nuclear export 
and stabilization of Y RNAs (Deutscher et al, 1988). The La protein on the other hand was 
found to stabilise newly synthesized RNA polymerase III transcripts and to protect them from 
exonuclease attack (Wolin & Cedervall, 2002). In addition La is involved in cap-independent 
translation of cellular and viral mRNAs, including RNAs from adenovirus and Epstein-Barr 
virus (Wolin & Cedervall, 2002). It is possible therefore that through the binding of C6 to 
TROVE2, VACV may exploit the cellular Ro RNP complex for the transcription and/or 
translation, or stability of viral RNAs.   
Finally, VACV protein I1, encoded by the I1L gene, was identified as a potential binding 
partner for C6. I1 has DNA-binding activity, is packaged in the virion core and is essential 
for the assembly of mature viruses (Klemperer et al, 1997). Small amounts of C6 protein 
were detected in the virion core (Chung et al, 2006) and it is possible that C6 is packaged by 
its interaction with I1. The significance of this interaction is not understood, but the presence 
of C6 within the virion might be of an advantage to the virus akin to the VH1 phosphatase in 
which cellular signalling pathways can be silenced before early virus gene expression. 
A yeast two-hybrid screen of VACV-host protein-protein interactions identified keratin 4 
(KRT4), programmed cell death 6 interacting protein (PDCD6IP) and troponin I (TNNI2) as 
potential C6 interaction partners (Zhang et al, 2009). Neither PDCD6IP nor TNNI2 were 
identified by mass spectrometry in this study. Multiple hits however were obtained for 
various forms of keratin, but this is likely to be keratin contamination routinely observed in 
mass spectrometry analysis due to the high sensitivity of the technique.  
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8.5 The contribution of C6 to VACV virulence 
The construction of vΔC6 in this study, and MVA-BΔC6 (Garcia-Arriaza et al, 2011) 
demonstrated that C6 is a non-essential VACV protein. Further, in cell culture both WR and 
MVA lacking C6 were found to replicate to equivalent titres as their wild type equivalents. In 
vivo however, recombinant WR viruses lacking C6 expression (vΔC6 and vC6FS) were 
found to be attenuated in both the i.n. (Figure 7.4) and i.d. (Figure 7.12) models of infection, 
suggesting an important role for this protein during the infection of an animal. With almost 
200 genes it is intriguing that the deletion of a single ORF can have drastic effects to 
virulence in an animal model of infection. The deletion of several genes involved in innate 
immune modulation results in viral attenuation in one, or more models of murine infection, 
presumably because in their absence an improved immune response to the pathogen is 
mounted, thus enhancing viral clearance. In the case of C6 viral titres in the lung following 
i.n. infection were indistinguishable between recombinant viruses at the time points tested 
(Figure 7.5C). These data were obtained from a single experiment and require further 
analysis, including viral titres in the ear following i.d. infection. The deletion of immune 
modulators however does not always lead to viral attenuation in vivo, for example the 
deletion of B15 leads to an exacerbated response due to higher levels of IL-1β that actually 
enhance pathology in mice in the i.n. model (Alcami & Smith, 1992). Further, the deletion of 
B13 leads to a larger lesion size in the i.d. model of murine infection (Tscharke et al, 2002). 
These experiments demonstrate the complexities of the immune response and the fine balance 
between a beneficial immune response and immune pathology.  
What is not clear from this study is whether it is the innate immunomodulatory role of C6 
that leads to viral attenuation in its absence, or in fact any other function that C6 plays during 
viral infection. Indeed C6 was found to interact with a number of cellular proteins and any or 
all of these interactions may contribute to the attenuation of vΔC6 and vC6FS in vivo. Testing 
which of these interactions contributes, or is most important during in vivo infection is 
challenging, but may be aided by infecting mice null for the identified C6 interaction 
partners, or with mutants of C6 that are able to interact with certain cellular proteins and not 
others. The structure of C6 in complex with its cellular binding partners would be very 
advantageous. These kinds of experiments have been completed recently with mutants of N1 
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that lack either anti-apoptotic ability, or anti-NF-κB signalling ability and demonstrated that 
the anti-signalling ability of N1 is more important in vivo (Maluquer de Motes et al, 2011).   
In the i.n. model of infection more infiltrating neutrophils (Figure 7.11A) and macrophages 
(Figure 7.11C) were found in the spleens of mice infected with vΔC6 compared to the wild-
type and revertant viruses at day 2 p.i.. By day 4 p.i. no differences were observed, 
suggesting that the effects of C6 are exerted very quickly, consistent with the rapid onset of 
the innate immune response. Differences in macrophage and neutrophil populations might 
also exist in the lung and BAL of vΔC6-infected animals at early time points p.i. and this 
remains to be tested. Increased numbers of these innate immune cell populations may 
contribute to the attenuated phenotype of the knockout virus, because these cells play a 
crucial role in the defence against VACV infection and macrophages in particular are 
important for activating the adaptive immune response. Macrophages and neutrophils are 
attracted to the site of infection by pro-inflammatory cytokines and chemokines, such as 
CCL2, CCL5 and CXCL10 for macrophages and members of the CXC group of chemokines 
for neutrophils (reviewed in (Laing & Secombes, 2004)). The expression of many of these 
genes is IRF3-dependent, and for CCL5 and CXCL10, their expression or production was 
reduced in the presence of C6 in vitro in this study (Figure 4.7). Further, human macrophages 
infected with MVA-BΔC6 showed enhanced transcription of CCL2 (Garcia-Arriaza et al, 
2011). In vivo C6 may therefore act to suppress the production of these proteins, resulting in 
reduced recruitment of innate immune cells such as macrophages and neutrophils.  
VACVs (strain WR) lacking C6 expression were also attenuated in the i.d. model of murine 
infection (Figure 7.12), although currently the mechanism of this attenuation has not been 
investigated. Given that C6 may be modulating macrophage and neutrophil recruitment in the 
i.n. model of infection, these cell populations may also be altered in the ear of i.d.-infected 
animals and this requires testing experimentally. Differences in the local expression and 
production of pro-inflammatory cytokines and chemokines, and the expression of type I IFN-
inducible genes in the VACV lesion could also be tested. 
In this study a virus lacking C6 expression was shown to provide enhanced protection against 
a lethal challenge dose of VACV WR, indicating these viruses to be better vaccines, with 
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enhanced immunogenicity compared to vaccination with wild-type WR (Figure 7.13). These 
data indicate that C6 may act to dampen parts of the immune response that contribute to 
immune memory. Enhanced immunogenicity has also been observed following the deletion 
of a number of other VACV proteins with immunomodulatory functions including A41 
(Clark et al, 2006), an A41 and B16 double deletion (Garcia-Arriaza et al, 2010), A35 (Rehm 
& Roper, 2011), C21 (Girgis et al, 2011), B15 (Staib et al, 2005) and N1 (H. Ren et al, 
unpublished results). Removal of immunomodulatory genes, however does not always lead to 
enhanced immunogenicity in a challenge experiment, as observed for C16 (Fahy et al, 2008). 
Currently, the mechanism of this enhanced immunogenicity is not known, but given that a 
poorer neutralising Ab response was observed following vaccination with a virus lacking C6 
expression (Figure 7.14A), the enhanced immunogenicity may reflect an enhancement in T 
cell-mediated immunological memory. Supporting this hypothesis, Garcia-Arriaza et al found 
significantly enhanced HIV-1-specific CD4+ and CD8+ T cell memory responses when mice 
were vaccinated with MVA-BΔC6 compared to MVA-B (Garcia-Arriaza et al, 2011). The 
authors of this study did not measure T cell memory responses to VACV antigens however. 
Given that C6 expressed from MVA is also able to inhibit IFNβ induction (Figure 4.3) and 
thus dampen the immune response this is a good candidate gene for rational deletion from the 
MVA genome to potentially enhance immunogenicity of this vaccine vector. This hypothesis 
has been tested by Garcia-Arriaza et al and although enhanced HIV-1 memory responses 
were measured with MVA-BΔC6, this virus remains to be tested in an HIV challenge study 
to confirm enhanced protection over wild-type MVA-B (Garcia-Arriaza et al, 2011).  
Thus far no differences have been observed in the number of T memory cells present in mice 
vaccinated with the various C6 recombinant viruses (Figure 7.15), or their ability to produce 
IFNγ (Figure 7.17) in response to VACV peptides, or to kill VACV-infected target cells 
(Figure 7.16). These experiments were specific for the activity of CD8+ T cells and therefore 
experiments examining the function of other T cell subsets, such as CD4+ T cells, TH17 cells, 
Treg cells or gamma-delta T cells should be considered. Other markers of immune memory 
could also be tested, for example Garcia-Arriaza et al used CD44 in conjunction with CD62L 
to examine memory populations by flow cytometry (Garcia-Arriaza et al, 2011). In addition 
to long-term protection offered by Ab and memory T cells, Thy1+ NK „innate memory‟ cells 
from VACV-primed mice were shown to confer protection against challenge in the absence 
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of adaptive lymphocytes and thus are a further subset of immune cells to analyse (Gillard et 
al, 2011).   
The SWI/SNF complex, to which C6 binds the SMARCC1 component, plays an important 
role in CD4/CD8-lineage bifurcation, repressing CD4+ T cell development and favouring 
CD8+ development (Chi, 2004). In addition it has been questioned whether the SWI/SNF 
complex plays a role in TH1/TH2 cell polarization (Chi, 2004). TH1 cells aid the killing 
capacity of macrophages and CTLs whereas TH2 play an important role in the production of 
Ab. By inhibiting the SWI/SNF complex C6 may skew the immune response, potentially 
explaining why in the absence of this viral protein a lower Ab neutralisation function was 
measured.  
8.6 Summary 
In conclusion this study presents the in vitro and in vivo characterisation of VACV WR ORF 
022 expressing protein C6. This protein is a predicted member of the VACV Bcl-2 protein 
family and like other members of this family C6 possesses immunomodulatory properties. C6 
is a broad spectrum inhibitor of IRF3 activation, as well as an inhibitor of ISRE activation 
downstream of IFNα. Three adaptor proteins of the non-canonical IKK complex; TANK, 
SINTBAD and NAP1 were identified as C6 binding partners and may explain the ability of 
C6 to inhibit IRF3 activation. Furthermore UBR1, UBR2, Hsp70, SMARCC1, TROVE2 and 
VACV protein I1 were identified as C6 interaction partners by mass spectrometry. Why 
VACV may want to target these cellular proteins is currently unclear, however these data 
suggest that C6 has multiple functions during the course of a viral infection. In vivo C6 is a 
virulence factor because viruses lacking C6 expression were attenuated in both the i.n. and 
i.d. models of murine infection. In addition, a virus lacking C6 showed enhanced 
immunogenicity in a VACV challenge model, identifying this gene as a good target for 
removal to improve VACV as a vaccine vector. The mechanism of this enhanced 
immunogenicity is currently unclear, but presents exciting future work and highlights the 
important role of the innate immune response in shaping the outcome of the adaptive and 
subsequent memory immune response. 
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